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ABBREVIATIONS USED IN THE TEXT 
  
DD:  Death domain 
ECM : Extracellular matrix  
ERK:  Extra-cellular regulated kinase  
FAK:  Focal adhesion kinase 
FasL:  Fas ligand 
GLP-1:  Glucagon-like peptide 1 
IAP:  Inhibitor of apoptosis protein 
IFN-γ:  Interferon γ 
IGF-I:  Insulin-like growth factor I 
IκB:  Inhibitor of NF-κB 
IKK:  IκB kinase 
IL-1β:  Interleukin-1 beta 
IMD: Integrin-mediated death 
iNOS:  inducible nitric oxide synthase 
MAP kinase: Mitogen activated protein kinase 
NF-κB:  Nuclear factor κB 
NO:  Nitric oxide  
PDGF:  Platelet-derived growth factor 
PDTC: Pyrrolidine dithiocarbamate 
PI(4,5)P2:  Phosphatidyl inositol-4,5-biphosphate 
PI(3,4,5,)P3: Phosphatidyl inositol-3,4,5-triphosphate 
PI3K: Phosphatidylinositol 3-kinase 
PKB/Akt:  Protein kinase B 
pLL:  poly-L-lysine 
SH2 domain: Src-homology 2 domain 
TNFα:  Tumor necrosis factor α 
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RESUME EN FRANÇAIS 
1. Introduction 
1.1. L’apoptose de la cellule bêta et le diabète 
L’îlot pancréatique de Langerhans est composé de quatre différents types de cellules 
qui sécrètent des hormones biologiquement actives dans la circulation sanguine : les cellules 
alpha, bêta, delta et PP. La fonction majeure de ces cellules est de maintenir une concentration 
plasmatique de glucose (glycémie) dans une fourchette restreinte (3.5 à 7 mmol/l). 
L’augmentation de cette dernière, suite à un apport exogène de glucose (lors d’un repas), induit 
la sécrétion d’insuline par la cellule bêta pancréatique. L’insuline sécrétée induit alors une 
diminution de la glycémie, maintenant ainsi l’homéostasie glucidique. L’absence de régulation 
correcte de la glycémie est l’un des symptômes principaux indiquant la présence de diabète. Il 
existe deux types de diabète : le diabète de type 1 résultant d’une destruction auto-immune 
progressive des cellules bêta pancréatiques, et le diabète de type 2 caractérisé par une 
résistance à l’insuline des tissus cibles (tels que le foie et le muscle) accompagnée d’un défaut 
de sécrétion d’insuline par la cellule bêta. Cette sécrétion insuffisante d’insuline résulterait d’une 
combinaison d’un dysfonctionnement cellulaire inhérent d’une part, et d’une diminution de la 
masse de cellules bêta d’autre part. Récemment, la mort cellulaire par apoptose a été impliquée 
dans la diminution de la masse de cellules sécrétrices d’insuline non seulement dans le cas du 
diabète de type 1 mais aussi dans le cas du diabète de type 2. La cellule bêta semble être 
particulièrement sensible aux stimuli pro-apoptotiques, probablement à cause de son phénotype 
particulièrement bien différencié. Quels sont les facteurs induisant l’apoptose des cellules 
bêta ? Les principaux stimuli pro-apoptotiques supposés être impliqués dans la pathogénèse du 
diabète de type 2 comprennent les cytokines, la lipotoxicité, et la glucotoxicité.  
Un modèle général pour expliquer le rôle de l’apoptose dans le développement du 
diabète de type 2 a été proposé. Au début de la maladie, au stade de la résistance à l’insuline, 
une augmentation de la masse des cellules bêta compensant la résistance à l’insuline peut être 
observée. Cependant, celle-ci est temporaire, et est suivie par un déclin progressif de la masse 
des cellules bêta, impliquant la mort cellulaire par apoptose. Le déclenchement du diabète 
proprement dit est caractérisé par une incapacité des cellules bêta résiduelles à compenser la 
résistance à l’insuline. Par conséquent, un état d’hyper-glycémie permanent et donc diabétique 
s’installe. La maintenance de la survie des cellules bêta et d’une masse de cellules bêta 
adéquate sont donc des stratégies prometteuses qui pourraient permettre soit de prévenir, soit 
de traiter le diabète de type 2. Toutefois, les mécanismes impliqués dans la protection des 
cellules bêta contre l’apoptose sont encore mal définis. Parmi ceux-ci, un élément encore mal 
connu pourrait contribuer à maintenir la survie des cellules bêta dans un environnement hostile : 
la matrice extracellulaire.  
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1.2. La matrice extracellulaire 
1.2.1. Généralités 
 La matrice extracellulaire a été longtemps considérée uniquement comme un 
échafaudage inerte qui sert à maintenir la structure physique des tissus. Des recherches 
effectuées ces vingt dernières années ont permis de mettre en évidence que la matrice 
extracellulaire est une structure extrêmement dynamique, capable d’activer des voies de 
signalisation intracellulaires influençant un large spectre de fonctions biologiques telles que 
l’adhésion cellulaire, la migration, la prolifération, la différenciation et la survie des cellules.  
C’est en particulier le rôle anti-apoptotique de la matrice extracellulaire qui nous intéresse ici. 
En effet, il existe un type d’apoptose spécifique, appelé anoikis, qui est induit soit par le 
détachement des cellules de leur matrice extracellulaire, soit par l’interaction des cellules avec 
une matrice extracellulaire non-adaptée. L’apoptose peut être inhibée par différents facteurs 
« pro-survie », capables de contrebalancer les stimuli pro-apoptotiques. Parmi ces facteurs 
bénéfiques figure la matrice extracellulaire. Les mécanismes impliqués dans l’anoikis ne sont 
pas encore bien caractérisés. Néanmoins, il semble que l’activation de la caspase-8 soit 
souvent impliquée dans cette forme d’apoptose. 
L’adhésion des cellules à la matrice extracellulaire s’effectue essentiellement par le 
biais d’une famille de récepteurs transmembranaires hétérodimériques : les intégrines. Ces 
dernières sont composées d’une sous-unité α et d’une sous-unité β. La famille des intégrines 
des vertébrés contient au moins 18 sous-unités α et 8 sous-unités β qui peuvent s’associer et 
former au moins 20 hétérodimères distincts. C’est la combinaison spécifique d’une sous-unité α 
avec une sous-unité β qui détermine l’affinité de l’hétérodimère pour une protéine spécifique de 
la matrice extracellulaire. Les ligands courants des intégrines sont des composants de cette 
matrice tels que le collagène, la fibronectine, la vitronectine, ainsi que la laminine. L’interaction 
d’une cellule avec une matrice extracellulaire induit un regroupement d’intégrines qui initie non 
seulement l’adhésion et l’organisation du cytosquelette via l’interaction physique des intégrines 
avec d’autres groupes de protéines, mais également l’activation de plusieurs voies de 
signalisation intracellulaires. Ces voies de signalisation intracellulaires ont été impliquées dans 
l’effet anti-apoptotique de la matrice extracellulaire.  
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1.2.2. Voies de signalisation induites par la matrice extracellulaire 
L’engagement des intégrines à une matrice extracellulaire adaptée peut induire 
l’activation d’un grand nombre de protéines impliquées dans des voies de signalisation 
intracellulaires. L’effet anti-apoptotique de la matrice extracellulaire peut être transmis par 
différentes cascades de signalisation impliquant les protéines Focal Adhesion kinase (FAK), 
Phosphatidylinositol 3-kinase (PI3K), protéine kinase B (PKB/Akt), les MAP kinases (MAPK) 
ERK1 et ERK2 (ERK1/2), ainsi que par l’activation du facteur de transcription NF-κB. 
FAK, une protéine localisée aux sites d’adhésion de la cellule avec la matrice 
extracellulaire (les adhésions focales), est une des premières protéines découverte pouvant 
être activée suite à l’interaction des intégrines avec leur ligand extracellulaire. Cette interaction 
induit la phosphorylation de la FAK sur des résidus tyrosine (le résidu tyrosine-397, 
notamment), ce qui conduit au recrutement de protéines adaptatrices et signalisatrices par la 
FAK. La phosphorylation du résidu tyrosine-397 est à l’origine du recrutement de la PI3K par 
FAK. De plus, l’activation de la FAK peut également induire l’activation de la voie des MAPK 
ERK1/2. Par conséquent, la phosphorylation du résidu tyrosine-397 de la FAK est souvent 
considérée comme un marqueur indiquant la présence d’intégrines activées.  
Une fois activée, la PI3K peut à son tour stimuler plusieurs protéines signalisatrices. 
Un des effecteurs majeurs de la PI3K est PKB/Akt (également appelée Akt). La phosphorylation 
d’Akt sur les résidus thréonine-308 et sérine-473 corrèle avec son niveau d’activation : la 
phosphorylation de ces résidus est donc considérée comme un marqueur indiquant l’activation 
de la voie PI3K-Akt. En général, la voie PI3K-Akt est considérée comme étant une voie de 
signalisation intracellulaire anti-apoptotique majeure.  
La voie des MAPK ERK1/2 a été impliquée dans la régulation de plusieurs fonctions 
cellulaires majeures telles que la migration cellulaire, la prolifération et la survie des cellules. Il 
existe deux isoformes de la protéine ERK : ERK1 et ERK2 (également appelés p44 et p42, 
respectivement). L’activation des ERK1/2 est induite par une double phosphorylation sur deux 
résidus (thréonine et tyrosine). Une fois phosphorylés, les ERK1/2 peuvent à leur tour activer un 
nombre important d’effecteurs, incluant des protéines membranaires et cytoplasmiques, ainsi 
que des facteurs de transcription.  
Deux mécanismes principaux ont été impliqués dans l’effet anti-apoptotique des voies 
de signalisation induites par la matrice extracellulaire et transmises par FAK, PI3K-Akt et 
ERK1/2. Le premier induirait un effet direct sur la phosphorylation et donc sur l’activité des 
protéines impliquées dans l’apoptose.  Le second mécanisme aurait lieu via une altération du 
niveau de l’expression de gènes impliqués dans la régulation de la survie cellulaire (à travers 
une régulation de l’activité des facteurs de transcription). Durant ce travail de thèse, nous nous 
sommes particulièrement intéressés à ce dernier mécanisme. En particulier, nous nous 
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sommes penchés sur l’effet de la matrice extracellulaire sur l’activité du facteur de transcription 
NF-κB. 
La famille des facteurs de transcription NF-κB est composée de cinq membres : p65 
(RelA), RelB, c-Rel, p50/p105 (NF-κB1) et p52/p100 (NF-κB2). Celui sur lequel nous nous 
sommes focalisés est l’hétérodimère communément appelé « NF-κB », composé des protéines 
p65 et p50. NF-κB a été impliqué dans la régulation de nombreuses fonctions biologiques et 
cellulaires, telles que l’inflammation, la prolifération, la migration et la survie des cellules. Dans 
une cellule non-stimulée, NF-κB est séquestré dans le cytoplasme par des protéines appelées 
« inhibitor of NF-κB », les IκBs.  L’activation de la cellule par un stimulus donné (tel que la 
cytokine IL-1β ou la matrice extracellulaire) semble induire la phosphorylation et l’activation d’un 
groupe de kinases : les IκB kinases (IKK), qui phosphorylent les IκBs. La phosphorylation des 
IκBs entraîne leur ubiquitination et par conséquent leur dégradation. Il en résulte la libération de 
NF-κB menant à sa translocation vers le noyau. Une fois dans le noyau, NF-κB va se lier à des 
sites promoteurs particuliers et va ainsi induire l’expression de gènes spécifiques (tels que 
IκBα, le chemokine IP-10 et le facteur de transcription c-Myc). IκBα est un des gènes-cible 
majeurs de NF-κB, et ceci constitue un mécanisme rétro-actif inhibant l’activité 
transcriptionnelle de NF-κB. L’activité transcriptionnelle de NF-κB est régulée non seulement 
via la dégradation d’IκB, mais aussi par la phosphorylation et/ou l’acétylation directe de la sous-
unité p65, ce qui module le potentiel de transactivation de NF-κB. Plusieurs protéines et voies 
de signalisation ont été impliquées dans l’activation de NF-κB, telles que la protéine FAK et les 
cascades de signalisation impliquant PI3K-Akt et ERK1/2. 
Il a été démontré que NF-κB peut jouer un rôle pro-apoptotique ou anti-apoptotique 
suivant le contexte, la nature, l’intensité et la durée du stimulus induisant son activité, ainsi que 
le type cellulaire étudié. L’activation de NF-κB par la matrice extracellulaire a été impliquée 
dans l’effet anti-apoptotique de cette dernière. De plus, les kinases FAK, PI3K, Akt et ERK1/2 
ont toutes été impliquées dans le rôle anti-apoptotique de NF-κB. 
En résumé, la matrice extracellulaire peut activer les kinases FAK, PI3K, Akt et 
ERK1/2, ainsi que le facteur de transcription NF-κB. De plus, un rôle anti-apoptotique a été 
proposé pour toutes ces protéines, et toutes ont été impliquées dans l’effet pro-survie de la 
matrice extracellulaire. Néanmoins, les rôles éventuels de ces protéines dans les effets de la 
matrice extracellulaire sur la cellule bêta pancréatique étaient inconnus au début de ce travail 
de thèse.  
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1.3. La matrice extracellulaire et la cellule bêta pancréatique 
Avant le début de ce travail de thèse, quelques travaux rapportant que la matrice 
extracellulaire pourrait améliorer la survie ainsi que la fonction (sécrétion d’insuline stimulée par 
le glucose) des cellules bêta en culture avaient été publiés. Etant donné que la laminine et le 
collagène IV sont présents dans la membrane basale des îlots de Langerhans, notre groupe 
s’est intéressé à l’expression des intégrines dans les cellules bêta de rat. Il a été observé que 
ces dernières expriment les intégrines α6β1 et α3β1, qui sont des récepteurs de la laminine-5. 
D’autre part, notre groupe a découvert qu’une matrice extracellulaire riche en laminine-5 
(appelée 804G-ECM) induit l’étalement des cellules bêta de rat et améliore leur sécrétion 
d’insuline en réponse au glucose. Les interactions entre la laminine-5 et l’intégrine α6β1 
semblent être responsables, du moins en partie, des effets bénéfiques de la matrice 804G-ECM 
sur la cellule bêta. 
Les voies de signalisation induites par la matrice extracellulaire en général ou par la 
matrice 804G-ECM en particulier dans la cellule bêta étaient complètement inconnues lors du 
début de ce travail de thèse. Aucun travail décrivant l’expression ou la fonction de FAK dans la 
cellule bêta n’avait alors été publié. Néanmoins, plusieurs papiers suggérant que les voies de 
signalisation PI3K-Akt et MAPK ERK1/2 puissent jouer un rôle dans le contrôle de la survie de 
la cellule bêta ont été publiés soit avant, soit pendant ce travail de thèse. La voie de 
signalisation PI3K-Akt est en général considérée comme une voie anti-apoptotique dans la 
cellule bêta, mais cela n’est pas encore complètement établi. Quant à la voie des MAPK 
ERK1/2, son éventuel rôle anti-apoptotique dans la cellule bêta est encore controversé. 
La fonction du facteur de transcription NF-κB dans la cellule bêta dans le contexte de 
la mort cellulaire induite par les cytokines (IL-1β, en particulier) a par contre été abondamment 
documentée. En effet, plusieurs travaux ont démontré que la cytokine IL-1β active NF-κB et que 
NF-κB est impliqué dans les effets néfastes de cette cytokine menant à un dysfonctionnement 
et à la mort de la cellule bêta. NF-κB est donc considéré comme une molécule transmettant des 
signaux pro-apoptotiques dans la cellule bêta, dans le contexte du diabète de type 1 et de la 
mort cellulaire induite par les cytokines. Néanmoins, d’autres travaux suggèrent que NF-κB, 
activé par des stimuli autres que les cytokines, pourrait avoir un rôle qui diffère des effets 
délétères sus-mentionnés. Notamment, il semble que NF-κB puisse être impliqué dans l’effet 
anti-apoptotique de GLP-1 (« Glucagon-like peptide 1 ») sur les cellules bêta.   
 10
2. But général du projet de thèse 
Le but général de ce travail de thèse était de répondre aux questions suivantes : 
- Est-ce que la matrice 804G-ECM protège les cellules bêta contre l’apoptose ? 
- Est-ce que la matrice 804G-ECM active les kinases FAK, PI3K-Akt et ERK1/2 
dans la cellule bêta ; si oui, est-ce que ces protéines sont impliquées dans l’effet pro-survie de 
la matrice 804G-ECM ? 
- Est-ce que la matrice 804G-ECM est capable d’induire l’expression de gènes, et 
est-ce que cette régulation est impliquée dans ses effets sur la cellule bêta ?  
Ce travail de thèse est composé de deux articles qui ont été publiés dans des revues 
internationales. Le but du premier article était d’analyser l’effet de la matrice 804G-ECM sur la 
survie des cellules bêta ainsi que son impact sur l’activité des kinases FAK, PI3K-Akt et 
ERK1/2. L’implication des voies de signalisation PI3K-Akt et ERK1/2 dans l’effet pro-survie de la 
matrice 804G-ECM a été évaluée en utilisant des inhibiteurs pharmacologiques. D’autre part, 
nous avons déterminé si la matrice 804G-ECM peut modifier l’expression de gènes dans la 
cellule bêta. Durant cette première partie de la thèse, nous avons notamment découvert que la 
matrice 804G-ECM induit l’expression de l’inhibiteur de NF-κB : IκBα. IκBα est un gène-cible de 
NF-κB, suggérant que la matrice 804G-ECM pourrait avoir un impact sur l’activité 
transcriptionnelle de NF-κB.  Le deuxième papier est focalisé sur l’activation de NF-κB induite 
par la matrice 804G-ECM et sur son rôle dans les effets de cette dernière sur la cellule bêta : 
l’étalement, l’organisation du cytosquelette, la fonction (sécrétion d’insuline en réponse au 
glucose), ainsi que la survie. Etant donné que NF-κB est en général considéré comme une 
molécule transmettant les effets néfastes des cytokines tels qu’IL-1β sur la cellule bêta, la 
possibilité qu’il puisse être impliqué dans les effets positifs de la matrice 804G-ECM sur la 
cellule bêta était fascinante. De plus, l’implication des voies de signalisation PI3K-Akt et MAPK 
ERK1/2 dans l’activation de NF-κB induite par la matrice 804G-ECM est également abordée 
dans cet article. 
Le niveau d’expression des intégrines, l’effet de la matrice extracellulaire et de ses 
différents composants sur la signalisation intracellulaire et sur la survie des cellules diffèrent 
suivant les types cellulaires étudiés. De plus, ces caractéristiques diffèrent également entre les 
cellules primaires et les lignées cellulaires (transformées ou pas) qui en dérivent. Par 
conséquent, nous avons décidé d’étudier exclusivement les cellules bêta primaires de rat 
purifiées par FACS. 
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3. Résumé des travaux 
Article 1: La matrice extracellulaire protège les cellules bêta pancréatiques de 
l’apoptose : rôles des voies de signalisation à court et à long terme 
 “ Extracellular Matrix Protects Pancreatic Beta-Cells Against Apoptosis : Role of Short- 
and Long-Term Signaling Pathways ”, Hammar et al. Diabetes, 53: 2034-2041 (2004) 
La matrice 804G-ECM a été utilisée comme modèle afin de déterminer si une matrice 
extracellulaire adaptée peut protéger les cellules bêta pancréatiques de la mort cellulaire. L’effet 
de cette matrice sur la survie des cellules bêta a été testée après 48h de culture, dans trois 
différentes conditions : en présence d’une concentration standard de sérum (10% FCS), en 
présence d’une basse concentration de sérum (1% FCS), ainsi qu’en présence de la cytokine 
IL-1β. Les cellules contrôle étaient cultivées soit sur des pétris non recouverts de matrice, soit 
sur des pétris recouverts d’un substrat adhésif « neutre » : la poly-L-lysine (pLL). Nous avons 
observé que la matrice 804G-ECM protège les cellules de l’apoptose et de la nécrose, dans 
toutes les conditions testées. Comme l’activation de la caspase-8 est souvent impliquée dans 
l’anoikis, nous avons mesuré cette activité dans les cellules cultivées sur la pLL et sur la matrice 
804G-ECM. L’activité de la caspase-8 est significativement diminuée dans les cellules cultivées 
sur la matrice 804G-ECM par rapport aux cellules contrôle. Ces résultats impliquent que la 
matrice 804G-ECM protège les cellules bêta de l’apoptose et suggèrent que la caspase-8 
pourrait être impliquée dans la mort de ces cellules cultivées sur la pLL. 
La matrice 804G-ECM est surtout composée de laminine-5, mais aussi d’autres 
protéines, telle que la fibronectine. C’est pourquoi nous avons vérifié que son effet anti-
apoptotique est bien une conséquence de l’engagement de la laminine-5 à ses récepteurs, les 
intégrines α3β1 et α6β1. Nous avons d’abord testé l’effet de la laminine-5 purifiée sur 
l’étalement et la survie des cellules, et nous avons constaté que son effet est similaire à celui de 
la matrice 804G-ECM. L’effet d’un anticorps bloquant l’intégrine β1 sur la survie des cellules 
bêta cultivées sur pLL et sur la matrice 804G-ECM a également été évalué. Le blocage de 
l’intégrine β1 induit une inhibition partielle mais significative de l’effet anti-apoptotique de la 
matrice 804G-ECM. Ceci implique que les interactions entre la laminine-5 et l’intégrine β1 sont 
responsables, du moins en partie, de l’effet anti-apoptotique de la matrice 804G-ECM sur les 
cellules bêta.   
Chacune des protéines FAK, Akt et ERK1/2 est susceptible de transmettre le signal 
anti-apoptotique généré par l’interaction des intégrines avec une matrice extracellulaire 
adaptée. C’est pourquoi nous avons étudié l’effet de la matrice 804G-ECM sur l’activité de ces 
kinases dans la cellule bêta. Nous avons entrepris des transfert Western (Western blotting) afin 
d’évaluer si la matrice 804G-ECM induit une phosphorylation rapide (30 minutes) de FAK (sur le 
résidu tyrosine-397), de Akt (sur résidu sérine-473) et de ERK1/2 (sur les résidus thréonine-202 
et tyrosine-204). Nous avons constaté que le niveau de phosphorylation de ces protéines sur 
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ces résidus est plus élevé dans les cellules cultivées sur la matrice 804G-ECM par rapport aux 
cellules cultivées sur la pLL. Dans un deuxième temps, l’effet de l’inhibition des voies de 
signalisation impliquant Akt et ERK1/2 a été étudié en utilisant des inhibiteurs 
pharmacologiques. Les résultats obtenus montrent que les inhibiteurs de PI3K (LY294002) et 
de MEK1 (PD98059) diminuent de manière partielle mais significative l’effet anti-apoptotique de 
la matrice 804G-ECM après 4h de culture, alors que la survie des cellules contrôle n’était pas 
altérée par ces inhibiteurs. Lors des études à plus long terme (48h), l’inhibiteur de PI3K n’a plus 
d’effet significatif sur la survie des cellules bêta, qu’elles soient cultivées sur la pLL ou la matrice 
804G-ECM. En revanche, l’inhibiteur de la voie ERK1/2 supprime de manière drastique l’effet 
anti-apoptotique de la matrice 804G-ECM, et augmente également la mortalité des cellules 
contrôle. Ceci implique que la voie des MAPK ERK1/2 joue un rôle majeur dans l’effet anti-
apoptotique à long terme de la matrice 804G-ECM. 
Afin d’étudier la possibilité que la matrice 804G-ECM induise l’expression de gènes qui 
pourraient être impliqués dans son effet anti-apoptotique, un « microarray » à basse densité 
suivi par une validation par RT-PCR quantitative ont été effectués. L’ARNm extrait de cellules 
bêta cultivées pendant 18h en présence ou en absence de la matrice 804G-ECM a été utilisé 
pour cette expérience. Les résultats obtenus ont montré que la matrice 804G-ECM induit une 
surexpression de l’inhibiteur de NF-κB (IκBα). Afin de déterminer si les voies PI3K-Akt ou 
MAPK ERK1/2 sont impliquées dans ce phénomène, l’effet de l’inhibition de ces voies sur la 
surexpression d’IκBα induite par la matrice 804G-ECM a été analysé. Nous avons constaté que 
l’inhibition de l’activité d’ERK1/2 diminuait de manière partielle la surexpression d’IκBα induite 
par la matrice 804G-ECM, tandis que la suppression de l’activité de PI3K n’avait pas d’effet. 
Ces résultats suggèrent que la voie ERK1/2 est en partie impliquée dans la surexpression 
d’IκBα induite par la matrice 804G-ECM. Deux hypothèses principales ont été émises suite à 
ces résultats. D’abord, comme IκBα est un gène-cible du facteur de transcription NF-κB, nous 
avons supposé que la matrice 804G-ECM pourrait induire l’activité transcriptionnelle de NF-κB. 
Ensuite, nous avons évoqué la possibilité que NF-κB pourrait être impliqué dans les effets de la 
matrice 804G-ECM sur la cellule bêta pancréatique ; à savoir l’étalement, l’organisation du 
cytosquelette, la sécrétion d’insuline en réponse au glucose et la survie cellulaire. Ces 
hypothèses constituent les bases de la deuxième partie de la thèse et de l’article 2.  
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Article 2: L’activation de NF-κB par la matrice extracellulaire est impliquée dans 
l’étalement et la sécrétion d’insuline stimulée par le glucose des cellules bêta 
pancréatiques 
“Activation of NF-κB by Extracellular Matrix Is Involved in Spreading and Glucose-
stimulated Insulin Secretion of Pancreatic Beta Cells”, Hammar et al. J Biol Chem, 280: 30360-
30637 (2005) 
Le but de ce deuxième article était d’établir si la matrice extracellulaire induit une 
activité transcriptionnelle de NF-κB et d’étudier si l’activité de ce facteur de transcription est 
impliquée dans un ou plusieurs effets de la matrice 804G-ECM sur la cellule bêta de rat. Nous 
avons observé qu’une heure d’exposition des cellules bêta à la matrice 804G-ECM induit une 
augmentation significative de la translocation nucléaire et de l’activité de liaison à l’ADN de la 
sous-unité p65 de NF-κB (appelée NF-κB par la suite) par rapport au substrat contrôle pLL. 
L’activité de liaison à l’ADN de NF-κB induite par la matrice 804G-ECM commence à augmenter 
après 30 minutes de culture, est maximale entre 1h-2h, et diminue après 4h de culture. 
L’expression de deux gènes-cible de NF-κB (IκBα et NF-κB1 (p105)) induite par la matrice 
804G-ECM en fonction du temps a été mesurée par RT-PCR quantitative. La surexpression de 
ces deux gènes est maximale après 4h d’exposition à la matrice 804G-ECM. Cette 
surexpression semble être transitoire, car elle disparaît après 24h de culture. Le schéma 
temporel de l’expression des deux gènes-cible de NF-κB induite par la matrice 804G-ECM 
corrèle donc avec celui de l’augmentation de son activité transcriptionnelle induite par cette 
matrice extracellulaire.  La surexpression de la protéine IκBα induite par la matrice 804G-ECM 
a été confirmée par transfert Western (Western blotting). De plus, nous avons observé que la 
translocation nucléaire et l’activité de liaison à l’ADN de NF-κB induites par la cytokine IL-1β 
(2ng/ml, 20 minutes) sont nettement plus intenses que celles induites par la matrice 804G-ECM. 
Ces résultats impliquent que la matrice 804-ECM induit une activité transcriptionnelle transitoire 
et modérée (par rapport à la cytokine IL-1β) de NF-κB.  
Afin d’étudier les effets de l’activité de NF-κB induite par la matrice 804G-ECM sur la 
cellule bêta, deux approches différentes ont été utilisées : d’une part, un inhibiteur 
pharmacologique empêchant la phosphorylation et la dégradation d’IκBα (Bay 11-7082) et 
d’autre part un adénovirus surexprimant IκBα sous la forme d’une protéine mutante non-
dégradable. Cette dernière approche n’a pas été utilisée pour déterminer l’effet de l’inhibition de 
l’activité de NF-κB sur la sécrétion d’insuline, car nous avons constaté que le virus contrôle 
inhibe de façon non-spécifique la sécrétion d’insuline induite par le glucose dans notre système 
(cellules bêta de rat triées par FACS). Contrairement à notre hypothèse de base, l’inhibition de 
l’activité de NF-κB par les deux approches sus-mentionnées n’a aucun effet sur la survie des 
cellules, quelque soit le substrat de culture (le contrôle pLL ou la matrice 804G-ECM). En 
revanche, l’inhibition de NF-κB réduit de manière significative l’étalement des cellules et 
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empêche l’organisation du cytosquelette d’actine induite par la matrice 804G-ECM. Finalement, 
l’inhibiteur pharmacologique Bay 11-7082 réduit de manière dose-dépendante la sécrétion 
d’insuline stimulée par le glucose, suggérant qu’une activité modérée de NF-κB est 
indispensable à la sécrétion d’insuline. Du fait que NF-κB est impliqué dans les effets de la 
matrice 804G-ECM sur le cytosquelette d’actine et sur l’expression de gènes (IκBα), notre 
hypothèse pour les futures expériences est que ces deux paramètres sont impliqués dans le 
rôle de NF-κB dans la sécrétion d’insuline.  
Comme la matrice 804G-ECM active les voies de signalisation PI3K-Akt et MAPK 
ERK1/2, leur rôle dans l’activation de NF-κB par la matrice 804G-ECM a été étudié. L’effet des 
inhibiteurs de PI3K (LY294002) et de MEK1 (PD98059) sur l’activité de liaison à l’ADN de NF-
κB ainsi que sur la surexpression de l’ARNm d’IκBα induite par la matrice 804G-ECM a été 
analysé. Nous avons observé que l’inhibiteur de la voie d’ERK1/2 réduit l’activité de liaison à 
l’ADN de NF-κB et la surexpression d’IκBα induites par la matrice 804G-ECM, tandis que 
l’inhibiteur de PI3K n’affecte aucun de ces effets induits par cette matrice extracellulaire. La voie 
MAPK ERK1/2 pourrait donc jouer un rôle important dans l’activation de NF-κB par la matrice 
804G-ECM. Néanmoins, il reste à éclaircir pourquoi l’inhibition de NF-κB et l’inhibition de la voie 
d’ERK1/2 n’ont pas les mêmes effets phénotypiques sur la cellule bêta. En effet, l’inhibition 
d’ERK1/2 inhibe l’effet pro-survie de la matrice 804G-ECM, tandis que l’inhibition de NF-kB 
n’affecte pas la survie de la cellule bêta. Nous proposons qu’un effecteur d’ERK1/2 autre que 
NF-κB pourrait être impliqué dans les effets de cette voie des MAPK sur la cellule bêta, menant 
à une divergence de ces deux voies de signalisation.  
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4. Conclusion 
Nos résultats montrent que la matrice extracellulaire a un impact important sur la 
cellule bêta : elle améliore sa survie et elle induit l’activation des voies de signalisation 
impliquant les kinases FAK, PI3K, Akt et ERK1/2. De plus, elle active le facteur de transcription 
NF-κB, menant à la surexpression d’IκBα. Nous avons vu que les voies de signalisation 
intracellulaires PI3K-Akt et ERK1/2 sont les deux impliquées dans l’effet anti-apoptotique de la 
matrice 804G-ECM à court terme, tandis que seulement la voie ERK1/2 joue un rôle dans l’effet 
anti-apoptotique de cette matrice à long terme. De plus, ERK1/2 semble être impliquée dans 
l’activation de NF-κB induite par la matrice 804G-ECM. Contrairement à l’hypothèse émise au 
début de la deuxième partie de cette thèse, le facteur de transcription NF-κB ne semble pas 
être responsable de l’effet anti-apoptotique de la matrice 804G-ECM. Par contre, NF-κB semble 
être impliqué dans l’organisation du cytosquelette d’actine et l’étalement des cellules induits par 
la matrice 804G-ECM, ainsi que dans la sécrétion d’insuline stimulée par le glucose. Ce dernier 
résultat est renforcé par une étude récente (par Norlin et al.) effectuée sur des souris 
transgéniques surexprimant un mutant non-dégradable d’IκBα (qui inhibe NF-κB) 
spécifiquement dans les cellules bêta. Ces souris transgéniques ont une sécrétion d’insuline en 
réponse au glucose défectueuse et une expression des gènes impliqués dans l’exocytose de 
l’insuline perturbée. Ces travaux, en plus de nos résultats, suggèrent fortement qu’une activité 
modérée de NF-κB est indispensable à la fonction de la cellule bêta pancréatique. Il est 
intéressant de constater que le rôle positif de NF-κB dans la cellule bêta que nous proposons ici 
diffère considérablement du rôle délétère de NF-κB (dans le contexte d’une activation induite 
par des cytokines) rapporté par un certain nombre de travaux. Nous proposons que l’activité de 
NF-κB induite par la matrice 804G-ECM ou par les cytokines diffère aussi bien par son intensité 
que par sa durée. D’autre part, il est possible que la matrice 804G-ECM et les cytokines 
induisent une phosphorylation de la sous-unité p65 sur des sites différents, ce qui pourrait 
mener à des effets biologiques différents. Ces hypothèses constituent les bases de nos futurs 
travaux. En effet, il nous semble primordial de mieux comprendre les mécanismes impliqués 
dans la régulation de l’activité de NF-κB menant à des conséquences biologiques aussi 
contrastées, suivant le contexte de son activation. La prochaine étape serait d’inhiber 
spécifiquement certains aspects de son activité (menant à ses effets néfastes), sans pour 
autant affecter ses effets positifs sur la fonction de la cellule bêta pancréatique.  
Finalement, nos résultats suggèrent que la matrice 804G-ECM induit une activité des 
kinases (FAK, PI3K, Akt et ERK1/2) et du facteur de transcription NF-κB indispensable au 
maintien de la fonction et de la survie de la cellule bêta pancréatique. Ainsi, la présence d’une 
matrice extracellulaire adéquate pourrait jouer un rôle important in vivo dans la protection des 
cellules bêta contre les effets délétères induits par des stimuli impliqués dans la pathogénèse 
du diabète.  
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PART I: GENERAL INTRODUCTION 
1. Regulation of pancreatic beta cell mass and diabetes 
1.1. Structure and function of the pancreatic islet of Langerhans 
The pancreatic islet of Langerhans consists of four main cell types that secrete 
biologically active hormones into the circulation. The islets are composed of insulin-producing 
beta cells (60-80%) and of other endocrine cell types secreting glucagon (alpha cell, 25%), 
somatostatin (delta cell, 2-8%), and pancreatic polypeptide (PP cell, 1-2%). The distribution of 
these endocrine cells is non-random, with a core of beta cells, surrounded by non-beta cells. 
The islet of Langerhans is highly vascularized and innervated. In addition, endocrine cells are in 
contact with extracellular matrix (ECM) molecules contained in the surrounding basement 
membrane (1; 2), ( Fig. 1).  
One of the main functions of the islet hormones is to maintain a proper level of blood 
glucose. Insulin, which is secreted in response to high blood glucose, primarily functions to 
trigger glucose/energy storage for later use, by stimulating liver and muscle to synthesize 
glycogen and protein, and adipose cells to synthesize fat (triacylglycerols). Glucagon, which is 
secreted in response to low blood glucose, has essentially the opposite effect: it stimulates the 
release of glucose and of fatty acids. There is a complex interaction between the different islet 
cell types, which determines the secretory activity of the islet.  
The principal characteristic of beta cells is that they function as “fuel-sensors” capable 
of adapting the rate of insulin secretion to the variations in plasma levels of glucose (the most 
important controller of insulin secretion) and other energetic substrates (amino acids, fatty acids, 
and ketone bodies). Furthermore, several hormones and neurotransmitters also exert control on 
beta cell function acting as potentiators or inhibitors of glucose-stimulated insulin secretion. 
Insulin is stored in vesicles and is released by exocytosis, a multistage process involving 
transport of vesicles to the plasma membrane, their docking, priming and finally their fusion with 
the plasma membrane (3).  
As described above, beta cells form the core of the islet, a structure favoring 
intercellular contacts. Interestingly, it has been reported that homologous contacts between beta 
cells promote secretion of insulin by individual cells (4). This effect seems to be specific, as the 
heterologous contacts of beta cells with non-beta cells do not increase insulin secretion (4). 
Furthermore, as it will be discussed more in detail below, ECM is also able to increase secretion 
of individual pancreatic beta cells in response to glucose (5). 
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Fig.1: A pancreatic islet of Langerhans, with a core composed of beta cells (blue spheres), 
surrounded by non-beta cells (yellow spheres). The islet is richly vascularized and innervated, and the 
cells are in contact with an ECM that is presumably secreted by surrounding endothelial cells. 
Reproduced and adapted from reference (6).   
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1.2. The pancreatic beta cell and diabetes 
1.2.1. Pancreatic beta cell mass and diabetes 
The islet cell mass is dynamic, and is able to adjust to meet changing metabolic 
demands. The homeostatic control of beta cell mass in normal and pathological conditions is 
based on the balance of proliferation, differentiation/neogenesis, regulation of size and death of 
the insulin-secreting cells (7; 8). In particular, beta cell functional mass in the adult is plastic. 
Pregnancy and obesity are two typical situations that require dramatic adaptations (increase) in 
the beta cell mass to compensate for changing insulin demands. Failure of the beta cell mass to 
adapt to the changing needs is believed to contribute to the development of diabetes (7-9).  
Diabetes is a chronic disease with severe secondary complications, reaching epidemic 
proportions (for type 2 diabetes) and for which there is yet no cure. The two major forms of 
diabetes mellitus are type 1 and type 2. Type 1 diabetes is characterized by autoimmune 
destruction of the insulin-producing pancreatic beta cells, which typically results in the near total 
loss of these cells (10). Type 2 diabetes is characterized by insulin resistance and defective 
insulin secretion (11). It has been debated whether this defective insulin secretion is due to 
reduced beta cell mass or to an intrinsic secretory defect or both. Increasing evidence indicates 
that decreased functional beta cell mass is the hallmark of both type 1 and type 2 diabetes, 
underlying insulin insufficiency in both conditions, albeit to different degrees (12). However, 
studies performed on pancreatectomized rats have shown that large pancreatectomies (at least 
50%) are required to induce mild/moderate hyperglycemia and/or insulin secretory defects, 
while only almost complete pancreatectomies lead to overt diabetes with severe insulin 
deficiencies (reviewed by (13)). Therefore, the decreased beta cell mass cannot be the only 
cause leading to insufficient insulin secretion to maintain normoglycemia. The defects in insulin 
secretion that characterize type 2 diabetes are thus likely to be a result of the combination of 
both cellular dysfunction and a reduction in beta cell mass (8; 11).  
The importance of a proper regulation of the beta cell mass to maintain normoglycemia 
and thus to avoid the onset of type 2 diabetes is quite a novel concept. Furthermore, the 
mechanisms involved in the control of beta cell mass are still poorly understood. Nevertheless, 
as discussed below, cell death by apoptosis is now generally accepted to be a major 
mechanism involved in the decrease of beta cell mass that contributes to the pathogenesis of 
diabetes.  
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1.2.2. Apoptosis and diabetes 
Two distinct modes of cell death, apoptosis or necrosis, can be distinguished because 
of differences in morphologic, biochemical and molecular changes. Apoptosis is a well-
characterized form of cell death that involves condensation and fragmentation of nuclei, 
internucleosomal DNA cleavage and randomization of the distribution of phosphatidyl serine 
(PS) between the inner and outer leaflets of the plasma membrane (14; 15). This form of 
physiological cell death differs from necrosis, in which cells swell and disintegrate in an 
unordered manner, eventually leading to the destruction of the cellular organelles and finally 
rupture of the plasma membrane and leakage of the cell content (16). 
The pancreatic beta cell is thought to be particularly sensitive to apoptotic stimuli due to 
the inherent features of the specialized beta cell phenotype. It has been proposed that beta cell 
differentiation signals (such as Pdx-1), glucose metabolism, calcium handling as well as 
regulation of naturally occurring inhibitors of cytokine signaling contribute to sensitize the beta 
cell to apoptotic stimuli (17). Accumulating evidence suggests that apoptosis is the main form of 
beta cell death in both types of diabetes. It is widely accepted that apoptosis is likely to be the 
main form of beta cell death in type 1 diabetes (18; 19). It has been debated whether the 
reduced beta cell mass in type 2 diabetes is due to an increased loss of beta cells and/or to 
inadequate beta cell expansion to compensate for insulin resistance and/or beta cell 
dysfunction. Now, there is increasing evidence indicating that decreased beta cell mass in 
obesity-linked type 2 diabetes is above all caused by an increase in beta cell apoptosis, and that 
altered rates of beta cell replication or neogenesis play minor roles (9). It has been shown that 
elevated glucose concentrations directly induce beta cell apoptosis in human islets (20) and in 
cultured islets from diabetes-prone Psammomys obesus, a rodent with a natural tendency 
towards diet-induced type 2 diabetes (21). Cell apoptosis has also been shown to be the 
mechanism leading to beta cell loss in the Zucker diabetic fatty (ZDF) rat, another model of type 
2 diabetes. In ZDF rats, hyperglycemia is detected when the expansion of the beta cells no 
longer compensates the degree of insulin resistance and beta cell apoptosis (22; 23). The 
involvement of apoptosis in type 2 diabetes has been reinforced by two recent studies 
performed with human autopsy specimens (24; 25). In particular, Butler and colleagues (25) 
have reported a deficit in relative beta cell volume in type 2 diabetic patients compared to non-
diabetic weight-matched controls and an increased frequency of beta cell apoptosis. It was 
observed that the frequency of beta cell regeneration is very low, and that it may not contribute 
significantly to beta cell mass in humans (25). However, these data are difficult to interpret since 
they are “snapshots” taken at the time of autopsy. Furthermore, apoptotic cells are rapidly 
cleared from tissues in vivo, rendering an accurate quantification of apoptosis difficult to perform 
in vivo (26). In addition, as these studies were performed on autopsy specimens, and 
prospective studies are not possible to perform in humans (because of lack of non-invasive 
means to measure the beta cell mass), it is still unknown what the beta cell mass was before 
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the onset of diabetes. Consequently, it remains to be established whether apoptosis is one of 
the triggers leading to the onset of diabetes, or whether it occurs at the late stages of the 
disease in humans.  
Which factors could contribute to the increased rate of apoptosis observed in type 2 
diabetes? It has been proposed that cytokines, lipids (lipotoxicity), glucose (glucotoxicity), as 
well as a synergic combination of glucose and lipids (glucolipotoxicity) are the main stimuli 
leading to beta cell apoptosis in the context of type 2 diabetes (12; 27-30). In addition, islet 
amyloid polypeptide (IAPP) and subsequent amyloid fibril formation (28), ER-stress (31), 
inadequate levels of circulating growth factors (8; 31) and signaling factors from the adipocytes 
are other possible causes for the decreased beta cell mass in type 2 diabetes (12).  
Obesity is a typical condition that leads to an insulin-resistant condition. This increased 
insulin demand is often compensated by an increase in beta cell mass. However, in some cases 
(about one-third of obese subjects), the compensatory beta cell mass and/or function is 
inadequate (9). It has been proposed that although there may be an initial compensatory 
increase in beta cell mass, the onset of type 2 diabetes in both human and rodent models is 
accompanied by a progressive decrease in beta cell mass, presumably due to increased 
circulating glucose and/or free fatty acid concentrations (8; 32). This beta cell loss arises from a 
marked increase in beta cell apoptosis, which far outweighs modest increases in beta cell 
replication and neogenesis (8; 25). This loss of beta cell mass may subsequently induce further 
dysfunction of the residual beta cells, possibly due to overstimulation of these beta cells or 
chronic hyperglycemia and/or hyperlipidemia (12), thus further worsening the condition of the 
patient. Eventually, in the most severe cases, a “point of no return” due to the loss of beta cell 
mass can be reached and a permanent type 2 diabetic state arises that must ultimately be 
treated with insulin replacement therapy. Therefore, maintaining beta cell survival and adequate 
beta cell mass appears to be one potential strategy to prevent and/or treat type 2 diabetes (9). 
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2. The Extracellular Matrix (ECM) 
2.1. General introduction on extracellular matrix (ECM) 
Until two decades ago, the ECM was viewed as a passive and inert scaffold stabilizing 
the physical structure of tissues (33). Indeed, attachment of cells to ECM is crucial for 
maintenance of tissue integrity. However, it has recently become clear that ECM is an extremely 
dynamic structure and that it is an essential regulator of primordial biological functions. 
Engagement of cells with ECM proteins is crucial for various biological processes, including cell 
adhesion, spreading, proliferation, differentiation, apoptosis, and gene induction, contributing to 
maintenance of tissue integrity, embryogenesis, wound healing, and the metastasis of tumour 
cells (34-37). The importance of the ECM is underscored by the existence of many genetic and 
autoimmune diseases that perturb ECM structure or the adhesion of cells to the ECM in humans 
(38). ECM remodeling is involved in many diseases including the development and progression 
of malignant tumours (39) and diabetic nephropathy and microangiopathy (40).  
There are two main types of ECM in the tissues: the basal lamina contained in the 
basement membrane, a condensed layer that is formed adjacent to epithelial cells, and the 
interstitial matrix that is present in connective tissues (Fig. 2). Basement membranes cover the 
basal surfaces of virtually all epithelia, surround the surfaces of muscle fibers, and ensheath 
nerves. Basement membranes are comprised of two, sometimes three distinct layers. Two 
layers are comprised in the basal lamina, which is produced by epithelial cells: lamina lucida 
adjacent to the plasma membrane of cells and lamina densa just below. In some cases there is 
a third layer (reticular lamina) that connects the basal lamina to the connective tissue. The basal 
lamina contains a variety of adhesive glycoproteins, including collagen IV, laminin, fibronectin 
and proteoglycans (33; 41; 42). Interaction of these ECM proteins with the cells is mediated by 
transmembrane receptors, of which the integrins constitute the most important class.   
                             
Fig. 2: The basal lamina and the connective tissue underlying an epithelial cell sheet. 
Reproduced and modified from reference (42). 
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2.2. ECM receptors: Integrins 
Cell adhesion to ECM is mainly mediated by heterodimeric transmembrane receptors 
belonging to the integrin family (34). Integrins are a part of a bridge between ECM and 
cytoskeletal proteins at sites of tight juxtaposition between the cell surface and ECM (43). These 
sites of adhesion include focal adhesions (also called focal contacts), fibrillar adhesions and 
focal complexes (44). Integrins are heterodimers that include α and β subunits with each 
subunit having an extracellular domain, a single transmembrane region, and (other than β4) a 
rather short cytoplasmic domain associating with the actin cytoskeleton and affiliated proteins 
(34),  (Fig. 3).  
                        
Fig. 3: Schematic representation of a cell-ECM adhesion site. Integrins connect ECM with the 
cell interior, where they are in contact with adaptor/signaling proteins and the actin cytoskeleton 
(reproduced from reference (45)). 
 
The vertebrate integrin family includes at least 18 distinct α subunits and 8 or more β 
subunits; these can associate to form over 20 distinct integrin heterodimers (34). The ligand 
binding abilities of the integrin heterodimers are determined by the α/β pairings (Fig. 4). The 
usual ligands for integrins are the ECM proteins collagen, laminin, vitronectin, and fibronectin 
(33). Some integrins, such as α5β1, the “classic” fibronectin receptor, interact only with a single 
ECM protein; however, more commonly, a given integrin will recognize several distinct ECM 
proteins (34).  Genes for the β subunits and for all but four of the α subunits have been knocked 
out and each phenotype is distinct, reflecting the different roles of the various integrins (46). 
Numerous and various biological defects have been observed in these knock-out mice, 
including peri-implantation, embryonic and perinatal lethality, major developmental defects and 
abnormal basement membrane assembly (46). However, tissue-specific and/or conditional 
integrin knock-out models have been under-exploited as tools to evaluate further the role of 
specific integrins in a given cell-type or tissue function in the adult.  
Integrin occupancy and clustering initiate not only adhesion and cytoskeletal 
organization via direct physical interactions of integrins with other proteins, but also activate 
many intracellular pathways that regulate cell growth, migration, polarity, survival, differentiation 
and gene expression (36). This signaling from engaged integrins to the cell interior is an 
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important aspect of outside-in signaling. Conversely, the capacity of integrins to bind their 
ligands is regulated by cellular signaling mechanisms through a process often called inside-out 
signaling (44). Integrins are therefore signaling receptors that transmit information in both 
directions across the plasma membrane. In addition, integrins can act as essential cofactors for 
growth factor signaling. Indeed, in many cases growth factor signaling does not occur unless 
cells are adherent to ECM (47; 48).  
The β1 integrins are expressed on most epithelial cells, where they bind collagen, 
fibronectin, laminin-1 and laminin-5. They have been suggested to play important roles in 
morphogenesis (49; 50), regulation of proliferation (51) and cell survival (52; 53). Within islets, it 
has been shown that the laminin-5 receptors α3β1 and α6β1 integrins are expressed on beta 
cells (5; 54).  
 
                
Fig. 4: The integrin receptor family. This figure shows the mammalian integrin subunits and the 
binding specificity of the given α/β heterodimer. Reproduced from reference (34).  
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2.3. ECM and cell survival 
2.3.1. Anoikis 
Apoptosis can be induced by numerous triggers, one of them being the loss of cell 
anchorage. Anoikis is a Greek word meaning “homelessness” (55) and is defined as apoptosis 
that is induced by inadequate or absent cell-ECM interactions (56). The role of cell anchorage 
for cell survival has been demonstrated and studied in several cell types, including the 
pancreatic islet cell (57; 58). It has been reported that basement membrane ECM, but not 
fibronectin or collagen suppresses apoptosis of mammary epithelial cells (59), indicating that for 
a given cell type only specific ECM components can promote cell survival. This specificity for a 
given ECM component has since been confirmed for different cell types, including for the 
pancreatic beta cell (60). 
Signaling pathways involved in apoptosis usually converge on a common machinery of 
cell destruction that is activated by a family of cysteine proteases: caspases (15; 61). Caspases 
are activated during most forms of apoptosis. They are divided into two major subgroups, the 
initiator caspases and the executioner (or effector) caspases. The initiator caspases (including 
caspases -2, -8, -9 and -10) contain long prodomains and interact with death domain (DD)-
containing adaptor proteins, bringing them into close proximity with death receptors. The 
executioner caspases (which include caspases -3, -6 and -7) mainly function by proteolytic 
fragmentation of structural and functional protein substrates, leading to dismantling of the cell 
architecture as well as the initiation of DNA-fragmentation, the end-point of the apoptotic 
process.  
As in most apoptotic pathways, anoikis is thought to be mediated by the activation of 
caspases. Caspase-8 activity has been shown to be induced by cell detachment (62-64). One of 
the major questions in anoikis research is how the caspase cascade is initially activated by 
simple detachment of cells from the ECM (56). Recently, it has been proposed that activation of 
Fas signaling complex leading to activation of caspase-8 plays an important role during anoikis 
(62-64). Another possible mechanism leading to activation of caspase-8 during anoikis is 
integrin-mediated death (IMD) (65). This is a mechanism whereby unligated integrins in cells 
adhering to substrates devoid of appropriate ECM ligands are proposed to directly recruit 
caspase-8 to the plasma membrane independent of death receptors, leading to the activation of 
the cascade caspase and ultimately to anoikis (65; 66). In summary, it appears that caspase-8 
activation can be induced by cell detachment from ECM as well as by interaction of the cell with 
inappropriate ECM. 
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2.3.2. Pro-survival signaling and integrins 
It was first proposed in 1992 that cells require survival signals to avoid their 
engagement into apoptosis (67). This concept has been reinforced since by numerous 
observations assessing pro-survival effects of different proteins such as growth factors and 
hormones. How do adequate ECM-cell interactions promote cell survival? The involvement of 
integrins in the pro-survival signaling emanating from the ECM is now well established (66).  
Meredith et al. were the first to demonstrate that contact of cells with anti-β1 integrin antibodies 
inhibits apoptosis induced by the absence of ECM (53). Many groups have since reported the 
importance of β1 integrin subunits in mediating survival signals emanating from the basement 
membrane (which is a complex ECM composed of laminin, collagen IV, nidogen and perlecan) 
in mammary epithelial cells (52; 59; 68; 69). Interestingly, it was observed that only normal but 
not tumor mammary epithelial cells are dependent on β1 integrin signaling for survival (52). 
Different α integrin subunits have also been shown to play a role in mediating ECM-dependent 
survival (70-72), including the α6 integrin subunit (69). It appears that different cell types have 
their own favored ECM for protection from apoptosis, depending on the repertoire of integrins 
expressed on their cell surface (73). Transgenic mice carrying a targeted deletion of the C-
terminal segment of the β1 integrin subunit cytoplasmic domain have been generated (74). 
Embryonic fibroblasts derived from the homozygotes carrying this deletion display disrupted 
fibronectin-induced survival, thus supporting the concept that integrins play an essential role in 
pro-survival signaling emanating from ECM (74; 75).    
In summary, the concept that ligation of integrins to cognate ECM ligand can induce 
pro-survival signaling in normal cells is now generally accepted. In the next section, the current 
state of knowledge on the role of ECM and integrins in the context of beta cell survival and 
function is discussed.  
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2.4. ECM and the pancreatic beta cell 
Studies assessing the impact of ECM on beta cell development and function are limited 
in number but provide important evidence that it can influence many aspects of beta cell biology 
including survival, proliferation, differentiation and insulin secretion. ECM is thus considered as 
one important component of the islet microenvironment. Islet basement membrane has been 
reported to be composed of collagen IV and laminin (2). Within islets, the laminin-5 receptors 
α3β1 and α6β1 integrins (76; 77) are expressed in pancreatic adult rat beta cells (5; 54). As 
described above, both type 1 and type 2 diabetes are characterized by reduced islet beta cell 
mass and impaired beta cell function. We will therefore go deeper into what is known about the 
effects of the ECM on the survival and the function of the pancreatic beta cell.  
 
2.4.1. ECM and pancreatic beta cell survival 
Transplantation of islets of Langerhans represents a viable therapeutic approach for 
the treatment of type 1 diabetes. Unfortunately, several problems can occur after allogeneic islet 
transplantation: primary non-function, rejection, the recurrence of autoimmune disease, as well 
as poor rate of survival of insulin-secreting cells before and after transplantation (78). In 
addition, the immunosuppression treatment following the transplantation process may itself 
impact negatively on the function and survival of transplanted islets.  
The causes of this poor rate of survival are not well understood. The procedure leading 
to pancreatic beta cell isolation involves disruption of cell-cell and cell-ECM contacts (1; 58; 79). 
It is suspected that the loss of ECM during the isolation process leading to cell death by anoikis 
might be one of the causes for the poor survival rate of the transplanted islets (1; 57; 58; 79). 
The beneficial effect of ECM on the survival of islet cells has been suggested by several groups 
(57; 58; 60). There is evidence indicating that ligation of integrins to proper ECM proteins is 
necessary for survival of pancreatic beta cells in culture (60). However, signaling pathways 
involved in this improved survival induced by the contact of islet cells with the ECM have not yet 
been explored. 
 
2.4.2. ECM and pancreatic beta cell function 
Beta cells isolated from islets of Langerhans display altered glucose-induced insulin 
secretion when maintained for several days in culture. Several groups have shown that long-
term culture of islet cells on different ECM (fibronectin, collagen, or bovine corneal endothelial 
cell matrix (BCEM)) improves their secretory capabilities compared to culture in suspension or 
on control substrates (non-coated plastic dishes or poly-L-lysine (pLL)-coated dishes) (58; 80-
83). Furthermore, it has been observed that incompletely digested, ECM-embedded islets 
display improved insulin secretion in response to glucose compared to well digested islets 
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(without ECM), suggesting that appropriate ECM-islets interactions are required for optimal islet 
function (57).  
The 804G extracellular matrix (804G-ECM, an ECM produced by the rat bladder 
carcinoma cell line 804G) is rich in laminin-5 (epiligrin) and also contains fibronectin (84-86). It 
has been reported that the 804G-ECM is able to induce attachment and spreading of many 
epithelial cell types, including pancreatic beta cells (85; 87).  Short-term culture (a few hours) on 
804G-ECM  improves glucose-stimulated insulin secretion of isolated beta cells compared to 
control condition (beta cells grown on plastic dishes or glass) (5). It has been suggested that the 
effects of 804G-ECM on beta cell spreading is mediated, at least in part, by engagement of 
laminin-5 to α6β1 integrins (5). However, the downstream signaling pathways involved in the 
effects of the 804G-ECM on the beta cell function have not yet been identified. 
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3. Summary and general aims of the thesis project 
It has recently emerged that cell death by apoptosis is involved in the development of 
not only type 1 diabetes, but also of type 2 diabetes, although to different extents. Therefore, 
studies aimed at understanding the mechanisms controlling pancreatic beta cell survival are an 
important area in diabetes research. It has been shown in numerous cell types that ligation of 
integrins to cognate ECM ligand is important for cell survival. Furthermore, several studies have 
suggested that ECM is an important factor in maintaining survival of pancreatic beta cells as 
well. However, the mechanisms involved in the pro-survival effects of the ECM on the 
pancreatic beta cell were completely unexplored at the beginning of this thesis project. 
As introduced in the next part, a number of reports have shown that engaged integrins 
can activate several signaling pathways that are able to mediate its pro-survival effects. These 
signaling pathways involve the kinases Focal Adhesion kinase (FAK), phosphatidylinositol 3-
kinase (PI3K), protein kinase B (PKB/Akt, hereafter called Akt), and the Mitogen-activated 
protein (MAP) kinase ERK. However, the relevance of a given signaling molecule in mediating 
the pro-survival signaling induced by ECM appears to be cell – type specific. It was therefore 
asked which of these intracellular signaling pathways might be involved in the effects of ECM on 
pancreatic beta cell survival.  
In our laboratory, it has been shown that primary rat pancreatic beta cells express the 
laminin-5 receptors α3β1 and α6β1 integrins (5; 54).  Furthermore, it has been found that the 
804G-ECM – a laminin 5-rich ECM - induces spreading and improves glucose-stimulated insulin 
secretion of primary rat pancreatic beta cells (5), indicating that this ECM most probably 
interacts with integrins expressed on the rat beta cells. Therefore, it appeared that the 804G-
ECM should be an appropriate model to study the effect of the ECM on primary pancreatic beta 
cell survival and the mechanisms involved. In addition, we chose to study primary cells and not 
cell lines, as the pattern of expression of integrins as well as the dependence of the cell on the 
presence of a cognate ECM for survival can differ considerably between primary cells and cell 
lines (transformed or not). Therefore, the general aims of this thesis work were to answer the 
following questions: 
1) Does the 804G-ECM improve primary pancreatic beta cell survival? 
2) Is the 804G-ECM able to activate signaling pathways and if so, are they involved in 
the pro-survival effect of the 804G-ECM? 
3) Is the 804G-ECM able to induce a gene expression program leading to altered 
function and/or survival of the pancreatic beta cell? 
This thesis is composed by two reports (“ Paper 1” and “Paper 2”) accepted for 
publication in peer-reviewed journals. The next part of this thesis (Part II, Paper 1) focuses on 
the two first points 1) and 2), while Part III (Paper 2) is mainly devoted to the point 3). 
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PART II (PAPER 1): 
ACTIVATION OF KINASES BY ECM AND PANCREATIC BETA CELL SURVIVAL 
1. Introduction to Part II (Paper 1) 
1.1. Pro-survival signaling from ECM : an overview 
Engagement of integrins by cognate extracellular ligands leads to activation of several 
pathways involving an astonishing number of signaling and/or adaptor proteins ((36; 88), Fig. 5 
and Fig. 7), that control many aspects of cellular responses to growth and survival factors. An 
early insight into a possible signaling via integrins was provided by the observation that integrin-
mediated adhesion and/or clustering of integrins lead to enhanced tyrosine phosphorylation 
(89). It soon became clear that adhesion was activating a cytoplasmic non-receptor tyrosine 
kinase now known as FAK (90; 91). In addition to FAK, integrin binding is thought to be involved 
in the regulation of activity of a multitude of signaling molecules, including PI3K, protein kinase 
B (PKB/Akt) and the mitogen activated protein (MAP) kinase  ERK (92-94). These proteins have 
all been implicated in integrin-mediated protection of cells against various apoptotic stimuli and 
in control of gene expression. In the next sections, we will go deeper into what is known about 
these proteins in the context of ECM-induced cell survival. 
 
            
Fig. 5: General outline of integrin signaling and its biological outcomes. This figure shows some 
major signal transduction pathways and their key players that lead to some major effects of ECM-integrin 
interactions on cell survival, proliferation, motility and cytoskeletal organization (reproduced and modified 
from reference (34)). 
Basement 
membrane 
            Integrins  → 
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1.2. Focal Adhesion kinase (FAK)  
1.2.1. Activation of FAK by integrins 
The cloning and characterization of FAK were reported in 1992 (90; 91). FAK is a non-
receptor tyrosine kinase, which consists of a central tyrosine kinase (catalytic) domain flanked 
by large N- and C-terminal non-catalytic domains (91; 95). The N-terminal region contains a 
FERM domain that is thought to mediate interactions of FAK with proteins associated with the 
plasma membrane. The C-terminal domain of FAK, designated “FAT”, for Focal Adhesion 
Targeting, is essential for localizing FAK to integrin-adhesion sites (92; 95). Finally, two proline-
rich motifs (PR1 and PR2) are located between the kinase and the FAT domains (Fig. 6). These 
motifs mediate interactions with Src-homology 3 (SH3)-domain-containing proteins. These 
functional and structural characteristics of FAK have led to its definition as a “scaffolding protein 
with kinase activity”. 
FAK is localized in focal adhesions (90; 91), and is widely expressed in different tissues 
(90). The first indication that FAK is a signaling protein was provided by the demonstration that it 
is phosphorylated on tyrosine residues when cells are plated on the ECM molecule fibronectin 
(90; 96; 97). It was subsequently reported that other ECM proteins (laminin, collagen IV and 
vitronectin) also induce tyrosine phosphorylation of FAK (89; 98). In addition, the overall 
phenotype of the FAK knock-out mouse is similar to the fibronectin knock-out mouse (99; 100), 
reinforcing the concept that  FAK is implicated in signaling induced by engagement of cells to 
ECM. 
Upon integrin ligation and clustering, FAK is phosphorylated at Tyr-397 as well as at 
several additional sites within the kinase and the C-terminal domains (101-103) (Fig. 6). Tyr-397 
is a major site of FAK auto-phosphorylation both in vivo and in vitro (104), and phosphorylation 
at Tyr-397 correlates with increased catalytic activity of FAK (101; 105). Therefore, 
phosphorylation of FAK at Tyr-397 is considered as a hallmark of integrin signaling.  
              
Fig. 6: Linear structure of FAK showing its major domains, motifs and sites of tyrosine 
phosphorylation. The 4.1/JEF domain is also called FERM domain, and is thought to mediate interactions 
with proteins associated with the plasma membrane. The two proline-rich motifs mediate interactions with 
SH3-domain-containing proteins. Reproduced and adapted from reference (95).  
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1.2.2. FAK and downstream signaling 
FAK interacts with a number of cytoskeletal and signaling proteins, including Src, PI3K, 
Grb2, p130Cas and paxillin (95; 106), (Fig. 7). The finding that FAK is phosphorylated when cells 
are plated on fibronectin led to the hypothesis that FAK might transmit a signal within the cell 
through association with, and phosphorylation of, proteins that contain Src homology 2 (SH2) 
domains (90). The SH2 domain is a conserved region of about 100 amino acids, which 
specifically and selectively binds phosphotyrosyl proteins and promotes intra- and 
intermolecular protein-protein interactions (107). Indeed, it was subsequently demonstrated that 
phosphorylation of residue Tyr-397 enables the recruitment of several signaling proteins 
harboring SH2 domains. One such protein is the p85 kDa subunit of PI3K (108-110), which 
recruitment and activation leads to the activation of the kinase Akt. Another example is Src 
kinase (104). Src kinase then mediates phosphorylation on other sites on FAK, creating 
additional SH2-binding sites (101; 102). One such site is the phosphorylated residue Tyr-925 
that can bind the SH2-domain of Grb2, leading to the activation of the MAP kinase ERK 
cascade (102; 111). Activation of these pathways involving the signaling proteins PI3K-Akt and 
ERK by engaged integrins is one of the main themas of this thesis project, and this topic is 
described more in detail below. 
 
 ECM 
 
 Actin    
Fig. 7: Signaling complexes associated with, or activated by, integrins. FAK
additional signaling molecules, creating a complex signaling network that is intimate
actin cytoskeleton network. Reproduced and adapted from reference (88).  
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1.2.3. Functions of FAK in the control of  spreading and survival of cells 
It is now acknowledged that integrin-induced FAK activation is involved in the 
regulation of cell proliferation (112-114), cell spreading/motility and cell survival (92; 93; 95).  
Fibroblasts derived from FAK knock-out mice display deficient integrin-triggered 
spreading and migration (100). By contrast, overexpression of FAK either in CHO cells (115) or 
in FAK-deficient fibroblasts (116; 117) leads to increased spreading and/or migration of cells on 
fibronectin (115-117). Interestingly, overexpression of a FAK mutant lacking the Tyr-397 
autophosphorylation site fails to rescue the effects of the inhibition or absence of FAK on cell 
spreading and/or migration (115-118). This suggests that auto-phosphorylation of FAK on 
residue Tyr-397 plays a crucial role in ECM-induced cell migration. Since, numerous studies 
have implicated FAK as a positive regulator of cell spreading and migration. 
One of the main functions of FAK is the protection of cells against apoptosis. It was first 
reported that tyrosine phosphatase inhibitors block apoptosis subsequent to detachment from 
ECM (53). Subsequently, Frisch et al. (119) showed that constitutively active FAK mutants 
rescue MDCK cells from anoikis. Conversely, attenuation of FAK expression by treatment with 
antisense oligonucleotides induces apoptosis of tumour cell lines (120) and microinjection of 
peptides blocking binding of FAK to endogenous integrins or of anti-FAK antibody induces 
apoptosis of fibroblasts (121). It has also been reported that FAK-deficient cells are more 
susceptible towards serum withdrawal-induced apoptosis (122), and different dominant-negative 
FAK mutants have been shown to induce apoptosis in absence (122) or in presence of serum 
(123; 124). Now, it is generally accepted that FAK plays a critical role in suppressing anoikis 
and apoptosis caused by diverse inducers. Interestingly, it has been shown by several groups 
that FAK mutated on residue Tyr-397 is unable to promote survival of cells (119; 125; 126), 
suggesting that phosphorylation of Tyr-397 plays a critical role also in the pro-survival function 
of FAK. However, it has also been reported that the survival signal from the α5β1 integrin (in 
CHO cells overexpressing integrin α5 subunit) does not correlate with increased FAK 
phosphorylation (71), suggesting that pro-survival signaling from integrins may in some contexts 
occur independently of FAK. 
In summary, FAK and phosphorylation of its tyrosine residue Tyr-397 have been shown 
to play central roles in integrin signaling leading to regulation of cell migration and survival. 
Several proteins have been involved in this signaling, including PI3K, Akt and ERK. 
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1.3. The PI3K-Akt signaling module 
1.3.1. Phosphatidylinositol 3-kinase (PI3K) 
There are multiple isoforms of PI3Ks in mammalian cells, and the best characterized is 
class I. Class I PI3Ks comprise a p110 catalytic subunit and a regulatory adapter subunit: p85. 
The p85 subunit contains an SH3 domain and two SH2 domains (127; 128). These SH2 
domains allow the interaction between p85 and proteins containing specific tyrosine-
phosphorylated sequences, such as the ones present on phosphorylated FAK proteins. This 
process recruits the p110 catalytic subunit to the plasma membrane, where it can phosphorylate 
phosphatidyl inositol-4,5-biphosphate [PI(4,5)P2] and thereby generate phosphatidyl inositol-
3,4,5-triphosphate [PI(3,4,5)P3] (129). This phosphorylated lipid is implicated in signaling 
pathways involved in the regulation of  cell survival, gene expression and cell metabolism, as 
well as cytoskeletal rearrangements (130; 131). It has been shown that the PI3K-generated 
[PI(3,4,5)P3] lipids recruit signaling proteins by direct binding to their PH domains, and either 
allosterically modify their activity or induce relocalization of the protein to defined areas of the 
plasma membrane, where activation can occur (132). Such signaling proteins include the 
serine-threonine kinase Akt (133; 134). Not all but a major part of PI3K signaling is mediated via 
Akt. The alternative signaling pathways mediated by PI3K are out of the scope of this 
introduction and are reviewed by Downward (135).  
 
1.3.2. Protein kinase B (PKB/Akt) 
In 1991, several groups independently identified the serine/threonine kinase Akt (also 
called PKB) (136-138). One of these groups identified this kinase as being the product of the 
oncogene v-akt of the acutely transforming retrovirus AKT8 found in a rodent T-cell lymphoma 
(136). Three isoforms of Akt exist in mammalian cells: Akt1, Akt2 and Akt3. These three Akt 
proteins, although encoded by distinct genes localized on different chromosomes, have 
approximately 80% amino acid identity and similar domain structures (139). Akt1 and Akt2 both 
show a wide distribution of expression, however their levels of expression differ (140; 141). Akt 
family proteins contain a central kinase domain with specificity for serine or threonine residues 
in substrate proteins (136; 137; 141; 142). In addition, the amino terminus of Akt includes a 
pleckstrin-homology (PH) domain which mediates lipid-protein and/or protein-protein 
interactions (141; 142). Akt has multiple effects on cell survival, metabolism and proliferation 
(134; 135). 
  Activation of Akt requires its translocation to the plasma membrane and 
phosphorylation of Akt is also a critical step leading to its activation (143; 144). Mutation of the 
residues Thr-308 and/or Ser-473 alters activation of Akt, suggesting that phosphorylation of 
these two residues is required for maximal activity (145). Akt binds specifically to PI3K-
generated [PI(3,4,5)P3] lipids, but these do not directly affect its activity (146). A model where 
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PI3K-generated [PI(3,4,5)P3] lipids may recruit Akt to the plasma membrane, where it is 
phosphorylated and activated by a membrane-associated protein has been proposed by Alessi 
and colleagues (145; 146). This model has been reinforced by the isolation of this putative 
[PI(3,4,5)P3]-dependent protein kinase (PDK-1) that phosphorylates and activates Akt on 
residue Thr-308 (147). The putative kinase(s) or mechanism(s) responsible for Ser-473 
phosphorylation have not yet been clearly identified (148). Nevertheless, several candidates 
have been proposed to be Ser-473 kinases, including integrin-linked kinase (ILK) (149).  
In summary, Akt is activated (indirectly) by the PI3K-generated [PI(3,4,5)P3] lipids, and 
its activity is thus sensitive to the specific PI3K inhibitors Wortmannin and LY294002 (150). Full 
activation of Akt requires phosphorylation at the residues Thr-308 and Ser-473.  
 
1.3.3. Activation of the PI3K-Akt pathway by ECM 
It is now known that a diverse array of physiological stimuli, including ECM, are 
capable of inducing Akt kinase activity, primarily in a PI3K-dependent manner (139). Diverse 
ECM molecules (including fibronectin, laminin and collagen) and integrin subunits have been 
shown to induce PI3K and/or Akt activities. As mentioned above, the p85 subunit of PI3K can 
associate directly with FAK in response to cell adhesion to the ECM protein fibronectin (151). 
Furthermore, it was shown in the same report that PI3K activity associated with FAK increases 
upon attachment to fibronectin and that this is concomitant with increased FAK tyrosine 
phosphorylation (151), providing a first indication that PI3K might be involved in the signaling 
downstream of cell adhesion-induced FAK activation. The same group subsequently reported 
that phosphorylation of FAK on residue Tyr-397 is required for its binding to PI3K and for the 
activation of PI3K (108). Furthermore, adhesion of cells to fibronectin leads to accumulation of 
PI3K-generated phosphorylated lipids, resulting in activation of Akt kinase activity (152). This 
fibronectin-induced activation of Akt is dependent on PI3K activity (152).  Generation of primary 
fibroblasts carrying a targeted deletion of the segment of β1 integrin cytoplasmic domain 
required for activation of FAK has been reported (74). These fibroblasts have impaired FAK-
PI3K-Akt signaling in response to adhesion to fibronectin (75). Therefore, it can be concluded 
that engagement of integrins to cognate ECM can activate the PI3K-Akt signaling pathway.  
 
1.3.4. Role of the PI3K-Akt pathway in cell survival 
Yao and Cooper provided the first evidence indicating that PI3K is implicated in the 
suppression of apoptosis (153). This report demonstrated that inhibition of PI3K activity using 
two pharmacological inhibitors of PI3K (LY294002 and Wortmannin) abrogates the ability of 
NGF to promote cell survival. Since, PI3K activity has been found to be required for growth 
factor-dependent survival of a wide variety of cultured cell types ranging from fibroblasts to 
neurons (139). The observation that Akt is a target of PI3K, together with the finding that PI3K 
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mediates growth factor-dependent survival, suggested that Akt might be a critical regulator of 
cell survival. This hypothesis has been confirmed by many groups (as reviewed by (139)), 
leading to the conclusion that the PI3K-Akt pathway is one of the major anti-apoptotic pathways 
operating in cells (139). In addition, it has been shown that specific deletion of Akt1 leads to 
partial neonatal mortality and the surviving Akt1 knock-out animals are smaller in size than 
control mice, suggesting that Akt1 may be involved in regulation of survival and/or proliferation 
of cells (154; 155). Several effectors downstream of activated Akt have been reported to 
mediate its survival signaling. For example, Akt has been shown to directly phosphorylate the 
pro-apoptotic Bcl2-family member Bad, leading to its binding to the 14-3-3 protein and thus 
preventing it from exerting its pro-apoptotic effects (156-158). Furthermore, Akt has been 
reported to regulate the activity of transcription factors such as members of the Forkhead family 
of transcription factors and NF-κB (159; 160), leading to altered gene expression. However, it 
seems that these effects of Akt on the activity and/or expression of proteins regulating apoptosis 
are cell-type and/or context-dependent. 
The PI3K-Akt pathway was first reported to mediate ECM-induced survival of normal 
epithelial cells in a study showing that overexpression of constitutively active PI3K and Akt 
mutants are able to protect MDCK cells against anoikis (161). Since, several groups have 
confirmed that the PI3K-Akt pathway can mediate the pro-survival signaling from ECM and/or 
integrins (69; 72; 162). The induction of the PI3K-Akt pro-survival signaling by ECM and/or 
integrins has been reported to occur specifically on a given ECM substrate or through a specific 
integrin subunit, and this specificity is cell type-dependent (72; 73). For example, it has been 
shown that overexpression of the α5 integrin subunit protects epithelial cells against serum 
deprivation-induced apoptosis through the PI3K-Akt pathway, whereas overexpression of α2 
subunit does not (72). The pro-survival signaling emanating from ECM-integrin interaction or 
FAK activation does not always involve PI3K-Akt pathway (122; 123). Indeed, other pathways 
such as JNK (123) and MAPK-ERK (73) have also been reported to mediate the pro-survival 
signaling from ECM.  
In summary, it has been shown that ECM and/or engagement of integrins to cognate 
ECM proteins can activate the PI3K-Akt survival signaling pathway. However, as discussed 
below, other pathways have also been shown to mediate the pro-survival signaling from ECM, 
such as the MAP kinase ERK pathway.  
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1.4. The MAP kinase ERK pathway 
1.4.1. General introduction   
 The MAP kinases comprise a large family of signal-regulated serine/threonine kinases. 
Three main MAP kinases cascades have been characterized: the extracellular-regulated 
kinases 1 and 2 (ERK1/2) pathway, the-Jun N-terminal kinases/stress-activated protein kinases 
(JNK/SAPK) cascade and the p38 pathway (reviewed by Pearson, 2001 #453}). The MAP 
kinase ERK pathway can be activated by many different stimuli, including growth factors, 
cytokines, and ECM. This pathway has been implicated in a wide range of cellular functions, 
including actin cytoskeleton reorganization, migration, cell proliferation, and survival (163), 
(reviewed by (164-166)). 
The “classic” ERK cascade begins with the activation and autophosphorylation of RTK 
(receptor tyrosine kinase) on the cell surface (167).  This creates phosphotyrosyl binding sites 
for SH2-domain adaptor proteins such as Grb2 and Shc, which in turn can recruit other proteins 
such as Sos, a partner of Grb2 that is an exchange factor for Ras GTPase. Activation of Ras at 
the membrane by Sos leads to recruitment of Raf-1 (also called MAPKKK) into the membrane 
and its subsequent activation. Raf-1 subsequently phosphorylates and activates MEK1 and 
MEK2 (also called ERK kinases, or MAP kinases kinases, MAPKK), which then can 
phosphorylate ERK1 and ERK2 (also called p44 and p42, respectively) on two residues 
(threonine and tyrosine) leading to their activation (reviewed by (164; 168; 169)). Once 
activated, ERK1/2 can target a multitude of proteins, including membrane proteins (such as 
phospholipase A2) and cytoplasmic proteins (including downstream kinases, such as ribosomal 
S6 kinases). Activated ERKs can also can translocate into the nucleus where they 
phosphorylate transcription factors, thereby regulating their activity (reviewed by (164; 169)). 
 
1.4.2. Activation of the MAP kinase ERK pathway by ECM 
ECM can activate the MAPkinase ERK pathway by two main mechanisms. First, it has 
been reported that activation of ERK by serum or by growth factors is strongly dependent on 
adhesion to ECM proteins (reviewed by (94; 168). The ability of integrin-mediated adhesion to 
regulate the efficiency of the growth factor activation of ERK has been observed in countless 
cell and tissue types (94). Second, ECM has been shown to directly activate the ERK pathway. 
Indeed, it has been shown that adhesion of fibroblasts onto different ECM (including fibronectin, 
laminin, vitronectin and collagen type IV) can lead to activation of the ERK pathway (109; 170; 
171). Mainiero and colleagues have shown that ligation of α6β4 to laminin-5 leads to tyrosine 
phosphorylation of Shc, recruitment of Grb2, activation of Ras leading to stimulation of the ERK 
pathway (172). This was specific for α6β4, as ligation of α3β1 and α2β1 or collagen did not 
cause these events (172), indicating that only ligation of specific integrins can activate the ERK 
pathway in a given cell type.   
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How does ligation of integrins to cognate ECM ligand lead to activation of ERK? 
Different mechanisms have been proposed, highlighting the complexity of integrin signaling 
(reviewed by (88)). For example, the role of FAK in ECM-induced ERK activation is 
controversial: FAK is capable of activating MAPK through recruitment of Grb2 (102), Shc or Src 
(173; 174), but other mechanisms independent of FAK that result in ERK activation have also 
been described (reviewed by (88; 94)). In addition, paradoxical effects of the PI3K-Akt pathway 
on ECM-induced activation of the ERK pathway have also been reported. For example, it has 
been shown that β1 integrin-induced ERK activation in monocytes is dependent on PI3K activity 
(175), while others have reported that PI3K-Akt and ERK pathways act independently from each 
other (176). It has been proposed that the role of FAK and/or of PI3K in integrin-induced ERK 
activation may be cell-type and/or context-dependent.  
What are the consequences of adhesion-dependent ERK activation? It has been 
reported to affect numerous cellular functions, including regulation of gene expression, cell 
proliferation, survival and migration (as reviewed by (94)). The effect of ECM-induced ERK 
signaling on the regulation of cell survival is discussed below.  
 
1.4.3. Role of the MAP kinase ERK pathway in cell survival 
In general, ERK is considered to be a pathway leading to increased cell survival and 
protection against several different pro-apoptotic stimuli, including death receptor-mediated 
activation and survival factor removal (reviewed by (166)). Disruption of the ERK kinase MEK1 
gene causes embryonic lethality (177). In addition, MEK1-deficient fibroblasts migrate more 
slowly than wild-type cells on a fibronectin substrate, but behave normally on a collagen 
substrate. These findings are consistent with a requirement for the ERK pathway for stimulation 
of migration by extracellular matrix and cell survival (177). However, ERK1 disruption causes 
minimal phenotypic changes, and has no effect on cell survival (178). Nevertheless, it is 
possible that ERK2 can compensate for the loss of ERK1. However, ERK has also been 
reported to promote apoptosis in neuronal cells (reviewed by (179)), in fibroblasts (180) as well 
as in pancreatic beta cells (as discussed below), indicating that the role of ERK in cell survival is 
not as absolute as previously proposed. It has been proposed that the duration and/or 
amplitude of ERK signals may affect the decision of cell fate (179; 180). In addition, it has been 
reported that the protective effects of ERK2 against distinct apoptogenic stimuli are dependent 
on its cellular localization (181).  
Several reports have described a role for the ERK pathway in providing protection 
against anoikis (70; 163; 176; 182; 183), (reviewed by (94)). For example, it has been shown 
that laminin-5 engagement by α3β1 integrins promotes keratinocyte cell survival through 
activation of the MAP kinase ERK pathway (70). However, other groups have reported that ERK 
is not involved in the control of survival of cells in the context of the ECM. For example, it has 
been reported that ECM-induced survival of MDCK cells involves the PI3K-Akt pathway, but not 
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the MAP kinase ERK pathway (161) and that laminin 5-induced breast tumour cell survival and 
anchorage independence is not affected by either PI3K or ERK activities (184). Finally, it has 
also been proposed that ERK activation can be involved in signaling leading to anoikis (185) but 
this remains to be confirmed. Therefore, it appears that the involvement of the MAP kinase ERK 
pathway in ECM-induced cell survival might be cell-type and/or context-dependent.  
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1.5. Signaling involving FAK, PI3K-Akt and ERK and the pancreatic beta cell 
Although FAK plays a central role in several crucial biological functions (such as cell 
migration and survival, in particular), no study assessing its expression and/or its function in the 
pancreatic beta cell was reported previous to, or during this thesis project. By contrast, both 
PI3K-Akt and the MAP kinase ERK pathways had been reported to be involved in the regulation 
of the function and/or the survival of the pancreatic beta cell, as described below. 
  
1.5.1. PI3K-Akt and the pancreatic beta cell 
The expression of the three Akt isoforms Akt1, Akt2 and Akt3 has been reported for the 
pancreatic islets and for the transformed beta cell lines HIT15, INS-1 and RINm5F (186). Akt 
expression in islets is weak as compared to adipocytes, and it is prominently expressed in beta 
cells as compared to non-beta cells (186). Several stimuli have been shown to promote beta cell 
survival through the PI3K-Akt pathway. These include glucose (at the 10mM-12mM range of 
concentration) (187), insulin-like growth factor-I (IGF-I) (188; 189), and glucagon-like peptide-1 
(GLP-1) (190; 191). Furthermore, constitutive active Akt1 has been shown to protect INS-1 cells 
against free fatty-acid induced apoptosis (192). However, whether ECM and/or integrins may 
affect the activity of Akt in the beta cell has not yet been reported.   
Several studies describing transgenic mice expressing constitutively active Akt mutants 
or dominant-negative (kinase-dead) Akt mutants specifically in pancreatic beta cells have been 
reported. Overexpression of constitutive active Akt1 (i.e. Akt1 lacking the PH domain, and 
containing an N-terminal Src-myristoylation domain) specifically in the pancreatic beta cells 
(using the rat insulin II promoter) has been reported by two groups, and both made similar 
observations (193; 194). It was observed that this mutation leads to an increase of islet beta cell 
mass that is due both to an increase in the number of beta cells and an increase in beta cell 
size (193; 194). In addition, Bernal-Mizrachi et al. reported an increase in the proliferation of 
islet cells (194). An increase in the number of beta cells scattered throughout the exocrine 
pancreas was also observed in the transgenic mice, leading to the suggestion that active Akt1 
might induce neogenesis of beta cells (194). Both groups reported an improvement of glucose 
tolerance, and hyperinsulinemia was observed in the transgenic mice. Furthermore, this 
mutation does not affect glucose-stimulated insulin secretion, but it induces resistance towards 
streptozotocin-induced diabetes (193; 194). These observations led to the following 
conclusions: 1) Akt1 pathway in vivo has major effects on the cell size, number and function of 
beta cells; 2) altered Akt1 activity might lead to development of type 1 and/or type 2 diabetes. 
Intriguingly, Tuttle et al. observed an increase in the rate of basal islet cell apoptosis, but a 
decrease in apoptosis induced by streptozotocin in the transgenic mice (193). However, two 
weaknesses in the model used by these two groups can be noted. First, the constitutively active 
Akt1 mutant with an N-terminal myristoylation domain was used, and the effects of this mutant 
 40
might differ from the physiological effects of activated Akt1 in vivo. Second, concerns have been 
raised about the use of the rat insulin promoter (RIP), because it has been reported that this 
promoter might affect expression of genes in the hypothalamus (195). Bernal-Mizrachi and 
colleagues have recently reported the generation of transgenic mice overexpressing a kinase-
dead mutant of Akt1 (kdAkt1, which serves as a dominant-negative inhibitor of Akt activity), 
specifically in the pancreatic beta cells (196). The possibly “leaky” RIP promoter was used, 
however it was verified that there is no aberrant expression of the RIP-kdAkt1 transgene in the 
hypothalamus. These mice exhibit impaired glucose tolerance and defective insulin secretion, 
suggesting that Akt1 is essential for normal beta cell function. Intriguingly, islet morphology and 
susceptibility to apoptosis were reported to not be altered in these mice compared to wild-type 
mice.   
In summary, these different models provide contrasting results. The in vitro studies 
performed on a wide range of cell types, including beta cells, using different tools, including 
constitutive active and/or dominant-negative Akt mutants, indicate that Akt plays a general pro-
survival role in the pancreatic beta cell. However, in vivo overexpression of the constitutive 
active Akt mutant specifically in beta cells was reported to induce an increase in basal beta cell 
apoptosis, while in vivo overexpression of the dominant-negative Akt1 mutant specifically in 
beta cells was reported to not affect islet morphology or beta cell apoptosis. However, 
quantification of apoptosis in vivo can be problematic, due to rapid clearance of apoptotic cells 
from tissues by macrophages (26), and this may explain the discrepancies observed between 
the in vitro and in vivo models. Furthermore, in vivo overexpression of dominant-negative and/or 
of dominant-positive Akt mutants might induce non-specific side effects. Therefore, further in 
vivo studies are mandatory to better define the role of Akt1 in beta cell survival. One potentially 
interesting model could be beta-cell specific, conditional Akt knock-out mice. 
 
1.5.2. MAP kinase ERK pathway and the pancreatic beta cell 
Several stimuli have been shown to activate ERK in the pancreatic beta cell, including 
cytokines (IL-1β, (197-199)), glucose (200-202), phorbol esters (202), GLP-1 (203; 204) and 
KCl-induced depolarization (202). However, whether ECM is able to activate the MAP kinase 
ERK pathway in the pancreatic beta cell has not yet been reported, either before or during this 
thesis work. 
ERK has been involved in the regulation of function (glucose-stimulated insulin 
secretion) and survival of beta cells, but both of these proposed functions of ERK are 
controversial. It has been reported by some groups that glucose-induced ERK activity is not 
involved in glucose-stimulated insulin secretion (200; 205), but that glucose-induced insulin 
gene transcription is regulated by ERK (201; 206). However, a recent paper has reported that 
ERK is involved in glucose-stimulated insulin secretion in MIN6 cells by controlling the 
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phosphorylation of the cytosolic protein synapsin I (207), and it was proposed that different 
experimental procedures might explain these contrasting results.  
The role of the MAP kinase ERK pathway in beta cell survival is also controversial. 
Indeed, in the context of cytokine-induced ERK activity, ERK has been reported to be involved 
in IL-1β-induced nitric oxide (NO) synthesis and NO synthase (NOS) mRNA expression (197), 
as well as in IL-1β-induced apoptosis (199). Furthermore, the ERK inhibitor PD98059 has been 
reported to prevent glucose-induced IL-1β release and beta cell dysfunction and death (208). 
On the other hand, it has been reported that inhibition of ERK aggravates IL-1β-induced death 
of the unusual cell lines AN-ins and AN-glu (198). It has also been reported that inhibition of 
ERK activity does not alter glucose-induced beta cell survival (187), nor serum or IGF-I-induced 
cell survival (189). Finally, it has been proposed by a rather superficial study that there could be 
a correlation between suppressed ERK phosphorylation and diminished islet survival 
consecutive to islet isolation and purification (209).  
In summary, although both the PI3K-Akt and MAP kinase ERK pathways have been 
involved in signaling leading to increased beta cell survival, their anti-apoptotic role remains to 
be confirmed (for the PI3K-Akt pathway), or is still controversial (for the ERK pathway). 
Furthermore, some reports examining their role in pancreatic beta cells remain to be confirmed, 
due to lack of conclusive results. Finally, the possible effect of ECM on the activity of these 
pathways in the pancreatic beta cell has not yet been examined. 
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1.6. ECM and regulation of gene expression  
It has been recognized for over twenty years that ligation of integrins to cognate ECM 
ligand can alter the expression of genes (reviewed by (88)). Integrin-mediated gene expression 
has been reported to be involved in many biological functions, including cell cycle regulation and 
control of cell survival (88; 94). It has been proposed by several groups that integrins can 
promote cell survival through induction of the expression of anti-apoptotic proteins, including 
Bcl-2 (71; 210) and the caspase-8 inhibitor c-FLIP (62). Furthermore, overexpression of FAK in 
a human leukaemia cell line activates a PI3K-Akt pathway leading to increased expression of 
the Inhibitor of Apoptosis protein (IAP) and improved cell survival (125). Several signaling 
proteins have been involved in integrin-induced gene expression leading to increased cell 
survival, and these include FAK, PI3K and Akt (210)  the MAPKKK c-Raf-1 (62) and ERK (62; 
211). Therefore, it can be concluded that activation of signaling pathways (including PI3K-Akt 
and ERK pathways) by engaged integrins can induce altered gene expression that ultimately 
leads to increased cell survival. 
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2. Specific aims of Paper 1 
As described above, ligation of integrins to cognate ECM ligand induces 
phosphorylation of FAK on residue Tyr-397. Two major pathways have been shown to be able 
to mediate the pro-survival signaling of activated integrins: the PI3K-Akt and the MAP kinase 
ERK pathways. Although FAK is not always involved in the activation of these signaling 
pathways by engaged integrins, the appearance of phosphorylated Tyr-397 residue is 
considered as a hallmark of integrin signaling. 
In the context of the pancreatic beta cell, the signaling pathways activated by 
engagement of integrins to cognate ECM ligand were completely unexplored at the beginning of 
this thesis project (i.e. 2001).  Furthermore, the expression and/or function of FAK in the beta 
cell were unknown at that time as well. By contrast, several breakthrough papers investigating 
the roles of PI3K, Akt and of the MAP kinase ERK in the function and/or survival of the 
pancreatic beta cell have been reported during that period. Although the pro-survival function of 
the PI3K-Akt pathway in beta cells is not completely established and that of the ERK pathway is 
controversial, these pathways are interesting potential candidates for a survival signaling 
emanating from the ECM leading to improved beta cell survival. As described previously (Part I), 
we chose to study the effect of 804G-ECM on survival of primary rat pancreatic beta cell as a 
model for the study of ECM-induced pro-survival signaling pathways that occurs in pancreatic 
beta cells. In this context, the specific aims were to: 
- establish whether 804G-ECM improves survival of pancreatic beta cells in culture 
- investigate whether 804G-ECM induces phosphorylation of FAK (on residue Tyr-397), 
in order to establish whether the 804G-ECM activates integrins expressed on beta cells 
- investigate whether 804G-ECM activates pathways involving the signaling kinases 
Akt and/or ERK 
- study the involvement of the PI3K-Akt and MAP kinase ERK pathways in the pro-
survival effect of the 804G-ECM 
- obtain a preliminary insight into whether the 804G-ECM is able to induce expression 
of specific genes that might be involved in its pro-survival effects. 
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3. Paper 1 
“ Extracellular Matrix Protects Pancreatic Beta-Cells Against Apoptosis : Role of Short- 
and Long-Term Signaling Pathways ” 
Hammar et al. Diabetes, 53: 2034-2041 (2004) 
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Extracellular Matrix Protects Pancreatic -Cells
Against Apoptosis
Role of Short- and Long-Term Signaling Pathways
Eva Hammar,1 Ge´raldine Parnaud,1 Domenico Bosco,2 Nadja Perriraz,1 Kathrin Maedler,3
Marc Donath,3 Dominique G. Rouiller,1 and Philippe A. Halban1
We have shown previously that culture of -cells on
matrix derived from 804G cells and rich in laminin-5
improves their function. The purpose of this study was
to investigate whether this matrix protects -cells
against apoptosis and to elucidate signaling pathways
involved. Matrix protected sorted rat -cells against
apoptosis under standard conditions (11.2 mmol/l glu-
cose, 10% serum), after serum deprivation (1% serum),
and in response to interleukin-1 (IL-1; 2 ng/ml),
compared with control (poly-L-lysine [pLL]). Caspase-8
activity was reduced in cells cultured on matrix, where-
as focal adhesion kinase (FAK), protein kinase B (PKB,
or Akt), and extracellular signal–regulated kinase
(ERK) phosphorylation was augmented. Treatment (4
h) with an anti-1 integrin antibody, with the ERK
pathway inhibitor PD98059, and/or with the phosphati-
dylinositol 3-kinase inhibitor LY294002 augmented cell
death on 804G matrix but not on pLL. In long-term
assays (48 h), PD98059 but not LY294002 drastically
augmented cell death on 804G matrix but did so to a
lesser extent on pLL. The protein inhibitor of nuclear
factor-B (IB) was overexpressed in cells cultured
18 h on matrix with partial blockade by PD98059. In
summary, this study provides evidence for activation of
signaling pathways and gene expression by extracellu-
lar matrix leading to improved -cell survival. Diabetes
53:2034–2041, 2004
Epithelial cells deprived of matrix attachmentundergo programmed cell death, a form of apo-ptosis termed anoikis (1). The role of cell an-chorage in cell survival has been demonstrated
in several cell types (reviewed in 2), including pancreatic
islet cells (3). Disengagement from extracellular matrix
(ECM) is known to prejudice islet cell survival, notably by
inducing apoptosis and necrosis (4). It has been reported
that reestablishment of appropriate cell-matrix contacts
reduces cell death (3,5); however, the molecular basis for
such pro-survival signaling remains largely unknown. Re-
cent evidence implicates integrins in mediating pro-sur-
vival signals emanating from the ECM (reviewed in 6).
Several signal transduction components activated by
integrins, including focal adhesion kinase (FAK) (7,8),
phosphatidylinositol (PI) 3-kinase (9,10), and the mito-
gen-activated protein (MAP) kinase/extracellular signal–
regulated kinase (ERK) (reviewed in 11) have been
implicated in mechanisms underlying anoikis (reviewed in
12). Recently, it has emerged that PI 3-kinase and its
downstream effector protein kinase B (PKB, or Akt) play
key roles in the regulation of pancreatic -cell survival
(13–17). The role of the MAP kinase ERK cascade in -cell
survival is controversial. Some studies have suggested an
antiapoptotic effect of this cascade (18), whereas others
claim that it serves as a mediator of cytokine-induced
apoptosis (19–21), this claim in itself being controversial
(22). Nevertheless, a possible involvement and impact of
PKB/Akt and ERK in outside-in signaling from ECM to
-cells remains to be investigated.
ECM produced by the rat bladder carcinoma cell line
804G is rich in laminin-5 (epiligrin) and also contains
fibronectin (23–25). This matrix is able to induce attach-
ment and spreading of many epithelial cell types, including
pancreatic -cells (24,26). Furthermore, our group has
shown that this matrix improves -cell function (27). In
the present study, we examined whether the 804G matrix
could rescue primary pancreatic -cells from apoptosis,
and we investigated the intracellular pathways involved.
RESEARCH DESIGN AND METHODS
Reagents and antibodies. The following materials were used: PD98059 and
LY294002 (Calbiochem, Darmstadt, Germany); In Situ Cell Death Detection
Kit (POD; Roche Molecular Biochemicals, Rotkreuz, Switzerland) for termi-
nal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling
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ERK, extracellular signal–regulated kinase; FAK, focal adhesion kinase;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HRP, horseradish per-
oxidase; IB, inhibitor of nuclear factor B; IL-1, interleukin-1; MAP,
mitogen-activated protein; MEK1, MAP kinase/ERK kinase; NF-B, nuclear
factor-B; PI, phosphatidylinositol; PKB, protein kinase B; pLL, poly-L-lysine;
TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-
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(TUNEL) assay with substrate 3,3-diaminobenzidine (DAB) from Dako
(Carpinteria, CA); cell death detection ELISAPLUS kit (Roche); CaspaTag
caspase-8 (LETD) activity kit (Intergen, Oxford, U.K.); Hoechst 33342 (Sigma
Fluka, Buchs, Switzerland); propidium iodide (Intergen, Purchase, NY);
recombinant rat interleukin-1 (IL-1; RnD Systems, Abingdon, U.K.) hamster
anti-rat CD29 (integrin 1 chain) and hamster IgM control antibodies (Becton
Dickinson Biosciences, San Jose, CA); polyclonal anti-phospho-FAK (Tyr-397)
and anti-FAK (Biosource International, Camarillo, CA); polyclonal anti-phos-
pho-ERK1/2 (Thr-202/Tyr-204), anti-ERK1/2, anti–phospho-PKB/Akt (Ser-473)
and anti-PKB/Akt (Cell Signaling Technology-Bioconcept, Allschwil, Switzer-
land); monoclonal anti-actin (Chemicon International, Temecula, CA); C-21
anti–inhibitor of nuclear factor (NF)-B (IB; Santa Cruz Biotechnology,
Santa Cruz, CA); anti-mouse horseradish peroxidase (HRP) and anti-rabbit
HRP (Amersham Pharmacia Biotech, Du¨bendorf, Switzerland).
Islet isolation and -cell purification. All experiments were performed on
primary pancreatic -cells sorted from adult rat islet cells by autofluores-
cence-activated flow cytometry. Islets of Langerhans were isolated by colla-
genase digestion of pancreas from male Wistar rats (weighing 150–200 g),
followed by Ficoll purification (28). Islets were digested with trypsin and
sorted by flow cytometry to obtain -cells as described (28). This purification
procedure yields a population consisting of 95% -cells (27).
Cell culture. Sorted -cells were washed and incubated overnight in suspen-
sion for recovery as previously described (27). Cells were then resuspended at
4  105 cells/ml, and aliquots of 50 l were plated as droplets on noncoated
plastic dishes or on plastic dishes coated with poly-L-lysine (pLL), with 804G
matrix, or with laminin-5 purified from 804G (provided by N. Koshikawal and
V. Quaranta, San Diego, CA). To assess the effect of the antibody directed
against 1 integrin subunit, cells were pretreated for 1 h in suspension with 0.5
g/ml hamster IgM (control) or with 0.5 g/ml anti–1 integrin antibody
(Ha2/5) before plating them on pLL- or 804G-coated dishes. When indicated,
cells were cultured for 48 h in culture medium containing 1% FCS (serum
deprivation). To study the effect of IL-1, cells were cultured for 48 h in
culture medium containing 10% FCS and then treated for 4 h with 2 ng/ml
IL-1. To assess the effects of inhibitors, cells were pretreated for 15 min with
50 mol/l PD98059 and/or 50 mol/l LY294002, before plating them on pLL- or
804G-treated dishes. Cells were then cultured in standard medium (10% FCS)
for 4 h or for 48 h (fresh inhibitor added at 24 h). DMSO was added to control
cells at the same final concentration as that used for the inhibitors. For the
protein phosphorylation analysis by Western blot, cells were serum starved
for 1–4 h in suspension in serum-free medium containing 0.1% BSA. They were
then plated on pLL- or 804G-coated dishes for 30 min in the same medium
before performing the protein extraction. For gene expression analysis by
low-density gene arrays and by quantitative real-time PCR analysis, cells were
serum starved (1% FCS) in suspension for 2 h before plating them on pLL- or
804G-coated dishes (or on noncoated dishes as control for the gene arrays).
Cells were then cultured for 18 h in medium containing 1% FCS before mRNA
extraction. For the IB protein analysis by Western blot, cells were treated
as for gene expression analysis and cultured for 24 or 48 h in medium
containing 1% FCS before protein extraction. Fresh medium (2 ml) was added
every 24 h.
804G matrix preparation. 804G cells (the kind gift of Desmos, San Diego,
CA) were grown in Dulbecco’s modified Eagle’s medium containing 10% FCS
and 5.6 mmol/l glucose. Conditioned medium (referred to hereafter as 804G
matrix) was prepared as previously described (27).
Coating of plastic dishes with pLL, 804G matrix, and laminin-5. Aliquots
(60 l) of pLL (0.1 mg/ml), crude 804G matrix, or laminin-5 purified from 804G
matrix (4 g/ml in PBS) were layered at the center of 35-mm culture petri
dishes (adherent dishes for mammalian cell culture). Dishes were kept in a
damp box at 37°C for 18–20 h before being rinsed three times with sterile H2O
and air dried. Uncoated Petri dishes (plastic) or dishes coated with 0.1 mg/ml
pLL were used as controls.
Analysis of cell death. To quantify cell death by TUNEL, attached cells were
washed with PBS and fixed with 4% paraformaldehyde (20 min at room
temperature). After permeabilization with 0.5% Triton X-100 (4 min at room
temperature), the TUNEL assay (detecting the free 3-OH strand breaks
resulting from DNA degradation) was performed with the In Situ Cell Death
Detection Kit, according to the manufacturer’s instructions. The preparations
were then rinsed with PBS and incubated (10 min at room temperature) with
the substrate DAB, and the quantification of dead cells was performed using
a light microscope. Unless stated otherwise, results are means  SD of three
independent experiments, with a minimum of 500 -cells examined for each
condition in each experiment. The type of cell death detected by TUNEL was
assessed as described by others (29). Cells were stained for 20 min at 37°C
with 1 g/ml Hoechst 33342 (to determine the morphology of the nuclei) and
with 1.25 g/ml propidium iodide (which stains the necrotic nuclei) before
fixation and staining with TUNEL reagent. Cells lacking propidium iodide
uptake and with condensed nuclei were counted as apoptotic. Late apoptosis
(or secondary necrosis) was defined by the uptake of propidium iodide and
the presence of nuclear condensation, and necrosis was defined by the uptake
of propidium iodide and normal nuclear morphology. Only TUNEL-positive
cells were considered for this assessment. The quantification by enzyme-
linked immunosorbent assay (ELISA) of mono- and oligonucleosomes present
in the cytoplasm of apoptotic cells was performed using the cell death
detection ELISAPLUS kit according to the manufacturer’s instructions (Roche).
Quantification of caspase-8 activity. To quantify caspase-8 activity, at-
tached cells were treated for 1 h with the fluorescein-labeled peptide
FAM-peptide-FMK (which irreversibly binds to active caspase-8) as indicated
by the manufacturer (Intergen). At 5 min before the end of the incubation, 25
mol/l of Hoechst 33342 (final concentration) was added to visualize the
nuclei. At the end of the incubation, cells were washed and fixed with 4%
paraformaldehyde (20 min at room temperature). The quantification of the
number of cells containing active caspase-8 as a percent of total was
performed using a fluorescence microscope (Axiocam).
Western blot analysis. To analyze FAK, PKB/Akt, and ERK protein phos-
phorylation, attached cells were washed with ice-cold PBS without Ca	2/Mg	2
supplemented with 1 mmol/l sodium vanadate, and they were lysed in sample
buffer 1 (62 mmol/l Tris-Cl, pH6.8, 2% SDS, 5% glycerol, and 1% 2-mercap-
toethanol). Protein concentrations were determined with the amido black
method (30), and equal amounts of total protein were loaded for SDS-PAGE.
To analyze IB protein expression, cells were washed with ice-cold PBS and
lysed in a buffer containing 150 mmol/l NaCl, 50 mmol/l Tris-HCl, 1% Nonidet
P40, 0.25% deoxycholate, 0.1% SDS, 1 mmol/l ditiothreitol, and 1 mmol/l
phenylmethylsulfonyl fluoride. After determination of protein concentrations
by the method of Lowry, sample buffer 3 was added to the proteins, and the
samples were analyzed on an 8% SDS-PAGE gel. All samples, after separation
on an SDS-PAGE gel, were electroblotted onto nitrocellulose membranes
(Schleicher & Schuell, Dassel, Germany) for immunoblotting with the appro-
priate antibody. An enhanced chemiluminescence protein detection kit (Am-
ersham Biosciences) and a Kodak image station were used for visualization of
the bands.
Gene expression analysis with microarrays. Low-density membrane
cDNA microarrays (Mouse Cancer Pathway Finder GEArray; SuperArray,
Bethesda, MD) were used to compare gene expression between cells cultured
on plastic and those cultured on 804G matrix. After cell culture, RNA from
attached cells was isolated using the QIAshredder and RNeasy Mini Kit
(Qiagen, Basel, Switzerland) according to the manufacturer’s instructions.
The RNA quality was verified performing agarose gel electrophoresis, and 1.5
g of the total RNA (for each condition) was used as the template for the
32P-labeled cDNA probe synthesis performed according to the manufacturer’s
instructions (SuperArray). The membranes were prehybridized and hybrid-
ized with the probe, as indicated by the manufacturer, before exposure to
X-ray film for various lengths of time at 
80°C.
Quantitative real-time PCR. The results for select genes obtained with the
microarrays were verified by real-time PCR. cDNA was synthesized with
Superscript II (Invitrogen, Basel, Switzerland) using 1 g of total RNA in a
20-l reaction volume. For real-time PCR, the cDNA was amplified using a
GeneAmp 5700 sequence detection system (PE Applied Biosystems, Foster
City, CA). For this purpose, primers were designed according to Primer
Express software (PE Applied Biosystems). The following oligonucleotide
primer sets were used: IB forward: 5 TGCTGAGGCACTTCTGAAAGC 3;
IB reverse: 5 TCCTCGAAA GTCTCGGAGGTC 3. The dsDNA-specific dye
SYBR Green I was incorporated into the PCR buffer (PE Applied Biosystems)
to allow for quantitative detection of the PCR product. The results were
analyzed using ABI Prism 7000 SDS software (PE Applied Biosystems). The
house-keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as internal control.
RESULTS
Effect of 804G matrix on -cell apoptosis induced by
serum deprivation or IL-1. To determine whether the
804G matrix is able to serve as a survival ligand for
primary rat pancreatic -cells, TUNEL and ELISA were
performed on cells cultured on 804G matrix or on pLL (a
nonspecific adhesive polymer)-coated Petri dishes. -Cells
were cultured for 48 h on pLL-coated (control) or 804G
matrix-coated dishes (hereafter called pLL or 804G, re-
spectively) in medium containing either 10% (control
conditions) or 1% FCS (low-serum conditions). The num-
ber of apoptotic cells as a percent of the total was
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determined under each condition by TUNEL (Fig. 1A).
Approximately 4% of -cells cultured on pLL were apopto-
tic under control conditions. Similar results were obtained
when noncoated plastic tissue culture dishes were used
instead of pLL-coated dishes (not shown). Culture under
low-serum conditions significantly increased the number
of TUNEL-positive cells on pLL (9%). When cells were
cultured on 804G, 1% of cells were TUNEL positive
under control conditions, and serum deprivation did not
significantly affect this number.
We next investigated whether the 804G matrix protects
-cells from apoptosis induced by IL-1, a proinflamma-
tory cytokine that has been shown to be involved in
pancreatic -cell apoptosis leading to the development of
type 1 and type 2 diabetes (31,32). For this purpose, the
cells were cultured for 48 h on pLL or 804G before being
treated for 4 h with 2 ng/ml IL-1. The apoptosis of -cells
under each condition was measured by ELISA. There was
a slight but highly reproducible increase of apoptosis in
cells cultured on pLL treated with IL-1, as compared with
nontreated cells (P  0.003). When cells were cultured on
804G, the apoptotic index was significantly decreased as
compared with cells cultured on pLL, and there was no
difference between nontreated and IL-1–treated cells
(Fig. 1B), indicating that this matrix also protects against
IL-1–induced cell death. These results have been con-
firmed by TUNEL (not shown).
Differential staining of nuclei of TUNEL-positive cells
with propidium iodide and Hoechst 33342 distinguished
between apoptotic and necrotic cells on pLL (Fig. 1C).
Under basal conditions (10% FCS), the majority of TUNEL-
positive cells were apoptotic or late apoptotic (secondary
necrotic). Serum deprivation induced apoptosis and, to a
lesser extent, necrosis, whereas IL-1 induced only apo-
ptosis (Fig. 1C).
To begin to elucidate the pathway leading to apoptosis
on pLL, the activity of caspase-8 in cells cultured for 4 or
48 h on pLL or on 804G was analyzed (Table 1). Caspase-8
activity was higher in cells on pLL compared with those on
804G, and this difference increased with time. These
results suggest that the 804G matrix might block caspase-8
activity in turn, explaining the pro-survival effect of the
804G matrix.
Effect of purified laminin-5 on rat islet -cell survival
and spreading. The 804G matrix is known to be rich in
laminin-5. However, it also contains fibronectin and may
also contain other signaling molecules. To investigate
whether laminin-5 is the extracellular molecule responsi-
ble for the effect of the 804G matrix, we compared the
effects on both cell survival and cell spreading of purified
laminin-5 and 804G matrix after 48 h of culture under
standard conditions (Figs. 2A and B). As shown before,
there was a significant difference in the number of TUNEL-
positive cells between pLL (11%) and 804G (0.5%). The
number of TUNEL-positive cells on pure laminin-5 was
similar to 804G matrix (Fig. 2A). It has been reported that
-cells rapidly flatten and spread on 804G matrix as on
pure laminin-5, indicating a strong adhesion of -cells on
these two matrices (27). Here we show that the morphol-
ogy of -cells after 48 h of culture on 804G is highly similar
to that of cells cultured on pure laminin-5 (Fig. 2B). By
contrast, rat -cells do not adhere well and/or do not
spread on vitronectin and fibronectin (unpublished re-
sults). These results suggest that laminin-5 is the major
component of 804G matrix responsible for its pro-survival
effect. Therefore, we decided to pursue our studies with
the 804G matrix, given its ready availability and conve-
nience of use.
The 1 integrin subunit is involved in the effects of
804G matrix on -cell survival and spreading. We have
previously reported that the laminin-5 receptors integrins
31 and 61 are expressed on rat -cells (27,33), and
that the latter is involved in the spreading of cells on the
804G matrix (27). To assess whether the 1 integrin sub-
unit is involved in the pro-survival effect of the matrix, we
TABLE 1
Active caspase-8–positive cells
Time pLL 804G
4 h 2.6  0.9 0.8  0.4*
48 h 4.1  0.5 0.5  0.1†
Data are means  SD of at least three independent experiments. Rat
-cells were plated on pLL or 804G, and caspase-8 activity was
measured after 4 and 48 h. *P 0.005 compared with pLL (4 h); †P
0.0002 compared with pLL (48 h).
FIG. 1. 804G matrix protects primary pancreatic -cells from apoptosis. A: Cells were cultured for 48 h in medium containing either 10 or 1% FCS
before identification of apoptotic (plus necrotic) cells by TUNEL. The number of TUNEL-positive cells as a percent of total was evaluated by
optical microscopy. *P < 0.02 compared with pLL 10% serum; **P < 0.001 compared with pLL 1% serum. B: After 48 h of culture, cells were treated
or not treated with 2 ng/ml IL-1 for 4 h. Apoptosis was measured by ELISA, and apoptotic index is the absorbance [A405 nm  A490 nm]. Results
are means  SD for n  5 replicates from three independent experiments. *P < 0.003 relative to pLL (control). C: After 48 h of culture and
treatment as described above, cells cultured on pLL were stained for 20 min with 1 mg/ml Hoechst 33342 and 1.25 mg/ml propidium iodide for 20
min at 37°C, before fixation and TUNEL analysis. Death was analyzed as described in RESEARCH DESIGN AND METHODS. , apoptosis; p, secondary
necrosis; f necrosis.
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tested the effect of an anti-1 antibody (Ha2/5) that blocks
the adhesion of this integrin to its ECM on the survival of
-cells after 4 h of culture (Fig. 3A). On pLL, there was no
difference between cells treated with the control antibody
IgM and cells treated with Ha2/5. However, on the 804G
matrix, the number of TUNEL-positive cells was signifi-
cantly higher when treated with Ha2/5 (4.9%) compared
with control cells (2.3%). Furthermore, the spreading of
cells after 4 h of exposure to the 804G matrix was reduced
by Ha2/5 (Fig. 3B). The control antibody had no effect on
cell spreading and cell death at the concentration used
(not shown). These results suggest that the 1 integrin
subunit mediates the signal from the 804G matrix into the
cell, leading to increased spreading and survival.
Effect of 804G matrix on phosphorylation of signal-
ing proteins FAK, PKB/Akt, and ERK. FAK, which is
activated by phosphorylation upon integrin ligand binding,
mediates survival signaling downstream of integrins and
suppresses anoikis and serum withdrawal–induced apo-
ptosis (7,34,35). The PI 3-kinase–PKB/Akt pathway is
known to block various apoptotic stimuli. We therefore
investigated whether 804G matrix induces activation of
FAK and/or PKB/Akt. Cells were serum-starved in suspen-
sion for 1 h to reduce constitutive (serum-induced) phos-
phorylation before plating them for 30 min on pLL or 804G
in serum-free medium. Phosphorylation of Tyr397-FAK
and Ser473-PKB/Akt was analyzed by Western blot. Adhe-
sion of cells to 804G induced an increased phosphoryla-
tion of both proteins compared with adhesion to pLL,
whereas the total amount of actin was the same on both
substrates (Figs. 4A and B). These results suggest that this
matrix does indeed activate integrin-binding signaling
pathways. The amounts of total FAK and total PKB/Akt
were slightly decreased in cells on pLL compared with
those on 804G (Figs. 4A and B). It has been reported that
caspases cleave specific signaling proteins (including FAK
and PKB/Akt) during apoptosis (36). Therefore, the slight
decrease of total FAK and PKB/Akt protein amounts in
cells cultured on pLL could be due to augmented caspase
activity on this substrate compared with matrix.
The FAK signaling complex is known to mediate the
activation of the MAP kinase ERK pathway (37,38), a
well-known pro-survival pathway in a number of cell types
(11). Exposure of serum-starved cells to 804G matrix for
30 min induced higher phosphorylation of ERK1 and ERK2
(Thr-202/Tyr-204 phosphorylation) than pLL (Fig. 4C).
Attachment of cells to pLL, however, induced higher
phosphorylation of ERK proteins as compared with cells
in suspension (Fig. 4C). In summary, the 804G matrix
activates FAK (hallmark of integrin activation) as well as
PKB/Akt and ERK pathways.
Signaling pathways involved in pro-survival effects of
the 804G matrix. To investigate whether PI 3-kinase–
PKB/Akt and ERK pathways are involved in the antiapop-
totic effect of 804G matrix, we examined the effects of
LY294002 and PD98059. These are specific inhibitors of
both PI 3-kinase and MAP kinase/ERK kinase (MEK1),
respectively, and were found to be effective in rat -cells at
the concentration used (data not shown). In the short term
(4 h), blocking PI 3-kinase and MEK1 activities signifi-
FIG. 2. The spreading and survival of -cells on purified laminin-5 is similar to that of cells cultured on 804G matrix. A: Rat -cells were cultured
for 48 h under standard conditions on pLL-, 804G matrix– or purified laminin-5 (Ln-5)-coated dishes. Apoptotic (plus necrotic cells) were
identified by TUNEL. *P < 0.001 relative to pLL (control). B: Phase-contrast microscopy after 48 h of culture as in panel A.
FIG. 3. The 1 integrin subunit is involved in the spreading and improved survival of -cells induced by the 804G matrix. A: Cells were pretreated
with control antibody (IgM) or with anti-1 integrin antibody (Ha2/5) and then attached on pLL- or on 804G-coated dishes. After 4 h of culture
under standard conditions, cells were fixed, and cell death was analyzed by TUNEL. *P < 0.03 relative to 804G (IgM), pLL (IgM), and pLL (Ha2/5).
B: Phase-contrast microscopy after 4 h of culture as in panel A. A group of spread cells is shown by the arrow.
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cantly augmented cell death on 804G to the same extent
(Fig. 5A). This treatment did not affect cell death on pLL.
The combination of both inhibitors did not alter the effect
of each individual inhibitor, suggesting that they block a
common pathway activated by the matrix. However, cells
on 804G survived better than cells on pLL, even in pres-
ence of inhibitors, suggesting that both pathways are only
partially involved in the short-term antiapoptotic effect of
804G, or that the inhibitors were only partially effective
under these conditions. Blockade of the MAP kinase ERK
pathway with PD98059 during 48 h induced a striking
increase of the number of apoptotic cells on 804G and also
affected cell survival on pLL, albeit to a lesser extent (Fig.
5B). In the presence of this inhibitor, attachment to the
804G matrix no longer exerted any protective effect com-
pared with control (pLL). The Western blot analysis (Fig.
4C) showed that the attachment on pLL itself induces ERK
phosphorylation to a limited extent as compared with
suspended cells, although to a lesser extent than on 804G,
which may explain why 48 h of treatment with PD98059
also induced higher cell death in cells on pLL. It was also
noted that 48 h of culture with PD98059 did not affect the
well-spread morphology of the cells cultured on 804G, and
that DMSO (used for the dilution of inhibitors) alone had
no effect on cell survival and cell spreading at the concen-
tration used (not shown). Treatment of cells with the PI
3-kinase inhibitor LY294002 did not significantly affect cell
death on either pLL or 804G after 48 h (Fig. 5B), and
combined treatment with both inhibitors gave similar
results as treatment with PD98059 alone (Fig. 5B). These
results suggest that the MAP kinase ERK pathway is the
dominant one for long-term survival of primary pancreatic
-cells induced by the ECM.
Effect of 804G matrix on gene expression. Differential
expression on 804G matrix of genes involved in specific
signal transduction pathways such as those implicated in
apoptosis and cell cycle was investigated using low-
density cDNA microarray membranes (GEArray). Only
one gene present on this array was significantly overex-
pressed in cells cultured for 18 h on the 804G matrix
compared with control cells: IB (not shown). IB has
been reported to have an antiapoptotic function in pancre-
atic -cells (39). This overexpression was confirmed by
real-time quantitative PCR: the IBmRNA (normalized to
GAPDH mRNA levels) was at least three times more highly
expressed in cells cultured on 804G matrix compared with
cells cultured on pLL (Fig. 6A). IB protein levels were
measured by Western blot. IB protein was increased
slightly on 804G vs. pLL after 24 h of culture, with a clear
increase by 48 h (Fig. 6B). There were no differences in
IB expression (mRNA and protein) between noncoated
and pLL-coated dishes (data not shown). Although this
augmented protein expression correlates with the in-
creased gene transcription, we cannot exclude that this
difference might be a consequence (partly or completely)
of an enhanced degradation of this protein in cells cul-
tured on pLL-coated dishes compared with 804G.
The MAP kinase ERK pathway is involved in IB
overexpression induced by the 804G matrix. Given
that the 804G matrix stimulates the ERK cascade and that
this signaling pathway is involved in the pro-survival
effects of this matrix, we hypothesized that this cascade
might mediate the effect of the matrix on IB gene
expression. This was tested using the inhibitor PD98059.
Treatment of cells with PD98059 did not significantly affect
IB expression (mRNA) in cells cultured on pLL, but it
did reduce by 60% the IB overexpression induced by
the 804G matrix (Fig. 6A). Thus, these quantitative PCR
FIG. 4. 804G matrix induces phosphorylation of signaling proteins FAK, PKB/Akt, and ERK. FAK (A), PKB/Akt (B), and ERK1/2 (C)
phosphorylation was determined by Western blotting with specific anti-phospho antibodies compared with blotting with antibodies specific for
each corresponding protein. Each figure is representative of three independent experiments. Susp., suspension.
FIG. 5. Involvement of both ERK and Akt/PKB pathways in the pro-survival effect of the matrix. Cells were pretreated with inhibitors of PI
3-kinase (LY294002: LY) and/or of MEK1 (PD98059: PD) and then attached on pLL- or 804G-coated dishes. After 4 h (A) or 48 h (B), cell death
was analyzed by TUNEL. Results are shown as means  SEM of a minimum of three independent experiments. *P < 0.04 compared with 804G
control; **P < 0.01 compared with 804G control; ***P < 0.005 compared with control conditions (for pLL and 804G).  pLL; f, 804G.
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analyses show that blocking the ERK pathway significantly
reduces the effect of the 804G matrix on IB gene ex-
pression. This result supports the notion that the activa-
tion of the MAP kinase ERK cascade by the 804G matrix
might contribute to long-term survival of pancreatic -cells
by inducing the expression of antiapoptotic genes.
DISCUSSION
We examined whether ECM can rescue primary pancreatic
-cells from apoptosis and investigated the intracellular
pathways involved. The 804G matrix protects pancreatic
-cells from apoptosis under three different conditions:
“standard” culture conditions, after serum deprivation, and
in response to the cytokine IL-1. These results demon-
strate the importance of adequate ECM for -cell survival.
It is interesting to note that signaling pathways induced by
IL-1 in islet -cells differ when this cytokine is adminis-
tered in vivo compared with in vitro treatment (40). It has
been suggested that one primary difference between the in
vivo and the in vitro model systems might be the absence
of ECM in the latter (41).
It has been shown that laminin is a component of the
basement membrane surrounding islets in vivo, and that
the loss of this basement membrane occurring during islet
isolation leads to increased cell death (4,42). Experiments
performed with laminin-5 purified from 804G matrix (Fig.
2A and B) suggest that it is the major component of this
matrix responsible for its pro-survival effect. The fact that
this matrix induces higher phosphorylation of FAK com-
pared with attachment to pLL (Fig. 4A) indicates that it
engages and activates integrins. Our group has shown that
rat pancreatic -cells express 61 and 31 integrins
(27,33), which have both been identified as receptors for
laminin-5. It was shown previously that function-blocking
antibodies directed against the 6 integrin subunit blocked
cell spreading induced by 804G matrix (27). Here we show
that a blocking antibody directed against the 1 integrin
subunit reduces both the spreading and the improved sur-
vival induced by the 804G matrix (Fig. 3A and B). Collec-
tively, these data lead us to suggest that 61 integrin is a
major conduit for outside-in signaling pathway in -cells
established on this particular matrix.
The intracellular molecule(s) responsible for transduc-
ing cell-matrix signaling in -cells have not been studied
previously in detail. We now show that compared with
pLL, attachment of cells to the 804G matrix induces higher
levels of phosphorylation of both MAP kinase ERK and
PKB/Akt (Figs. 4B and C). Furthermore, apoptosis of cells
cultured on 804G was increased in the presence of the
MEK1 inhibitor PD98059 (4 and 48 h) and/or in the
presence of the PI 3-kinase inhibitor LY294002 (4 h only)
(Figs. 5A and B). These results strongly suggest that the
short-term pro-survival effect emanating from the 804G
matrix is mediated by both of these pathways, whereas
longer term effects are mediated at least in part by MAP
kinase ERK but not by PKB/Akt.
We propose that the role of both the PI 3-kinase–PKB/
Akt and MAP kinase ERK pathways in mediating the
short-term (4 h) pro-survival effects of the 804G matrix
may be related to their effects on preventing the cleavage
and subsequent activation of procaspase-8. Indeed, it has
been reported that activated PKB/Akt prevents apoptosis
by inhibiting death-inducing signaling complex assembly,
thus preventing procaspase-8 cleavage (43), whereas MAP
kinase activation deflects DISC signaling from activating
caspase-8 (44). This would also explain the nonadditive
effect of both inhibitors on short-term cell survival. During
the short-term studies, cells on 804G matrix survived bet-
ter than cells on pLL, even in the presence of inhibitors,
suggesting that the ERK and PKB/Akt pathways may be
only two components of the short-term antiapoptotic ef-
fect of the matrix. A potential mechanism contributing to
cell death on pLL, presumably unrelated to ERK and PKB/
Akt pathways, is “integrin-mediated death,” whereby unli-
gated integrins in cells adhering to substrates devoid of
appropriate ECM ligands can act as negative regulators of
cell survival (45,46). Unligated integrins are reported to
promote apoptosis by recruitment of caspase-8 to the
plasma membrane independent of death receptors or
Fas-associating protein with a death domain. Our results
showing that caspase-8 activation is significantly reduced
in cells cultured on 804G compared with cells cultured on
pLL (Table 1) support both of the above hypotheses.
The present work shows for the first time the impor-
tance of the ERK pathway in promoting survival of pan-
creatic -cells induced by the ECM. The fact that the ERK
FIG. 6. IB expression is induced by the 804G matrix, and this overexpression is reduced by treatment with the ERK inhibitor PD98059. A: Cells
were treated or not treated with PD98059 before plating them on pLL- versus 804G-coated dishes. After 18 h, RNA was extracted, and real-time
PCR was performed. The results (means  SD from two independent experiments) show the IB/GAPDH relative mRNA expression, which was
normalized to the control (pLL). B: The IB protein levels in cells cultured for 24 and 48 h, on pLL or on 804G, were analyzed by Western
blotting. This Western blot is representative of three independent experiments.
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pathway is involved in the antiapoptotic effect of the 804G
matrix on pancreatic -cells is intriguing because activa-
tion of this pathway has been reported to be involved in
cytokine-induced apoptosis in -cells (19,47). One poten-
tial explanation for this discrepancy is that cytokine- and
ECM-induced activation of ERKs may be significantly dif-
ferent in terms of duration and intensity, which may lead
to opposite effects on life-or-death decisions by the cell (48).
The finding that the 804G matrix induces overexpres-
sion of IB is most interesting because IB has been
shown to inhibit NF-B nuclear translocation and tran-
scriptional activity (49). In general, NF-B is reported to
mediate antiapoptotic signals. However, NF-B is consid-
ered as an important transcription factor, mediating IL-1–
induced signal transduction and regulating groups of
genes contributing to death in pancreatic -cells (31).
Overexpression of a nondegradable IB mutant, which
specifically blocks cytokine-induced NF-B activation,
prevents -cell apoptosis (39). The overexpression of the
IB gene induced by the 804G matrix may thus contrib-
ute to its antiapoptotic effect. It is well established that
ECM can influence gene expression via the MAP kinase
ERK pathway (11). In the present work, we show that
activation of the ERK pathway by the 804G matrix medi-
ates the overexpression of IB in -cells. This suggests
that activation of the MAP kinase ERK cascade by the
804G matrix might contribute to long-term survival of
pancreatic -cells by inducing the expression of antiapo-
ptotic genes.
Inadequate culture conditions have been suggested to
be responsible, at least in part, for the important loss of
islet cell viability before transplantation in diabetic pa-
tients. A prerequisite for the improvement of islet cell
maintenance in vitro, and consequently for increased
survival of the grafted cells, is to gain better knowledge of
both the intracellular pathways involved in cell survival
and factors regulating these signaling pathways. In this
context, these results are particularly relevant in providing
an insight into important signaling pathways activated by
ECM, which lead to improved pancreatic -cell survival
before transplantation.
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4. Major findings and perspectives of Part II (Paper 1) 
In this first part of the thesis work, the aims were the following: 1) to establish whether 
the interaction of primary rat pancreatic beta cells with an appropriate ECM (804G-ECM) might 
promote survival and 2) to get a preliminary insight into the pathways involved. 
This work establishes that 804G-ECM protects beta cells from death (both apoptosis 
and necrosis) as compared to control substrate pLL. This was assessed after 48h of culture in 
three different culture conditions: in presence of 10% FCS, in presence of 1% FCS (“serum-
deprived”), as well as in presence of the cytokine IL-1β. Beta cells cultured on 804G-ECM 
display reduced levels of caspase-8 activity compared to cells on pLL, providing a possible 
explanation for the anti-apoptotic effect of 804G-ECM. It was also found that the interaction 
between the ECM protein laminin-5 and the β1 integrin subunit is involved in the pro-survival 
effect of 804G-ECM. The phosphorylation state of the signaling proteins FAK, Akt and ERK on 
specific residues (reflecting their activity) was assessed by western blot. It was found that 804G-
ECM induces a rapid (within 30 minutes) phosphorylation of all of these kinases. The 
appearance of phosphorylated FAK sustains the hypothesis that 804G-ECM induces integrin 
signaling. To investigate the roles of the PI3K-Akt signaling module and the MAP kinase ERK 
pathway in the pro-survival effect of the 804G-ECM, the effect of blocking these pathways using 
pharmacological inhibitors was assessed. Inhibition of both of the PI3K-Akt and ERK pathways 
reduces the short-term pro-survival effect of the 804G-ECM (4h), while only inhibition of the 
ERK pathway abrogates the long-term (48h) anti-apoptotic effect of the 804G-ECM. Finally, low-
density microarrays using cDNA derived from beta cells cultured for 18h on pLL or on 804G-
ECM were performed to assess whether 804G-ECM is able to induce expression of genes. One 
gene was found to be overexpressed in cells cultured on 804G-ECM as compared to cells on 
pLL: the inhibitor of NF-κB (IκBα). Furthermore, it was found that the MAP kinase ERK pathway 
is involved in this 804G-ECM-induced overexpression of IκBα.  
 In summary, these results provide a first insight into signaling pathways induced by the 
804G-ECM leading to increased gene expression and improved cell survival. While many 
papers have reported a pro-survival role for Akt in beta cells, such a role for ERK is more 
controversial. For example, ERK has been shown to mediate cytokine-induced beta cell death. 
However, as discussed in Paper 1, cytokine- and 804G-ECM-induced activation of ERKs may 
significantly differ in terms of duration and intensity, which may lead to opposite effects on the 
cell. Furthermore, it has been recently reported that subcellular localization of activated ERK 
also plays a role in determining its biological outcomes (181). Therefore, it should be interesting 
to compare the subcellular localization, duration and intensity of ERK activity induced by 804G-
ECM compared to that induced by the cytokine IL-1β.  
What could be the downstream effectors of 804G-ECM-activated ERK and Akt/PKB? 
To date, over 50 ERK substrates have been characterized, including protein kinases, 
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transcription factors, transmembrane receptors and structural proteins, among others. These 
are distributed in different cellular compartments, including cytoplasm, nucleus and cytoskeleton 
(169). One ERK substrate that is an interesting candidate in the context of diabetes is the 
cAMP-reponse element binding protein (CREB). Loss of the ERK-CREB signaling pathway has 
been proposed to be involved in beta cell apoptosis induced by long-term hyperglycemia (212). 
Furthermore, CREB has been reported to mediate cAMP-mediated signaling leading to 
increased beta cell survival (213). In addition, mice deficient in CREB activity have been 
reported to develop diabetes secondary to beta cell apoptosis (213). Akt has a myriad of protein 
substrates involved in its anti-apoptotic signaling as well. In the context of the pancreatic beta 
cell survival, the potentially interesting substrates include the pro-apoptotic member of Bcl-2 
family  Bad, the X-linked inhibitor of apoptosis protein (XIAP), glycogen synthase kinase 3β 
(GSK3β) and forkhead transcription factors (including FoxO-1) (9; 192).  
 One unexpected and particularly interesting result was the finding that 804G-ECM 
induces the overexpression of IκBα. We found it most important to pursue this path not only 
because IκBα inhibits the transcription factor NF-κB, but also because its expression is induced 
by NF-κB. In addition, NF-κB has been reported to be a downstream effector of both the PI3K-
Akt and MAP kinase ERK pathways leading to increased cell survival. This led to the hypothesis 
that 804G-ECM might induce the transcriptional activity of NF-κB, which is the central 
hypothesis for the next part (Part III, Paper 2) of this work.  
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PART III (PAPER 2): 
 ACTIVATION OF THE TRANSCRIPTION FACTOR NF-κB BY ECM 
1.  Introduction to Part III (Paper 2) 
1.1. General Introduction on NF-κB 
The transcription factor NF-κB was discovered in 1986 as a factor in the nucleus of B 
cells that binds to the enhancer of the kappa light chain of immunoglobulin (214). Since, NF-κB 
has been shown to be expressed ubiquitously in the cytoplasm of all cell types, and to be 
conserved from Drosophila to man. NF-κB is a complex signaling module that plays a critical 
role in many biological processes, in response to various environmental stimuli. NF-κB 
regulates the expression of cytokines, growth factors and effector enzymes in response to many 
extra-cellular stimuli (215). The biological system in which the role of NF-κB seems to be the 
most important is the immune system (216). However, NF-κB has also been reported to play 
important roles in other biological processes such as embryonic development and the 
development, and the physiology of tissues such as the mammary gland, bone, skin and central 
nervous system (215). Dysregulation of NF-κB activity can mediate a wide variety of diseases 
(217), including cancer (218). In addition, NF-κB has been reported to play a role in the 
development of diabetes, at both the beta cell and insulin target tissues levels (217; 219). The 
role of NF-κB in the pancreatic beta cell is described below (Part III, § 1.5).  
The mammalian NF-κB family consists of five members: p65 (RelA), RelB, c-Rel, 
p50/p105 (NF-κB1), and p52/p100 (NF-κB2), (Fig. 8). NF-κB1 and NF-κB2 are synthesized as 
large precursors, p105 and p100, that are post-translationally processed to the DNA-binding 
subunits p50 and p52, respectively. NF-κB proteins are characterized by the presence of a 
conserved 300-amino acid motif Rel homology domain (RHD), containing a nuclear localization 
sequence (NLS), that is located at the N-terminus and is responsible for dimerization, interaction 
with inhibitors of NF-κB (IκBs) and  sequence-specific binding to DNA. In addition, p65 (RelA), 
RelB and c-Rel contain transactivation domains (TAD) in their C-terminus. The NF-κB proteins 
are able to form several different hetero- and/or homo-dimers that differentially control gene 
expression and are thus associated with specific biological responses. Dimers that contain RelA 
(p65) or c-Rel are transcriptional activators (215; 216; 220). The most common and studied 
dimer, which is simply called NF-κB, is the p50/p65 (RelA) heterodimer.  
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Fig. 8: Schematic representation of the NF-κB family of proteins. RHD: Rel homology domain; 
TAD: transactivation domain. Reproduced from reference (215).   
 
Two main pathways leading to activation of NF-κB have been defined: the classical 
(“canonical”) pathway and the alternative pathway (Fig. 9). These two pathways are thought to 
have distinct regulatory functions (216; 220). The canonical pathway is the best-characterized 
one, while the alternative pathway has been described recently (220). In the canonical pathway, 
in non-stimulated cells, NF-κB dimers (that can consist either of p50-RelA (p65) or of p52-RelA 
(p65) complexes) remain in the cytoplasm, where they are bound to and inactivated by inhibitory 
IκB subunits (221). Upon stimulation of the cell (with the pro-inflammatory cytokine TNFα, for 
example), signaling pathways lead to activation of the IKK (IκB kinase) complex resulting in 
phosphorylation of the IκB proteins which are subsequently recognized by the ubiquitin ligase 
machinery and targeted for degradation (222). The freed NF-κB dimers translocate to the 
nucleus, where they bind to specific sequences in the promoter or enhancer regions of target 
genes (215). In the pancreatic beta cell, only the canonical pathway leading to NF-κB activation 
has been described to date. Therefore, we will from now on focus on this pathway and on the 
p50/p65 (RelA) heterodimer. In addition to translocation to the nucleus subsequent to IκB 
degradation, regulation of p65 transcriptional activity also occurs by post-translational 
modifications, independently of IκB proteins. Indeed, increasing evidence indicates that 
phosphorylation and degradation of IκB and subsequent liberation of NF-κB are not sufficient to 
activate NF-κB-dependent transcription. One means of modulating the NF-κB transcriptional 
activity is by site-specific phosphorylation and acetylation of the p65 subunit itself (223-227).    
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Fig. 9: Two pathways leading to NF-κB activation: canonical (left), and non-canonical (right). 
Reproduced from reference (220). 
 
Once activated, NF-κB can then be down-regulated by multiple mechanisms. The best 
characterized pathway involves the IκBα proteins. As the IκBα gene is an NF-κB target, 
activation of NF-κB leads to generation of newly synthesized IκBα proteins that are able to 
inhibit nuclear translocation of NF-κB (215; 228-231). In addition, newly synthesized IκBα 
proteins have been reported to be able to export NF-κB from the nucleus into the cytoplasm 
(232).  Feed-back inhibition of NF-κB activity by the newly synthesized IκBα proteins leads to 
oscillations and thus temporal control of NF-κB activity. It has been proposed that precise 
temporal regulation of NF-κB activity by IκBα-induced feed-back inhibition allows an additional 
level in the control of gene expression (230; 231).   
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1.2. Functions of NF-κB 
NF-κB regulates the expression of genes involved in many different biological 
processes, such as proliferation, cell spreading and cell motility, differentiation, angiogenesis, 
normal immune function, and regulation of cell survival (218; 225). As the 804G-ECM has been 
shown to induce cell spreading (5) and cell survival (Paper 1), we were particularly interested in 
the possible roles of NF-κB in the two latter biological functions.  
 
1.2.1. Role of NF-κB in cell spreading and cell migration 
In the context of cancer, a number of studies have focused on the role of NF-κB in 
cellular invasion (reviewed by (218)). Cellular invasion involves migration of cells, a process that 
requires cell anchorage and spreading (233). It has been shown that NF-κB induces expression 
of several genes that are involved in spreading and/or migration of cells, including chemokines 
(such as IL-8 and IP-10) and matrix metalloproteinases (MMPs, (218; 234)). Furthermore, NF-
κB is involved in Fas apoptosis inhibitory molecule (FAIM)-induced neurite outgrowth (235) and 
NF-κB-dependent gene expression has been shown to be required for αvβ5-dependent cell 
motility on ECM (236). Finally, it has been proposed that there might be a functional relationship 
between the NF-κB subunit p65 and the actin cytoskeleton (237), suggesting that NF-κB may 
play a yet uncharacterized role in the cytoplasm.  
 
1.2.2. Role of NF-κB in the control of apoptosis 
NF-κB has been reported to both play pro-apoptotic and anti-apoptotic roles. The 
function of NF-κB in cell survival has been proposed to depend on the context of activation, type 
of inducer and/or cell type (224; 238). The last years have witnessed an explosion in the 
number of publications focusing on the role of NF-κB in apoptosis (more than 3000 PubMed-
cited publications between 1999 and 2004), and this topic will only be briefly summarized here.  
The first evidence of the anti-apoptotic role of NF-κB came from the analysis of p65-/- 
mice that died on embryonic day 15 from massive liver apoptosis (239). Embryonic fibroblasts 
(EFs) derived from these p65-/- mice are more susceptible to TNFα-induced apoptosis than 
control EFs, and this can be corrected by p65 reexpression (240). The role of NF-κB in 
preventing TNFα-induced apoptosis was confirmed the same year by three groups using a 
mutant, non-phosphorylatable form of the inhibitor of NF-κB (IκB) that acts as “super-repressor” 
by sequestering NF-κB in the cytoplasm (241-243). Since, NF-κB has been found to protect 
numerous cell types against diverse apoptotic insults, and to induce expression of many anti-
apoptotic genes, such as the inhibitor of apoptosis (IAP) proteins, c-FLIP, or Bcl-2 family 
proteins (224; 238). Furthermore, NF-κB is also able to repress induction of pro-apoptotic genes 
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such as Bax (244), and to inhibit transcriptional activity of the pro-apoptotic transcription factor 
GADD153/CHOP (245). Finally, NF-κB has been shown to play a role in growth factor-induced 
survival signaling including that induced by PDGF (246).  
On the other hand, NF-κB has also been reported to play pro-apoptotic roles (224; 
238). It can induce expression of pro-apoptotic genes, such as FasL following T-cell receptor 
engagement (247; 248), and also repress anti-apoptotic gene expression following ultraviolet C 
radiation (249). Intriguingly, as described below, the majority of studies investigating the role of 
NF-κB in pancreatic beta cells have led to the conclusion that it plays a pro-apoptotic role in 
these cells. 
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1.3. Activation of NF-κB by ECM 
As mentioned in Part II (§ 1.6. ECM and regulation of gene expression), the effect of 
ECM on the expression of genes is now well acknowledged (88; 250). Lin and colleagues were 
the first to show that fibronectin attachment specifically increases nuclear translocation and 
transcriptional activity of the p50/p65 NF-κB heterodimer in monocytic leukemia cells THP-1 
(251). Subsequently, activation of NF-κB following attachment to ECM was reported to occur in 
other cell types, such as fibroblasts, smooth muscle cells (on fibronectin, (252)), and endothelial 
cells (by EHS matrix (253), or by the αvβ3 ligand osteopontin (254)). The effects of fibronectin 
on monocyte gene expression has been analyzed by a global gene expression analysis 
(GeneCalling (255)). This analysis revealed that adhesion of cells to fibronectin results in 
increased expression of a large number of genes regulated by NF-κB, and that this increased 
gene expression is strongly potentiated by growth factors (255). However, since cells in 
suspension (and not attached cells) were used as controls for this gene expression analysis, 
and since simple attachment of monocytes onto plastic activates NF-κB (256; 257), these latter 
data remain to be confirmed using a more appropriate control (e.g. attached cells).  
Several groups have shown that antibody-induced crosslinking of β1 integrins can 
induce nuclear translocation and transcriptional activity of NF-κB (175; 211; 251; 258; 259). The 
global effect of the engagement of α5β1 integrins by fibronectin on endothelial cell (HUVEC) 
gene expression has been analyzed, using cells plated on pLL as control (260).  This study 
confirmed that α5β1 integrin engagement by fibronectin is sufficient to activate a broad gene 
expression program, and that endothelial cell attachment activates the NF-κB pathway of gene 
induction (260). By contrast, adhesion of endothelial cells to laminin through α2β1 integrin has a 
much more modest effect on NF-κB activity and on gene expression pattern (260). The effect of 
a given integrin on NF-κB activity appears to be cell-type specific. For example, in endothelial 
cells, laminin does scarcely affect NF-κB activity (260), while in mammary tumors, laminin-5 
ligation of α6β4 has a strong effect on the activity of NF-κB (184). In addition, it has been 
reported that osteopontin, an αvβ3 integrin ligand, and fibronectin activate NF-κB (through β3 
integrin), while collagen type 1 or β1 integrin ligation are unable to induce NF-κB activation in 
endothelial cells (254). This is in contrast to monocytes, where β1 integrin ligation is sufficient to 
activate NF-κB. It is thus most likely that the effects on NF-κB activity and on gene expression 
induced by the interaction of a given cell with a particular ECM depends on the repertoire of 
integrins present on this cell, and the composition of the ECM to which it adheres. 
The first discovered function of ECM-induced NF-κB activity was regulation of survival. 
Overexpression of the non-degradable form of IκBα (that blocks NF-κB nuclear translocation 
and activation) abolishes αvβ3 integrin-mediated endothelial cell survival, indicating that αvβ3 
integrin-induced NF-κB activity can play a pro-survival role (254). Furthermore, the same study 
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reports that although NF-κB activity is required for the pro-survival effects of osteopontin (αvβ3 
ligand) and vitronectin on endothelial cells, it is not involved in fibronectin-, laminin-, and 
collagen I-induced cell survival (254). Thus, only specific ECM induce integrin-mediated survival 
that is dependent on NF-κB. It has also been reported that NF-κB activation by engagement of 
α6β4 integrins to autocrine laminin-5 leads to increased survival of mammary tumor cells and to 
acquisition of anchorage independence (184). Thus, this work suggests that the laminin-5 – 
α6β4 – NF-κB pathway provides protection against anoikis in mammary epithelial cells (184).   
By contrast, it has been reported that NF-κB antisense oligonucleotides do not affect 
viability but instead inhibit differentiation of endothelial cells cultured on ECM (253). However, 
as this report does not show the effects of these antisense oligonucleotides on NF-κB protein 
levels, it is difficult to establish to which extent ECM-induced NF-κB activity is affected by this 
treatment. Therefore, these latter data remain to be confirmed. 
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1.4. Pathways involved in the control of NF-κB activity 
As indicated above, activation of NF-κB can be regulated at several levels. Two main 
levels of NF-κB activation have been defined: the first occurs in the cytoplasm, upon 
degradation of the inhibitory IκB proteins that allows the nuclear translocation of NF-κB, while 
the second takes place in the nucleus, regulating the transcriptional activity of NF-κB (215; 223; 
225). A multitude of signaling pathways generated by a large array of stimuli have been 
reported to regulate one or both levels controlling NF-κB activity. These pathways include 
signaling proteins such as protein kinase A (PKA), casein kinase II (CKII), protein kinase C 
(PKC), PI3K, Akt and ERK (215; 223; 225; 261). We will focus on the signaling pathways that 
seem to be activated in pancreatic beta cells by 804G-ECM (see Paper 1): the PI3K-Akt 
signaling module and the MAP kinase ERK pathway. 
 
1.4.1. PI3K-Akt pathway and NF-κB activity 
In a study aimed at identifying signaling pathways utilized by the cytokine IL-1β to 
activate NF-κB, it was observed that IL-1β induces an increase in PI3K activity, as well as a 
physical interaction between IL-1 receptor and the p85 subunit of PI3K (262). Furthermore, 
inhibition of PI3K activity alters IL-1β-induced DNA binding and transcriptional activation of NF-
κB, as assessed by EMSA and reporter gene assay, indicating that activation of NF-κB by IL-1β 
requires PI3K. In an another study, it was reported that PI3K inhibitors inhibit IL-1β-induced p65 
phosphorylation and NF-κB-dependent gene expression (263). These results suggest that PI3K 
can be involved in IL-1β-induced p65 transactivation potential (263). A role for Akt in NF-κB 
activation was reported in 1999 by four different groups (246; 263-265). It was observed that 
overexpression of Akt (wild-type or constitutive active form) induces NF-κB activation (263; 
264). Furthermore, the involvement of Akt in NF-κB activation induced by PDGF or by TNF was 
also reported (246; 265). Numerous groups have since reported a role for Akt in NF-κB 
activation induced by diverse stimuli. However, there are also some studies that show that PI3K 
and/or Akt are not involved in the regulation of NF-κB activity (266; 267). It has been proposed 
that the role of Akt in NF-κB activity is cell-type dependent, and that the IKKα/IKKβ ratio may be 
a factor that determines to which extent Akt activity influences NF-κB activity (268). 
Rosmashkova and colleagues (246) were the first to report an anti-apoptotic role of the 
PI3K/Akt/NF-κB signaling pathway. Since, several stimuli (including oncogenes, PDGF and 
TGF-β1) have been reported to induce the anti-apoptotic PI3K/Akt/NF-κB pathway in diverse 
cell types (159; 246; 269). In the context of the ECM, treatment of cells with PI3K inhibitors 
(LY294002 and/or wortmannin) has been reported to prevent nuclear translocation of p65 upon 
adhesion to fibronectin (260) and to inhibit the transcriptional activity of NF-κB induced by an 
activating β1 integrin antibody (175). However, it has been shown that osteopontin-induced NF-
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κB activity is not altered upon treatment with LY294002 (254), suggesting that the involvement 
of PI3K in integrin-induced NF-κB activity is not a general mechanism. Studies investigating a 
possible role of Akt in ECM and/or integrin-dependent NF-κB transcriptional activity have not yet 
been reported.  
In summary, both PI3K and Akt have been reported to be involved in IL-1β-induced NF-
κB activity, while only PI3K has been reported to be involved in fibronectin and/or β1 integrin-
induced NF-κB activity to date. In addition, the ability of PI3K and/or of Akt to mediate the 
activation of NF-κB induced by diverse stimuli appears to be cell-type specific. Finally, the 
PI3K/Akt/NF-κB pathway has been reported to play an anti-apoptotic role in different contexts.  
 
1.4.2. ERK pathway and NF-κB activity 
ERK has been shown to be involved in NF-κB activation induced by different stimuli, 
including TNFα (270), LPS (271), IL-1β (272) and TGF1-β (269). ERK has also been involved in 
serum-induced, calcium-mediated NF-κB activation (273). Interestingly, it has been proposed 
that ERK is involved in the expression of some, but not all IL-1β-induced, NF-κB-dependent 
genes (274). In particular, this report proposes that ERK is required for the induction of the “late” 
NF-κB-dependent genes, and therefore that ERK is an important temporal regulator of NF-κB-
dependent gene regulation (274). ERK-induced NF-κB activity has been reported to play an 
anti-apoptotic role. Interestingly, the anti-apoptotic effect of ERK-induced NF-κB activity appears 
to be highly dependent on the nature of the pro-apoptotic stimuli (181). In the context of ECM-
induced NF-κB activity, ERK has been shown to be partially involved in α4β1-induced NF-κB 
binding to DNA in THP-1 cells (211). However, several groups have reported that ECM and/or 
integrin-induced NF-κB activity do not depend on MEK1 activity (175; 254; 260). Thus, the role 
of the MAP kinase ERK pathway in integrin-dependent NF-κB activity may be cell type-
dependent and/or context-dependent.   
In summary, ECM has been shown to be able to induce expression of genes through 
induction of the transcriptional activity of NF-κB. The signaling molecules FAK, PI3K, Akt and 
ERK have all been reported to be able to activate NF-κB. Several signaling molecules have 
been shown to be involved in ECM-induced NF-κB activity, and these include PI3K and ERK. 
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1.5. NF-κB and the pancreatic beta cell 
As described above, type 1 diabetes mellitus is an auto-immune disease causing 
specific destruction of pancreatic beta cells. Pro-inflammatory cytokines, in particular IL-1β, IFN-
γ and TNF-α, that are released by macrophages, monocytes and natural killer cells, play 
important roles in beta cell dysfunction and destruction associated with type 1 diabetes. 
Activation of NF-κB by pro-inflammatory cytokines IL-1β and TNFα in the pancreatic beta cell is 
well documented, and this pathway is now considered as one of the major factors involved in 
beta cell dysfunction and death in type 1 diabetes (29; 32).  
Increased production of nitric oxide (NO), due to induction of inducible nitric oxide 
synthase (iNOS), is thought to be an important signal in cytokine-induced cell death (29). IL-1β-
induced iNOS expression is inhibited by treatment of cells with proteasome inhibitors that block 
NF-κB activation (diethyldithiocarbamate DETC, and PDTC) (275), suggesting that NF-κB plays 
a critical role in IL-1β-induced iNOS expression and in cytokine-induced beta cell death. 
Adenoviral transfer of non-phosphorylatable and non-degradable IκBα variant (hence called Ad-
IκB), that sequesters NF-κB in the cytoplasm, has also been used as a more specific means 
than proteasome inhibitors to assess the role of NF-κB in beta cells. Ad-IκB prevents IL-1β-
induced dysfunction, NO production and Fas-triggered, IL-1β-mediated induction of apoptosis in 
human islets, indicating that NF-κB is involved in the deleterious effects of IL-1β leading to beta 
cell dysfunction and death (276). The protective effect of Ad-IκB against cytokine (IFNγ + IL-1β)-
induced apoptosis has also been reported for purified rat beta cells (277). MIN6 clones that 
stably express the same IκB variant are protected against cytokine (IL-1β + IFNγ + TNFα)-
induced apoptosis compared to control clones (278); and peptide-mediated transduction of the 
IKK inhibitor Nemo-binding domain (NBD), that inhibits IL-1β-induced NF-κB activation, blocks 
IL-1β-mediated dysfunction of mouse islets (279). Furthermore, in vivo transduction of this 
peptide in mice prior to isolation prevents loss of function and viability of islets due to isolation 
(279).  Thus, these papers indicate that cytokine-induced NF-κB activity plays a pro-apoptotic 
role in pancreatic beta cells. However, there is one report that indicates that cytokine (TNFα)-
induced NF-κB activity can have anti-apoptotic effects on the mouse insulinoma cell line MIN-6 
and in primary mouse islets (280). Indeed, TNFα alone is not able to induce apoptosis of beta 
cells. However, treatment of cells with the proteasome inhibitor MG132 (that inhibits NF-κB) or 
with Ad-IκB sensitizes cells to TNFα-induced apoptosis, suggesting that TNFα-induced 
activation of NF-κB protects beta cells (MIN-6, mouse islets) from TNFα-mediated apoptosis 
(280). 
To better understand the mechanisms of this cytokine-NF-κB connection in cytokine-
induced beta cell dysfunction and death, microarray analysis has been performed on purified 
primary rat beta cells that were treated or not with cytokines (IL-1β + IFNγ), and that were 
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infected with either a control adenovirus or with Ad-IκB (281). This approach led to the 
identification of 66 cytokine-modified and NF-κB-regulated genes in beta cells. Most notably, it 
was found that cytokine-induced NF-κB activation leads to an increase in the expression of pro-
apoptotic genes (such as c-Myc, Fas and iNOS) and of chemokines and cytokines, that might 
contribute to the activation and the recruitment of inflammatory cells to the area of insulitis. 
Furthermore, it was observed that cytokine-induced NF-κB activity leads to a decrease in the 
expression of genes involved in the maintenance of the differentiated beta cell functions, such 
as Pdx-1, Isl-1 and Glut-2. Finally, cytokine-induced modifications of the expression of several 
transcription factors, such as C/EPBβ, C/EBPδ, c-Myc and Isl-1 were found to be NF-κB-
dependent (281). In summary, these data suggest that NF-κB is a key switch regulator of 
transcription factors and gene networks controlling cytokine-induced beta cell dysfunction and 
death occurring in the pathogenesis of type 1 diabetes.  
Until recently, IL-1β production and release by islets was considered to be limited to 
type 1 diabetes. However, in a recent breakthrough report, it was suggested that this 
mechanism is also involved in the development of type 2 diabetes (282). As described above 
(Part I, § 1.2.2.), glucotoxicity is considered as one of the main mechanisms leading to 
apoptosis in type 2 diabetes. Maedler and colleagues have reported that culture of human islets 
with high glucose concentrations induces secretion of IL-1β by the beta cells themselves, 
leading to their dysfunction as well as an increase in beta cell death (282). Inhibition  of IL-1β 
signaling (using IL-1Ra) blocks high glucose- and IL-1β-induced NF-κB activity; and blockade of 
IL-1β signaling and of NF-κB activity (with the proteasome inhibitor PDTC) block the deleterious 
effects of high glucose concentrations on both beta cell function and survival. Thus, these 
results indicate that release of IL-1β by beta cells cultured in high glucose concentrations is 
followed by NF-κB activation and, ultimately, by impaired beta cell function and survival (282). In 
addition, IL-1β-producing cells are observed in pancreatic sections of poorly controlled type 2 
diabetic patients but not in non-diabetic control subjects (282). The diabetes-prone gerbil 
Psammomys obesus is an animal that develops type 2 diabetes upon high-energy diet (21). 
Interestingly, IL-1β expression is induced in the beta cells of the diabetes-prone Psammomys 
obesus fed with a high-energy diet, but not in the diabetes-resistant counterparts (282). These 
observations indicate that the effect of high glucose on IL-1β production leading to NF-κB 
activation in the beta cell might be a physiologically relevant mechanism involved in the 
development of type 2 diabetes. Furthermore, it was recently reported that two drugs that inhibit 
NF-κB activity (pioglitazone and sodium salicylate) protect human beta cells against impaired 
function and apoptosis induced by IL-1β and high glucose (283).  
As described above, NF-κB is known to play both pro- and anti-apoptotic roles in 
diverse cell types. In particular, it seems that the context, nature, duration and dose of the 
stimuli leading to activation of NF-κB determine the biological outcome of NF-κB-dependent 
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gene expression (230; 284-286). This seems to also be the case for the pancreatic beta cell. 
Indeed, in the studies described above, beta cells were exposed for prolonged times to high 
doses of cytokines. However, it has been reported that when beta cells are exposed for a limited 
period (24h) to low concentrations of IL-1β, the protective effects of NF-κB-regulated genes 
preponderate and beta cells are protected against conditions that cause necrosis (287). This 
suggests that the effects of IL-1β-induced NF-κB activity are dose- and/or duration-dependent. 
This concept is supported by a recent report indicating that the first phase of IL-1β-induced NF-
κB activity leads to an increase of beneficial beta cell defense/repair protein expression (288). 
By contrast, the second phase of NF-κB activity induced by IL-1β seems to be harmful because 
it then leads to a sustained decrease of specific beta cell proteins like insulin, Glut-2 and Pdx-1 
with a concomitant increase of other “aspecific” proteins and iNOS transcription (288). However, 
in this study, the effects of IL-1β-induced NF-κB activity were assessed using the protease 
inhibitor TPCK, and thus remain to be confirmed with more specific means to inhibit NF-κB.   
Other stimuli than cytokines have been shown to activate NF-κB in pancreatic beta 
cells, such as depolarization and Ca2+ influx (289). However, the consequences of this NF-κB 
activity remain to be characterized. GLP-1 has been reported to induce the NF-κB DNA-binding 
activity and the expression of the anti-apoptotic NF-κB target genes IAP-1 and Bcl-2 in INS-1 
cells (190). Interestingly, GLP-1-induced protection of beta cells from glucolipotoxicity is 
abolished upon treatment of cells with the NF-κB inhibitor Bay 11-7082, suggesting that NF-κB 
mediates the anti-apoptotic effect of GLP-1 on beta cells cultured in glucolipotoxic conditions 
(190). Stable overexpression of c-FLIP in the mouse beta cell line βTc-Tet leads to protection of 
mouse beta cells against cytokine-induced caspase-8 activation and apoptosis, as well as to an 
enhanced NF-κB activity (290). Although this report does not show evidence that these two 
phenomena are related, it is proposed by the authors that protection of beta cells against 
cytokine-induced apoptosis by c-FLIP overexpression may be linked to its effect on NF-κB 
activity (290).  Finally, in a very recent report Norlin and colleagues report the generation of 
mice harbouring beta-cell specific overexpression of a non-phosphorylatable mutant of IκBα 
that inhibits NF-κB activity (291). Interestingly, glucose-stimulated insulin secretion was 
impaired in the transgenic mice, while beta cell survival was not affected (291).  
In summary, the majority of studies assessing the effects of IL-1β-induced NF-κB 
activity report a deleterious effect of this activity for pancreatic beta cell function and survival. 
Furthermore, this signaling module has been suggested to be potentially involved in the 
pathogenesis of both types of diabetes. Little is known about the functional consequences of 
NF-κB activity induced by stimuli other than cytokines. However, these data suggest the 
functional consequences of NF-κB activity induced by stimuli other than cytokines may differ 
considerably from the deleterious effects of cytokine-induced NF-κB activity on the beta cell. 
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Finally, no studies on the possible effects of ECM and/or integrins on NF-κB activity have been 
reported yet for the pancreatic beta cell.  
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2. Specific Aims of Paper 2 
Gene expression analysis performed with gene arrays (as shown in Paper 1) and 
additional experiments performed in our laboratory with Affymetrix microarrays, followed by real-
time RT-PCR validation have shown that 804G-ECM induces overexpression of a number of  
genes, including IκBα, NF-κB1 (p105), and the chemokines Mob-1 (also called IP-10) and 
GRO-1 (growth-related oncogene 1). As these genes have all been reported to be induced by 
NF-κB, we hypothesized that 804G-ECM might induce the transcriptional activity of NF-κB. 
Furthermore, we hypothesized that activated NF-κB might mediate at least some of the effects 
of 804G-ECM on the pancreatic beta cell. The possibility that NF-κB might mediate some of the 
positive effects of 804G-ECM was most intriguing, as this transcription factor has mostly been 
reported to play deleterious roles in the pancreatic beta cell (in the context of cytokine-induced 
NF-κB activity). However, there are some evidences that indicate that NF-κB activity induced by 
stimuli other than cytokines can lead to biological outcomes that differ from those induced by 
cytokine-induced NF-κB activity.  
While this work was in progress, our lab started to compare the organization of the 
actin cytoskeleton in cells cultured on 804G-ECM with cells cultured on control substrate (pLL). 
It was found that 804G-ECM induces a remodeling of the actin cytoskeleton. 804G-ECM can 
thus affect the following biological functions in the pancreatic beta cell: spreading, actin 
cytoskeleton remodeling, glucose-stimulated insulin secretion and cell survival. Therefore, the 
specific aims of this second part of the thesis were to: 
- establish whether 804G-ECM is able to induce nuclear translocation and/or 
transcriptional activity of NF-κB; 
- investigate whether 804G-ECM-induced NF-κB activity plays a role in the following 
effects of 804G-ECM on the pancreatic beta cell: cell spreading, actin cytoskeleton remodeling, 
glucose-stimulated insulin secretion and cell survival 
- determine whether the MAP kinase ERK pathway and the PI3K-Akt signaling module 
are involved in 804G-ECM-induced NF-κB activity. 
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3. Paper 2 
“ Activation of NF-κB by Extracellular Matrix Is Involved in Spreading and Glucose-
stimulated Insulin Secretion of Pancreatic Beta Cells” 
Hammar et al. J Biol Chem, 280: 30360-30637 (2005) 
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Laminin-5-rich extracellular matrix derived from
804G cells (804G-ECM) engages 1 integrins to induce
spreading, improve glucose-stimulated insulin secretion
(GSIS), and increase survival of pancreatic beta cells.
The present study examines whether 804G-ECM acti-
vates the transcriptional activity of NF-B and the in-
volvement of NF-B in those effects of 804G-ECM on
pancreatic beta cells. 804G-ECM induces nuclear trans-
location and the DNA binding activity of the p65 subunit
of NF-B. 804G-ECM-induced nuclear translocation of
NF-B was weak as compared with that induced by in-
terleukin-1. Transient 804G-ECM-induced DNA bind-
ing activity of NF-B (peak at 2 h) and overexpression of
NF-B target genes IB and NF-B1(p105) (peak at 4 h)
were observed. When NF-B was inhibited by an inhib-
itor of IB phosphorylation (Bay 11-7082) or by a re-
combinant adenovirus expressing the nonphosphorylat-
able form of IB, 804G-ECM-induced cell spreading and
actin cytoskeleton organization were reduced. GSIS
from cells on 804G-ECM was inhibited 5-fold, whereas
cell survival was not affected. In summary, the results
indicate that 804G-ECM induces a transient and moder-
ate NF-B activity. This study shows for the first time
that ECM-induced NF-B activity is necessary in main-
taining GSIS, although it does not affect survival of pan-
creatic beta cells. The effects of ECM-induced NF-B
activity contrast with the deleterious effects of cyto-
kine-induced NF-B activity. It is proposed that tran-
sient and moderate NF-B activity is essential for
proper function of the pancreatic beta cell.
Engagement of cells by cognate components of the extracel-
lular matrix (ECM)1 is crucial for various biological processes,
including cell adhesion, spreading, proliferation, differentia-
tion, migration, apoptosis, and gene induction (1). This engage-
ment involves cell adhesion mediated by integrins, a family of
heterodimeric molecules composed of an  and a  subunit,
with a long extracellular domain binding to the ECM, and a
short cytoplasmic domain associating with the actin cytoskel-
eton and affiliated proteins (2). ECM is an important compo-
nent of the pancreatic islet microenvironment. It is a dynamic
complex of different molecules that serve as a cellular scaffold
regulating both differentiation and survival.
Our group has reported recently (3) that the laminin-5-rich
ECM secreted by 804G cells (804G-ECM) induced increased
spreading and improved insulin secretion in response to glu-
cose in purified pancreatic beta cells. It was subsequently
shown that this ECM has a beneficial effect on cell survival and
that it activates intracellular signaling pathways involving the
signaling proteins focal adhesion kinase, Akt/PKB, and ERK
(4). It has been shown that its effects on pancreatic beta cells
(spreading, glucose-stimulated insulin secretion, and survival)
are mediated by the engagement of 1 integrins to laminin-5
(3, 4).2 Furthermore, it was found that plating pancreatic beta
cells on 804G-ECM causes overexpression of the inhibitor of
NF-B (IB) (4), which is a well established NF-B target
gene. This finding led us to hypothesize that 804G-ECM might
activate the NF-B signaling pathway, leading to the expres-
sion of a subset of genes, which might be involved in the effects
of 804G-ECM on the pancreatic beta cell. Engagement of inte-
grins to different ECM molecules (vitronectin, fibronectin, and
laminin) has been shown to activate NF-B (5–9) and to pro-
mote an NF-B-dependent program of gene expression (10, 11).
However, this has not yet been reported for the pancreatic beta
cell nor indeed for primary, nondividing cells.
NF-B is a transcription factor that plays a pivotal role in
many cellular responses to environmental changes, including
control of the host immune and inflammatory response, apo-
ptosis, cell cycle progression, cell migration, development, in-
duction of proliferation, and differentiation (12, 13). In non-
stimulated cells, NF-B remains in the cytoplasm, where it is
bound to and inactivated by inhibitory IB subunits (14). Upon
stimulation of the cell (with pro-inflammatory cytokines for
example), signaling pathways lead to phosphorylation of the
IB proteins that are subsequently recognized by the ubiquitin
ligase machinery and are targeted for degradation. The freed
NF-B heterodimers translocate to the nucleus, where they
bind to specific sequences in the promoter or enhancer regions
of target genes (reviewed in Ref. 12). Activated NF-B can then
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be down-regulated by multiple mechanisms, including the well
characterized feedback pathway involving newly synthesized
IB proteins (12, 15, 16).
In the pancreatic beta cell, NF-B is considered as an impor-
tant transcription factor mediating IL-1-induced signal trans-
duction and regulating groups of genes contributing to death
and dysfunction (17). Indeed, inhibition of NF-B has been
shown to protect against the deleterious effects of IL-1 in
purified mouse islets (18), rat beta cells (19), and human islets
(20, 21). Given that NF-B has thus been considered previously
to be pro-apoptotic in the beta cell, the possibility that activa-
tion of NF-B signaling by 804G-ECM may be beneficial for
beta cell function and/or survival was quite intriguing. The
aims of this study were to investigate whether 804G-ECM
activates the NF-B transcriptional activity in primary pancre-
atic beta cells, to study the kinetics of this activity, and to
determine the involvement of this pathway on the effects of
804G-ECM on the pancreatic beta cell. Here we show that
804G-ECM induces transient nuclear translocation of NF-B
and its transcriptional activity in pancreatic beta cells, which is
followed by overexpression of IB and NF-B mRNAs. Block-
ing the MAP kinase ERK pathway with PD98059 inhibited the
DNA binding activity of NF-B and overexpression of IB,
whereas the PI3K inhibitor LY294002 did not. We report, for
the first time, that long term blockage of NF-B activity dis-
rupts cytoskeleton remodeling, inhibits spreading induced by
804G-ECM, and reduces glucose-stimulated insulin secretion.
Furthermore, we show that induction of NF-B activity by
804G-ECM is not involved in its control of pancreatic beta
cell survival.
MATERIALS AND METHODS
Reagents and Antibodies—Bay 11-7082 (an inhibitor of IB phospho-
rylation) was purchased from BioMol Research Laboratories (Hamburg,
Germany). PD98059 (a specific MEK1 inhibitor) and LY294002 (a phos-
phatidylinositol 3-kinase (PI3K) inhibitor) were purchased from Calbio-
chem, and both were used at final concentration of 50 M as described
previously (4). The polyclonal antibodies against the p65 subunit of NF-B
(C-20) and against the inhibitors of NF-B (IB, C-21; IB, C-20) were
from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal anti-actin
was purchased from Chemicon International (Temecula, CA). Anti-mouse
horseradish peroxidase and anti-rabbit horseradish peroxidase antibodies
were from Amersham Biosciences. Alexa Fluor® 546 phalloidin was pur-
chased from Molecular Probes.
Islet Isolation and Beta Cell Purification—All experiments were per-
formed on primary pancreatic beta cells sorted from adult rat islet cells
by autofluorescence-activated flow cytometry. Islets of Langerhans
were isolated by collagenase digestion of pancreas from male Wistar
rats (weighing 150–200 g), followed by Ficoll purification using a mod-
ification of procedures described previously (22). Cell preparation was
performed as described previously (3). Pancreatic beta cells were then
separated from non-beta cells by autofluorescence-activated sorting
using a fluorescence-activated cell sorter, FACStar-Plus (BD Bio-
sciences), as described previously (22). This purification procedure
yields a population consisting of 95% beta cells (3).
804G-ECMMatrix Preparation—The 804G cells were the kind gift of
Desmos (San Diego, CA). They were grown in Dulbecco’s modified
Eagle’s medium containing 10% fetal calf serum and 5.6 mM glucose. At
confluence, cells were rinsed and maintained for a further 3 days in the
same medium in the absence of fetal calf serum. Conditioned medium
(referred to hereafter as 804G-ECM) was collected, centrifuged at 120
g for 10 min to remove any detached cells and debris, filtered through
a 0.22-m Millipore filter, and frozen at 20 °C for later use.
Coating of Plastic Dishes with pLL and 804G-ECM—Aliquots (60 l)
of pLL (0.1 mg/ml) or of 804G-ECM were layered at the center of 35-mm
culture Petri dishes (adherent dishes for mammalian cell culture).
Dishes were kept in a damp box at 37 °C for 18–20 h before being rinsed
three times with sterile H2O and air-dried. Dishes coated with pLL
were used as controls.
Cell Culture—Sorted beta cells were washed twice in 10–15 ml of
sterile Dulbecco’s modified Eagle’s medium (Invitrogen) containing 10%
fetal calf serum, 11.2 mM glucose, 110 g/ml sodium pyruvate and
supplemented with 110 units/ml penicillin, 110 g/ml streptomycin,
and 50 g/ml gentamycin, followed by centrifugation for 10 min at
130  g. Aliquots of 3  105 cells were seeded in nonadherent 100-mm
diameter Petri dishes containing 9 ml of medium. Cells were then
incubated for 20 h at 37 °C to allow full recovery of any cell surface
molecules that may have been lost or damaged during islet isolation or
cell purification. After recovery, cells were resuspended at a density of
4  105 cells/ml, and aliquots of 50 l were plated as droplets on plastic
dishes coated with pLL or with 804G-ECM.
NF-B Activation—The cellular localization of NF-B in various
conditions was analyzed by immunofluorescence. Cells were fixed with
4% paraformaldehyde (20 min, room temperature) and permeabilized
with 0.5% Triton X-100 (5 min, room temperature), and immunofluo-
rescence for NF-B was performed. The percentage of cells with domi-
nant nuclear NF-B staining was determined (five different fields were
examined for each condition). DNA binding activity of NF-B was
quantified using an ELISA-based kit (Trans-AMNF-B p65 from Active
Motif, Rixensart, Belgium) using attached oligonucleotides correspond-
ing to an NF-B consensus site and detected by an anti-p65 subunit
antibody according to the manufacturer’s instructions.
Western Blot Analysis—To analyze IB and IB protein expres-
sion, attached cells were washed with ice-cold PBS supplemented with
1 mM sodium vanadate and protease inhibitors and lysed in sample
buffer 1 (62 mM Tris-Cl, pH 6.8, 2% SDS, 5% glycerol, 1% 2-mercap-
toethanol). Protein concentrations were determined with the Amido
Black method (23), and equal amounts of total protein were loaded for
SDS-PAGE. All samples, after separation on an SDS-polyacrylamide
gel, were electroblotted onto nitrocellulose membranes (Schleicher &
Schuell) for immunoblotting with the appropriate antibody. An ECL
protein detection kit (Amersham Biosciences) and a Kodak image sta-
tion were used for visualization of the bands.
Quantitative Real Time PCR—RNA was isolated using RNeasy mini
kit (Qiagen). cDNA was synthesized with Superscript II (Invitrogen),
using 1 g of total RNA in a 20-l reaction volume. The double-stranded
DNA-specific dye SYBR Green I (Eurogentech, Belgium) and fluores-
cein (Bio-Rad) were incorporated into the PCR buffer (qPCR core kit,
Eurogentech) to allow for quantitative detection of the PCR product.
The results were analyzed using the iCycler iQ System (Bio-Rad). The
housekeeping gene L3 was used as an internal control. The primers
used were as follows: NF-B forward 5 GTC TAG CAA TCA CGG CTG
CA 3, NF-B reverse 5 CTC AAG CCA CCA TAC CCC AA 3; IB
forward 5 TGC TGA GGC ACT TCT GAA AGC 3, IB reverse 5 TCC
TCG AAA GTC TCG GAG GTC 3.
Inhibition of NF-B Activity—Two approaches were used to inhibit
NF-B activity as follows: use of recombinant adenoviruses expressing
GFP (control virus) or mutated nondegradable IB (IBnp), and
pharmacological inhibition of IB phosphorylation with Bay 11-7082
(24). The recombinant adenoviruses were a kind gift from Dr. Wrede,
University of Regensburg, Germany (19, 25). The adenoviruses were
titrated using Adeno-XTM Rapid Titer kit (Clontech) according to the
manufacturer’s instructions. Cells (105 cells/ml) were infected in sus-
pension for 2 h at 37 °C with 2300 infectious units/ml, washed twice
with culture medium, and left in suspension for 24 h before plating
them on pLL or on 804G-ECM-coated dishes. To investigate the effect of
the inhibition of NF-B activity using Bay 11-7082, cells were pre-
treated for 1 h with 2.5 and 5 M Bay 11-7082 before plating them on
pLL- or on 804G-ECM-coated dishes. Me2SO was added to the controls
at the same final concentration as used for the inhibitors. Cells were
then cultured in the continued presence of the inhibitor. The analyses of
the effects of IBnp-expressing virus and of Bay 11-7082 on NF-B
nuclear translocation, cell spreading, cell function (insulin secretion),
and cellular death were performed in parallel.
Measurement of Spreading of Cells—After 24 h of culture and treat-
ment of cells as described above, cells were fixed with 4% paraformalde-
hyde (20 min, room temperature) and stained with Evans Blue. Phase-
contrast views of different fields were photographed, and spreading of
cells was quantified using ScionImageTM software (Frederick, MD).
F-actin Cytoskeleton Visualization—After 24 h of culture and treat-
ment of cells as described above, cells were fixed with 4% paraformalde-
hyde (20 min, room temperature) and permeabilized with 0.5% Triton
X-100 (4 min at room temperature). After blocking with PBS  0.5%
bovine serum albumin, cells were incubated for 30 min with Alexa Fluor®
546 phalloidin (5 units/ml), subsequently rinsed, and mounted under
glass coverslips. The preparations were observed with a confocal
microscope.
Analysis of Cell Death by TUNEL—Attached cells were washed with
PBS and fixed with 4% paraformaldehyde (20 min, room temperature).
After permeabilization with 0.5% Triton X-100 (5 min, room tempera-
ture), the TUNEL assay (with fluorescein-dUTP detecting the free
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3-OH strand breaks resulting from DNA degradation) was performed
with the In Situ Cell Death Detection kit, according to the manufactur-
er’s instructions (Roche Applied Science). The preparations were then
rinsed with PBS and incubated (15 min, room temperature) with 1
g/ml Hoechst 33342 to allow detection of nuclei and to facilitate the
analysis. The quantification of dead cells was performed by using an
Axiocam fluorescence microscope.
Insulin Secretion Assay and Insulin Content—Cells were washed
three times with a modified Krebs-Ringer bicarbonate HEPES buffer
(KRBH: 125 mM NaCl, 4.74 mM KCl, 1 mM CaCl2, 1.2 mM KH2PO4, 1.2
mM MgSO4, 5 mM NaHCO3, 25 mM HEPES, pH 7.4, 0.1% bovine serum
albumin) supplemented with 2.8 mM glucose and preincubated with this
same buffer for 1 h at 37 °C. Cells were then incubated for 1 h at 37 °C
with KRBH containing 2.8 mM glucose (basal secretion), followed by 1 h
at 37 °C with KRBH containing 16.7 mM glucose (stimulated secretion).
The incubation buffer was recovered, and the cells were extracted with
acid/ethanol. The buffer was centrifuged to remove any detached cells
and debris. Aliquots were stored at 20 °C for subsequent insulin
measurement performed by radioimmunoassay using the charcoal sep-
aration technique described previously (26). GSIS is expressed as se-
creted insulin upon glucose challenge (16.7 mM glucose, for 1 h), as a
percentage of insulin content. Insulin content is expressed as the quan-
tity of insulin extracted at the end of the stimulation test. The total
protein levels after 24 h of culture in all conditions used were quantified
using the Amido Black method (23), as described above.
Presentation of Data and Statistical Analysis—Unless stated other-
wise, data are presented as mean  S.E. for “n” independent experi-
ments, and levels of significance for differences between groups were
assessed by Student’s t test for unpaired groups.
RESULTS
804G-ECM Induces NF-B Nuclear Translocation—This
study was performed with laminin-5-rich extracellular ma-
trix derived from 804G rat bladder carcinoma cells (804G-
ECM). 804G-ECM induces attachment and spreading of rat
primary beta cells, because of engagement of 1 integrins by
laminin-5 contained in this ECM (3, 4). 804G-ECM is thus
used as a validated model to study signaling pathways acti-
vated by this engagement.
In the canonical NF-B pathway, one of the first steps in-
volved in NF-B-dependent gene regulation is the phosphoryl-
ation and subsequent degradation of the inhibitor of NF-B
(IB)), leading to the nuclear translocation of the p65 subunit
of NF-B (RelA). To investigate a possible involvement of 804G-
ECM in NF-B transcriptional activity, the cellular localization
of NF-B after short term exposure (1 h) to 804G-ECM com-
pared with control (pLL-coated dishes) was assessed by immu-
nofluorescence for the p65 subunit of NF-B (Fig. 1A). The
number of cells with nuclear NF-B localization was quantified
(Fig. 1B). 804G-ECM induced a significant increase in the
number of cells with nuclear NF-B (19%) compared with con-
trol (less than 5%, Fig. 1B). The cytoplasmic staining for NF-B
was still apparent in all cells on 804G-ECM, suggesting that
only a fraction of the total pool of cytoplasmic NF-B is trans-
located into the nucleus in response to 804G-ECM (Fig. 1A). By
contrast, treatment of cells for 20 min with 2 ng/ml IL-1
induced the nuclear translocation of p65 in all treated cells, and
this was complete as there was no more cytoplasmic staining
for NF-B (not shown).
804G-ECM Induces NF-B Transcriptional Activity—To as-
sess whether DNA binding activity of NF-B is induced by
804G-ECM, the amount of p65 complexes binding to oligonu-
cleotides containing an NF-B consensus binding site was
quantified by ELISA. The DNA binding activity of NF-B in
cells cultured on 804G-ECM-coated dishes as compared with
control was increased after 1 h of culture, and this increase was
significant after 2 h of culture (Fig. 2). This activity was de-
creased after 4 h of culture suggesting that 804G-ECM-induced
NF-B DNA binding activity is transient.
It is well established that activated NF-B induces expres-
sion of IB. Newly synthesized IB binds to NF-B, provid-
ing a negative feedback loop for the NF-B signaling pathway
(12). Activated NF-B is also able to induce the expression of
NF-B1 (p105) in several systems (11, 27). To investigate
whether 804G-ECM is able to induce NF-B transcriptional
activity, IB and NF-B1 mRNA levels were quantified by
real time PCR in cells cultured on pLL- or on 804G-ECM-coated
dishes. IB mRNA levels were increased after 2 h on 804G-
ECM, and both IB and NF-B1 mRNA levels were signifi-
cantly increased by 804G-ECM after 4 and 8 h of culture to
return to control (pLL) levels at 24 h (Fig. 3, A and B). The
kinetics of 804G-ECM-induced IB and NF-B1 gene expres-
sion thus correlate with those of NF-B DNA binding activity
(Fig. 2). In summary, these data indicate that 804G-ECM in-
duces NF-B transcriptional activity transiently, most proba-
bly as a consequence of feedback inhibition resulting from
increased expression of IB.
Regulation of IB and IB Protein Levels by 804G-
ECM—To investigate whether 804G-ECM induces IB and/or
IB degradation, Western blots were performed with protein
extracts from cells cultured for 1 h on pLL or on 804G-ECM-
coated dishes. Quantification of the resulting bands normalized
to actin showed that there was no significant decrease of IB
and IB protein levels on 804G-ECM as compared with pLL
after 1 h of culture (Fig. 4).
IB and IB protein levels were also analyzed after 24 h of
culture on pLL- or on 804G-ECM-coated dishes. Levels of IB
FIG. 1. 804G-ECM induces NF-B nuclear translocation. A, cells
were fixed after 1 h of exposure to pLL (control) or 804G-ECM, and
NF-B was detected by immunofluorescence. Arrows show examples of
cells with nuclear localization of NF-B. B, the number of cells with
nuclear NF-B localization was quantified as a percent of total. *, p 
0.05 relative to pLL (n 4), with a minimum of 100 beta cells examined
for each condition in each experiment.
FIG. 2. Kinetics of NF-B DNA binding activity induced by
804G-ECM. NF-B DNA binding activity (normalized to pLL, 1 h) was
measured by ELISA (absorbance, 450–650 nm) after different times of
culture on pLL or on 804G-ECM-coated dishes. *, p  0.05 relative to
pLL at respective time point (n  3).
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protein were significantly increased on 804G-ECM after 24 h of
culture as compared with pLL and as compared with 804G-
ECM after 1 h of culture (Fig. 4). By contrast, IB protein
levels were not altered with time or by the substrate used.
Although NF-B induces expression of IB, it does not control
expression of IB (28). Therefore, these results suggest that
the 804G-ECM-induced IB overexpression occurs specifically
through NF-B.
Inhibition of NF-B Activity; Effects on Spreading and Actin
Cytoskeleton Remodeling—To investigate the function of the
804G-ECM-induced NF-B activity, Bay 11-7082, an inhibitor
of IB phosphorylation and thus of NF-B nuclear transloca-
tion (24), was used. Bay 11-7082 induced a dose-dependent
decrease of 804G-ECM-induced NF-B nuclear translocation,
and a final concentration of 5 M of Bay 11-7082 was necessary
to induce a complete and significant decrease compared with
control condition (Fig. 5A). Similar results were observed when
the effect of this inhibitor on 804G-ECM-induced NF-B DNA
binding activity was assessed by ELISA (not shown). Further-
more, Bay 11-7082 inhibited overexpression of IB mRNA
induced by 804G-ECM, thus confirming that it inhibits the
transcriptional activity of NF-B (Fig. 8B). We have shown
previously (3) that 804G-ECM induces spreading of the pan-
creatic beta cell, and this effect is glucose-dependent. NF-B
has been shown to be involved in cell motility through its effect
on gene expression (reviewed in Ref. 29), leading us to hypoth-
esize that 804G-ECM-induced NF-B activity might be in-
volved in spreading of beta cells by 804G-ECM. Treatment of
cells with Bay 11-7082 significantly reduced spreading of cells
on 804G-ECM as assessed after 24 h of culture (Fig. 5B).
In order to visualize actin cytoskeleton organization in cells
after 24 h of culture, F-actin was labeled with phalloidin. As
reported by our group (30), and as shown in Fig. 5C, cells
cultured on 804G-ECM organize their actin to form distinct
fibers in the cell interior, whereas no clear actin organization
could be seen in cells plated on pLL. When treated with Bay
11-7082, the intracellular actin fibers were disrupted in cells
cultured on 804G-ECM. Although evaluation of cortical actin
organization can be hampered by the shape of a cell, and cells
FIG. 3. NF-B and IB mRNA levels are regulated by 804G-
ECM. Cells were cultured on pLL or on 804G-ECM-coated dishes;
mRNA was extracted at the indicated time points, and real time reverse
transcription-PCR was performed. The results shown are NF-B (A)
and IB (B) mRNA levels relative to L3 (internal control), normalized
to control conditions (cells on respective substrate for 30 min). *, p 
0.05; **, p  0.005 relative to pLL at the respective time point (n  3).
FIG. 4. Regulation of IB and IB protein levels by 804G-
ECM. Cells were cultured for 1 or 24 h on pLL or 804G-ECM-coated
dishes; proteins were extracted, and Western blot was performed for
IB and IB. The resulting bands were scanned, and the density of
each band (measured using ScionImageTM software) was normalized to
the corresponding actin band. Control, suspended cells. §, p  0.05
versus 804G 1 h; *, p  0.05 versus pLL 24 h (n  3).
FIG. 5. Inhibition of NF-B activity with Bay 11-7082 alters
spreading and actin cytoskeleton remodeling. Cells were preincu-
bated for 1 h with Bay 11-7082 (2.5 or 5 M), before plating them on pLL
or 804G-ECM-coated dishes in the continued presence of the inhibitor
and for the indicated times. A, effect of Bay 11-7082 on NF-B nuclear
translocation. Cells were fixed after 1 h, and NF-B was detected by
immunofluorescence. The number of cells with a predominant nuclear
NF-B localization was quantified as a percent of total. Results are
shown as means  S.D. (n  3 for control and 5 M Bay; n  2 for 2.5
M Bay). *, p 0.02 relative to pLL control; **, p 0.02 relative to 804G
control, with a minimum of 100 beta cells examined for each condition
in each experiment. B, effect of Bay 11-7082 on spreading of cells
induced by 804G-ECM. Cells were fixed after 24 h; photographs were
taken, and the area of cells was quantified using ScionImageTM soft-
ware. Cell area is expressed as arbitrary units (a.u.). *, p 0.005 versus
pLL control; **, p  0.02 versus 804G control (n  3–4). C, effect of Bay
11-7082 (5 M) on actin cytoskeleton organization. Cells were fixed after
24 h, and F-actin filaments were labeled with Alexa Fluor® 546 phal-
loidin. Scale bar  10 m. The confocal plane was set at the basal face
(contact with culture surface) of the cells.
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on 804G-ECM in the presence of the inhibitor were less spread,
close inspection of the confocal images (Fig. 5C) suggests a
better developed and more consequent cortical actin ring in the
treated cells.
Recombinant adenovirus expressing nondegradable IB
(IBnp) has been shown to be an effective inhibitor of NF-B
nuclear translocation and transcriptional activity (19, 20).
804G-ECM-induced nuclear translocation of NF-B was de-
creased in cells transduced with the recombinant IBnp virus
as compared with cells transduced with the control (GFP) ad-
enovirus (data not shown). The effect of IBnp on cell spread-
ing was analyzed after 24 h of culture on pLL or on 804G-ECM.
Spreading of cells infected with IBnp was reduced compared
with cells infected with the control virus (Fig. 6), confirming
that 804G-ECM-induced NF-B activity is involved in the
spreading of pancreatic beta cells induced by 804G-ECM.
Inhibition of NF-B Activity; Effects on Insulin Secretion—
The importance of cell-matrix interactions for optimal GSIS
(insulin secreted at 16.7 mM glucose) by pancreatic beta cells in
culture has been demonstrated by us (3) and by other groups
(31–36). However, the mechanism involved has yet to be clar-
ified. It has been suggested that there is a correlation between
increased spreading of cells with their ability to respond opti-
mally to glucose (3). As NF-B activity seems to be involved in
spreading of cells and organization of the actin cytoskeleton
induced by 804G-ECM (Figs. 5 and 6), we hypothesized that it
might be involved in the beneficial effects of 804G-ECM on
GSIS. As shown in Fig. 7A and in Table I, GSIS of cells cultured
for 24 h on 804G-ECM was significantly increased compared
with cells cultured on pLL. Bay 11-7082 induced a dose-de-
pendent decrease of GSIS of cells cultured on 804G-ECM, and
a final concentration of 5 M of this inhibitor induced a signif-
icant decrease of GSIS in cells on both pLL and 804G-ECM
(Fig. 7A and Table I). Furthermore, the fold stimulation of
insulin secretion (amount of insulin secreted at 16.7 mM glu-
cose compared with that secreted at 2.8 mM glucose) was sig-
nificantly decreased in treated cells, both on pLL and on 804G-
ECM (Table I). In addition, Bay 11-7082 induced a significant
decrease in “absolute” stimulated insulin secretion (i.e. amount
of secreted insulin at 16.7 mM glucose, per dish and hour) as
well as an increase in total insulin content of cells plated on
804G-ECM, as compared with the control condition (Table I).
Cellular protein content was similar in all conditions (Table I).
Bay 11-7082 thus inhibits insulin secretion. In summary, these
results indicate that 804G-ECM-induced NF-B activity is in-
volved in spreading, actin cytoskeleton organization, and GSIS
of pancreatic beta cells.
Inhibition of ECM-induced NF-B Activity Does Not Affect
Cell Survival—804G-ECM protects pancreatic beta cells
against apoptosis (4), so we hypothesized that NF-B might
mediate its pro-survival effect. TUNEL assays were performed
on cells cultured for 24 h on pLL or on 804G-ECM-coated
dishes, in the absence or in the presence of Bay 11-7082. Treat-
ment of cells with 5 M Bay 11-7082 did not affect cell survival
either on pLL or on 804G-ECM (Fig. 7B). Similar results were
obtained using adenoviruses expressing nonphosphorylatable
IB (data not shown). Therefore, it seems that 804G-ECM-
induced activity of NF-B is not involved in the control of
survival and/or apoptosis of pancreatic beta cells.
Involvement of the MAP Kinase ERK Pathway in 804G-ECM-
induced NF-B Activity—We have shown previously that
804G-ECM induces phosphorylation of the MAP kinases ERK1
and ERK2, as well as of Akt/PKB, and that both pathways
seemed to be involved in the anti-apoptotic effect of 804G-ECM
(4). The signaling pathways involving ERK and Akt/PKB have
both been reported to be able to activate NF-B (5, 10, 29, 37).
To get a preliminary insight into how 804G-ECM activates
NF-B transcriptional activity, the effects of PD98059 (inhibi-
tor of MEK1 and thereby of the MAP kinase ERK pathway) and
of LY294002 (inhibitor of PI3K and thereby of Akt/PKB signal-
ing) on the DNA binding activity of NF-B and on the overex-
pression of IB induced by 804G-ECM were analyzed. As
shown in Fig. 8A, PD98059 inhibited the NF-B DNA binding
activity by 40% (p  0.0005). We have shown previously that
PD98059 inhibits the overexpression of IB induced by 804G-
ECM (4). Taken together, these results suggest that the MAP
kinase ERK pathway might be involved in the activation of
NF-B induced by 804G-ECM. By contrast, the inhibitor
FIG. 6. Adenovirus-mediated inhibition of NF-B alters
spreading of cells induced by 804G-ECM. A, effect of nonphospho-
rylatable IB mutant (IB np) on cell spreading. Cells were infected
with control virus (GFP) or with IBnp and plated on pLL- or on
804G-ECM-coated dishes. Cells were fixed 24 h later. B, the area of cells
was quantified using ScionImageTM software. The data shown are rep-
resentative of two independent experiments. a.u., arbitrary units.
FIG. 7. Inhibition of 804G-ECM-induced NF-B activity affects
glucose-stimulated insulin secretion but does not affect sur-
vival. Cells were pretreated or not for 1 h with Bay 11-7082 before 24 h
of culture on pLL or on 804G-ECM-coated dishes in the continued
presence of the inhibitor. A, after the 24-h culture period, short term
insulin secretion was measured over 1 h in static incubation at 2.8 and
16.7 mM glucose as indicated. For stimulated insulin secretion (16.7 mM
glucose): *, p  0.01 versus pLL control; **, p  0.02 versus pLL 2.5 M;
***, p  0.001 versus 804G control (n  5–6 from three independent
experiments). B, cells were fixed 24 h later, and cellular death was
quantified by TUNEL. *, p  0.05 versus pLL in respective condition
(n  3).
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LY294002 (50 M) had no effect either on the DNA binding
activity of NF-B (Fig. 8A) or on the expression of IB (Fig.
8B), suggesting that the PI3K-Akt/PKB pathway is not in-
volved in the regulation of the transcriptional activity of NF-B
by 804G-ECM.
DISCUSSION
In this report we show that 804G-ECM induces nuclear
translocation of NF-B, that it increases binding of NF-B to
DNA, and that it induces overexpression of the well established
NF-B target genes NF-B1 (p105) and IB. Collectively,
these data indicate that 804G-ECM induces NF-B transcrip-
tional activity in primary pancreatic beta cells. Others have
reported that various ECMs are able to activate NF-B in
different cell types; however, most studies have been performed
in cell lines (transformed or not), and to our knowledge there
has been no such study in primary, nondividing cells.
In the canonical pathway leading to NF-B activation, others
have observed a substantial degradation of IB prior to
NF-B nuclear localization. In our system, the degradation of
IB after 1 h of culture on 804G-ECM was not significant as
compared with control (pLL), suggesting that only a small
fraction of the total IB pool is degraded. The consequence
would be that only a minor fraction of NF-B cytosolic dimers
is translocated to the nucleus. The fact that the cytoplasmic
staining for NF-B was still apparent in all cells exposed for 1 h
to 804G-ECM sustains the latter hypothesis.
After 24 h of culture, IB protein levels were significantly
increased on 804G-ECM as compared with pLL, and this in-
crease was sustained for at least 48 h (4). This prolonged
overexpression of IB is most interesting, because increased
IB expression will both prevent additional NF-B nuclear
translocation and remove NF-B from its nuclear binding sites
(12) and could thus be responsible for the observed transience
of 804G-ECM-induced NF-B activity.
Several different signaling proteins have been reported to
mediate signaling from ECM to NF-B, including MAP kinase
ERK (37), PI3K (5, 10), and Rho GTPase Rac (5, 10, 38). We
have reported previously (4) that the MAP kinase-ERK and
PI3K-Akt/PKB pathways are activated by 804G-ECM, suggest-
ing that these latter pathways might be involved in 804G-
ECM-induced NF-B activity. Based on the use of selective
inhibitors, we now show that the MAP kinase ERK pathway,
but not the PI3K-Akt/PKB pathway, mediates the increased
DNA binding activity of NF-B as well as overexpression of
IB induced by 804G-ECM.
As reported previously by our group, plating beta cells on
804G-ECM induces their attachment, cytoskeleton remodeling,
and cell spreading. Here we report that long term blockage of
NF-B activity by pharmacological means (Bay 11-7082) or by
adenoviral overexpression of nonphosphorylatable IB im-
pairs 804G-ECM-induced spreading of the cells. This inhibitory
effect might depend on expression of genes induced by NF-B.
Indeed, it has been reported by other groups that NF-B can
mediate overexpression of proteins involved in spreading
and/or migration of cells (29).
Furthermore, we have observed that blocking NF-B activity
with Bay 11-7082 impairs GSIS, but it does not affect cell
survival. While this work was in preparation, Norlin et al. (39)
reported the effects of attenuating basal NF-B activity on
GSIS and on cell survival, using transgenic mice expressing
nonphosphorylatable IB. Most interestingly, although their
FIG. 8. A, effects of inhibitors of the MAP kinase ERK and the
PI3K-Akt/PKB pathways (PD98059 and LY294002) on NF-B DNA
binding activity. Cells were pretreated or not with PD98059 (50 M) or
with LY294002 (50 M) for 15–30 min before plating them on pLL- or on
804G-ECM-coated dishes. NF-B DNA binding activity (normalized to
control) was measured by ELISA (absorbance, 450–650 nm) after 2 h of
exposure to 804G-ECM. *, p  0.0005 (n  4). B, effects of NF-B
inhibitor Bay 11-7082 and LY294002 on 804G-ECM-induced overex-
pression of IB mRNA. Cells were pretreated or not with Bay 11-7082
(5 M) or with LY294002 (50 M) for 15–30 min before plating them on
pLL- or on 804G-ECM-coated dishes. mRNA was extracted after 4 h of
culture, and IB mRNA levels were measured by reverse transcrip-
tion-PCR. The results (means  S.D. of two independent experiments)
are shown as IB mRNA levels relative to the internal control L3,
normalized to control condition (pLL, control).
TABLE I
Effect of inhibition of 804G-ECM-induced NF-B activity on secretion and cell content of insulin
Cells were pretreated or not with 5 M Bay 11-7082, plated on pLL- or 804G-ECM-coated dishes, and cultured for 24 h in the continued presence
of this inhibitor. Fold increase indicates insulin secretion at 16.7 mM glucose/2.8 mM glucose.
pLL 804G-ECM
Control Bay 11-7082 Control Bay 11-7082
Insulin secretion (16.7 mM Glc) (% content/h) 4.38  0.06 1.36  0.25a 9.23  1.34a 1.71  0.44b
Insulin secretion (2.8 mM Glc) (% content/h) 0.42  0.04 0.21  0.01c 0.47  0.04 0.21  0.025c
Fold increase 10.7  1.7 6.1  1.1d 19.7  4.6 8  1.6d
Insulin secretion (16.7 mM Glc) (ng/(dish  h)) 14.96  1.34 5.93  1.01d 13.17  2.58 4.42  1.27d
Insulin secretion (2.8 mM Glc) (ng/(dish  h)) 1.34  0.2 0.97  0.13 0.67  0.08e 0.55  0.07f
Insulin content (ng/dish) 325.8  31 459.2  51.9 141.5  7.4e 276.5  29.7b
Cellular protein content (g/dish) 4.25  0.38 4.42  0.4 3.96  0.39 4.56  0.29
a p  0.01 versus pLL control.
b p  0.002 versus 804G-ECM control.
c p  0.005 versus control condition on respective substrate.
d p  0.02 versus control condition on respective substrate.
e p  0.02 versus pLL control.
f p  0.02 versus pLL Bay 11-7082 (n  5–6 from three independent experiments). The cellular protein contents were measured in a separate
series of experiments (n  3 from two independent experiments).
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approach was different from ours, the observed phenotypes
because of NF-B inhibition were similar in both models; GSIS
was impaired, whereas beta cell survival was not affected.
We have shown previously that the MAP kinase ERK path-
way could be involved in the pro-survival effect of the 804G-
ECM but that it does not affect spreading of beta cells (4). As
discussed above, this pathway seems to be involved in 804G-
ECM induction of NF-B activity as well. It is intriguing in this
context that inhibition of NF-B did not affect beta cell survival
but that it did inhibit spreading of cells. ERK is known to affect
the activities of a multitude of signaling pathways and tran-
scription factors (40), regulating migration and survival of
cells. Therefore, we propose that ERK effector(s) other than
NF-B might mediate its pro-survival effect. Spreading and/or
migration of cells is an extremely complex process, involving
the interplay of several signaling pathways (41). Further stud-
ies are therefore mandatory to better dissect the inter-depen-
dence of the MAP kinase ERK and NF-B pathways as well as
other candidate signaling proteins (such as the Rho GTPases)
involved in the effects of the 804G-ECM on the pancreatic
beta cell.
What is the connection between NF-B and GSIS? Different
mechanisms may be involved, and in our opinion, they might
well complete each other. One possible connection between
NF-B and GSIS is the actin cytoskeleton, and another one is
regulation of gene expression. The actin filaments are orga-
nized in two ways in secretory cells as follows: a cortical F-actin
web (rim or ring) underneath the plasma membrane and actin
filament fibers distributed throughout the cytosol (42, 43).
Many studies, including in pancreatic islets, have reported that
the actin web limits the access of the secretory granules to the
cell boundary; disruption or remodeling of the web is believed
to be a prerequisite for exocytosis (42, 44–46). On the other
hand, the function of actin filaments in the cell interior is less
well understood. However, dynamic association of insulin-con-
taining granules with actin cytoskeleton is thought to be in-
volved in insulin exocytosis. As shown in this work, 804G-ECM
induces remodeling of the actin cytoskeleton, leading to the
appearance of actin filament fibers in the cell interior. Upon
treatment with Bay 11-7082, these actin fibers were no more
apparent, and this may underlie impaired insulin secretion.
The cortical actin web appeared more prominent in the treated
cells, and this may further impair insulin secretion. Therefore,
we suggest that NF-B might be involved in GSIS through the
remodeling of the actin cytoskeleton. Depolarization-induced
Ca2 is a required step for GSIS to occur. Most interestingly, it
has been reported that depolarization/Ca2 influx can activate
NF-B transcriptional activity and that the ERK inhibitor
PD98059 blocked this activation of NF-B (47). However, the
consequences of such depolarization-induced NF-B activity
are still unknown (47).
It has been shown that expression of genes implicated in
glucose uptake, oxidative metabolism, and Ca2-triggered exo-
cytosis is perturbed in transgenic mice expressing nonphospho-
rylatable IB (39). Furthermore, long term treatment of
neuronal cells with tumor necrosis factor- enhances depolar-
ization-induced increases of Ca2, and it has been suggested
that these effects are induced via altered gene expression me-
diated by NF-B (48). Therefore, we propose that blockage of
804G-ECM-induced NF-B activity might repress expression of
genes necessary for well regulated GSIS.
It is now well acknowledged that NF-B plays a major role in
cytokine-induced beta cell dysfunction and apoptosis (17). How-
ever, this study shows a completely different aspect of NF-B
function in beta cells. A critical question arises: how does a
given stimulus lead to specific biological end points through
regulation of NF-B activity? The functional consequences of
NF-B activity seem to depend on several different factors,
such as the kinetics, extent, and context of activation of NF-B.
804G-ECM-induced nuclear translocation of NF-B appeared
to be moderate when compared with that occurring after cyto-
kine treatment. Furthermore, we show that 804G-ECM-in-
duced binding of NF-B to DNA declines after 2 h of exposure
to 804G-ECM and that 804G-ECM-induced overexpression of
IB and NF-B1 (p105) mRNAs begins to decay after 8 h of
culture, indicating that 804G-ECM-induced NF-B activity is
transient. This contrasts with the sustained activity of NF-B
induced by cytokines.3 These differences in kinetics and extent
of NF-B activity may explain the different functional out-
comes mediated by 804G-ECM- and cytokine-induced NF-B
activation. It has been reported that the first phase of IL-1-
induced NF-B activity leads to the beneficial increase of beta
cell defense/repair protein expression. By contrast, the second
phase of NF-B activity induced by IL-1 is harmful, because it
leads to a sustained decrease of specific beta cell proteins like
insulin, GLUT-2, and PDX-1 with a concomitant increase of
other “aspecific” proteins and inducible nitric-oxide synthase
transcription (49). In summary, these data combined with our
own data support the concept that transient and/or low NF-B
activity is beneficial, whereas sustained and/or strong NF-B
activity is deleterious for the pancreatic beta cell.
Recently it has emerged that the transactivation potential of
NF-B is modulated by post-translational modifications, in-
cluding phosphorylation and acetylation of NF-B subunits as
well as of histones surrounding NF-B target genes (reviewed
in Refs. 50 and 51). Site-specific phosphorylation of the p65
subunit of NF-B can occur by a large variety of kinases in
response to different stimuli (51) and may target NF-B to a
particular subset of genes (52). We hypothesize that IL-1 and
804G-ECM might induce phosphorylation of p65 on distinct
sites, leading to different biological responses. Experiments
aimed at exploring this hypothesis are underway in our labo-
ratory. The next challenge would be to inhibit selectively the
NF-B activity leading to its deleterious effects without inter-
fering with its beneficial outcomes.
The procedure leading to pancreatic beta cell isolation prior
to pancreatic islet transplantation involves disruption of cell-
cell and cell-ECM contacts (33, 53). The isolated pancreatic
beta cells lose glucose responsiveness and eventually die when
maintained in culture for a long period of time. By contrast,
when layered on appropriate ECM, pancreatic islet cell func-
tion and survival can be maintained (3, 4, 31–33, 35, 36, 54).
Here we show that ECM induces transient and moderate ac-
tivity of the transcription factor NF-B (p65) and that ECM-
induced NF-B activity is involved in spreading, cytoskeleton
organization, and improved function (GSIS) of primary pancre-
atic beta cells. We propose that transient and moderate NF-B
activity is essential for well regulated glucose-stimulated insu-
lin secretion in the pancreatic beta cell.
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4. Major findings and perspectives of Part III (Paper 2) 
In this second part of the thesis work, the major aims were to establish whether 804G-
ECM is able to activate the transcription factor NF-κB, and to investigate the function(s) of 
804G-ECM-induced NF-κB activity in the pancreatic beta cell.  
As expected from the gene expression analyses (described in Part III, § 2), 804G-ECM 
does induce nuclear translocation of NF-κB (p65), its binding to DNA, as well as its 
transcriptional activity leading to the increased expression of IκBα. We observed that the effect 
of 804G-ECM on NF-κB nuclear translocation and DNA-binding activity is weak as compared to 
the effect induced by the cytokine IL-1β. Furthermore, DNA-binding activity of NF-κB and over-
expression of IκBα induced by 804G-ECM are transient (as assessed up to 24h of culture).  
To get an insight into how 804G-ECM activates NF-κB, we investigated whether 
blockade of the MAP kinase ERK and of the PI3K-Akt pathways would affect the 804G-ECM-
induced NF-κB activity. We found that blockade of the MAP kinase ERK pathway but not of the 
PI3K-Akt pathway reduced DNA-binding activity of NF-κB as well as 804G-ECM-induced IκBα 
overexpression. It is difficult to reconcile these data with the fact that blockade of the MAP 
kinase ERK pathway inhibits the pro-survival effect of the 804G-ECM while that of the NF-κB 
pathway does not. Probably, another effector of the ERK pathway might mediate the pro-
survival effect of the 804G-ECM, and this warrants further investigation. 
As described in the introduction, NF-κB is known to play either anti- or pro-apoptotic 
roles, and it has been reported that ECM-induced NF-κB activity can play an anti-apoptotic role.  
Therefore, the finding that 804G-ECM-induced NF-κB activity seems not to be involved in the 
pro-survival effect of the 804G-ECM was unexpected. By contrast, NF-κB appears to be 
involved in 804G-ECM-induced actin cytoskeleton organization and cell spreading, and glucose-
stimulated insulin secretion. It has been reported by others that NF-κB induces expression of 
genes that are involved in spreading and/or migration of cells, such as chemokines (218; 234). 
As 804G-ECM induces overexpression of chemokines, it will be interesting to assess whether 
this is involved in its effects on actin cytoskeleton organization and/or spreading. In addition, we 
hypothesize that actin cytoskeleton organization and regulation of gene expression are both at 
least in part involved in the function of 804G-ECM-induced NF-κB activity in glucose-stimulated 
insulin secretion.  
Our finding that 804G-ECM-induced NF-κB activity is involved in the function of the 
pancreatic beta cell is supported by a recent study using transgenic mice (291). This study 
reports that beta cell-specific expression of a non-phosphorylable IκBα mutant (that inhibits NF-
κB) leads to deficient glucose-stimulated insulin secretion (291). Our data showing that 804G-
ECM-induced NF-κB activity is involved in glucose-stimulated insulin secretion lead to a number 
of new questions. The most important ones are the following: 
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- Which is the NF-κB subunit involved? Reducing the expression of specific NF-κB 
subunits (the p65 subunit for example) using the RNAi technology should provide an answer to 
this question. In addition, this approach would confirm the results obtained with the NF-κB 
inhibitor Bay 11-7082. Indeed, it is important to keep in mind that this pharmacological inhibitor 
blocks NF-κB activity indirectly via inhibition of IκBα phosphorylation and subsequent 
degradation.  
- How does ECM-induced NF-κB activity regulate cell spreading, actin cytoskeleton 
organization and glucose-stimulated insulin secretion? Is this regulation due to direct effects (via 
protein phosphorylation and/or acetylation, …) or due to altered gene expression?  
- Which are the signaling pathways leading to ECM-induced NF-κB activation? How is 
the ERK signaling pathway involved? What is the role of Ca2+? Indeed, it has been shown that 
Ca2+ plays a primordial role in glucose-stimulated insulin secretion and Ca2+ has been reported 
to be involved in the activation of NF-κB. 
- Is the ECM which surrounds the islets in vivo providing signals leading to basal NF-κB 
activity? It has been proposed that beta cells do have a basal NF-κB activity in vivo, which 
allows these cells to function normally (291). It is tempting to hypothesize that this activity is at 
least in part provided by the surrounding ECM. 
- Why are the biological outcomes of IL-1β-induced and ECM-induced NF-κB activities 
so different? Several hypotheses might explain those differences:  
1) The temporal pattern and intensity of IL-1β and ECM-induced NF-κB activities are 
different.  This might lead NF-κB to target a different subset of genes. It would be interesting to 
perform a Chromatin immunoprecipitation (CHIP) experiment to confirm this hypothesis. 
2) Alternatively, IL-1β and/or ECM might induce phosphorylation and/or acetylation of 
NF-κB subunits on different sites, leading to different patterns of gene expression. Part of the 
gene expression specificity may also be codetermined by the surrounding chromatin 
modifications, as well as by the surrounding transcription cofactors. 
3) Finally, NF-κB has been proposed to play a yet uncharacterized role in the 
cytoplasm, which might be involved in the effects of the ECM on cell spreading and cytoskeleton 
organization. This hypothesis merits further investigation.  
In conclusion, we have found that 804G-ECM induces an NF-κB activity that is involved 
in 804G-ECM-induced actin cytoskeleton organization and cell spreading, as well as glucose-
stimulated insulin secretion in pancreatic beta cells. However, the mechanisms involved in these 
effects of 804G-ECM-induced NF-κB activity remain to be unveiled.  
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PART IV : SUMMARY AND GENERAL DISCUSSION 
It is now generally accepted that cell death by apoptosis is involved in the pathogenesis 
of type 1 but also of type 2 diabetes. In addition, the pancreatic beta cell seems to be 
particularly sensitive towards apoptotic insults (as discussed in Part I, § 1.2.2.). Therefore, a 
better understanding of mechanisms regulating survival of the pancreatic beta cell is a major 
topic in diabetes research. 
Anoikis, apoptosis induced by detachment from or by interaction of cells with non-
adapted ECM, is now a well accepted concept. However, it has been proposed that 
detachment-induced apoptosis in different cell types and consecutive to different biological 
events is mediated by entirely different mechanisms. Therefore, much work remains to be done 
to establish the mechanistic linkages between absent and/or deficient cell-ECM adhesion and 
anoikis for each given cell-type and/or context.  
ECM has been shown to play a crucial role in several biological functions, including cell 
migration, survival and regulation of gene expression. The role of ECM in the protection of cells 
against apoptotic insults is now generally acknowledged for a number of cell types. Prior to the 
beginning of this thesis work, there had been some reports indicating that ECM may also play 
an important role in pancreatic beta cell survival and function, but those data remained to be 
confirmed. The ECM protein laminin has been detected in the pancreatic islet of Langerhans. 
Previous work in our laboratory has shown that rat pancreatic beta cells express the laminin-5 
receptors integrins α3β1 and α6β1. Furthermore, the 804G-ECM, that contains laminin-5, 
induces spreading of beta cells and improves glucose-stimulated insulin secretion, indicating 
that this ECM might interact with the integrins expressed on rat beta cells. The 804G-ECM was 
therefore chosen as a model for this thesis work, in order to investigate the following points: 
- the role of ECM in the survival of pancreatic beta cells 
- the signaling pathways activated by ECM and their involvement in the pro-survival 
effect of ECM 
- the effect of ECM on gene expression and signaling involved 
In our first paper, we show that 804G-ECM improves survival of beta cells, and that 
interactions between laminin-5 and β1 integrins are involved in this improved survival induced 
by 804G-ECM. Caspase-8 activity is reduced in cells cultured on 804G-ECM as compared to 
cells on cultured on the control substrate pLL. 804G-ECM induces a rapid phosphorylation of 
FAK, reinforcing the hypothesis that it activates integrins expressed on beta cells. 804G-ECM 
also induces phosphorylation of the signaling proteins Akt and ERK. Blockage of the PI3K-Akt 
pathway (using the PI3K inhibitor LY294002) and of the MAP kinase ERK pathway (using the 
MEK1 inhibitor PD98059) both increase cell death on 804G-ECM after 4h of culture, while only 
the ERK pathway inhibitor was found to inhibit the long-term (48h) pro-survival effect of 804G-
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ECM. Finally, 804G-ECM was found to induce the overexpression of one NF-κB target gene: 
IκBα. 
In our second paper, the central hypothesis was that 804G-ECM induces the 
transcriptional activity of the transcription factor NF-κB, and that 804G-ECM-induced NF-κB 
activity might be involved in some of the effects of 804G-ECM on the pancreatic beta cell. We 
found that 804G-ECM induces weak and transient NF-κB DNA-binding and transcriptional 
activities. Furthermore, we found that blockage of NF-κB activity reduces 804G-ECM-induced 
spreading and cytoskeleton organization, inhibits glucose-stimulated insulin secretion, while it 
has no effect on cell survival. This however does not exclude that 804G-ECM might activate 
other transcription factors, leading to altered gene expression that could underlie its anti-
apoptotic effect. Finally, we found that blockage of the ERK pathway reduces both the DNA-
binding and transcriptional activities of NF-κB.  
There are some additional questions raised by these studies that merit further 
investigation. First, the studies performed with the 804G-ECM do not exclude that there might 
exist other ECMs that are better adapted for the rat pancreatic beta cell to function and survive 
optimally. In addition, it remains possible that the 804G-ECM might activate other signaling 
pathways that have an even more important role in the pancreatic beta cell survival than the 
PI3K-Akt and MAP kinase ERK pathways. Furthermore, we cannot exclude that insulin may 
play a role in the observed effects of 804G-ECM on the pancreatic beta cell. An autocrine role 
for insulin on the pancreatic beta cell function and survival has been reported, although this 
concept is still controversial. Previous work performed in our laboratory has shown that 
exposure of pancreatic beta cells to 804G-ECM enhances glucose-stimulated insulin secretion. 
Signaling pathways activated by growth factors and insulin are often very similar to those 
activated by ECM. In addition, engagement of integrins to cognate ECM has been shown to 
cooperate with insulin signaling pathways to protect cells from apoptosis. Therefore, and 
particularly since the experiments were performed in stimulatory glucose concentrations (11.2 
mM glucose), we cannot exclude that the increased insulin secretion by cells on 804G-ECM as 
compared to cells on pLL may contribute to the pro-survival effect of 804G-ECM as well as to 
induction of signaling pathways by 804G-ECM. A possible effect of insulin on the effects of 
804G-ECM on the pancreatic beta cell thus warrants further investigation. 
Based on the fact that the MAP kinase ERK pathway can mediate integrin-mediated 
overexpression of anti-apoptotic genes such as c-FLIP or Bcl-2, we hypothesized that 804G-
ECM may induce overexpression of these genes. FLIP was considered as a particularly 
interesting candidate, as it has been reported to inhibit caspase-8, which activity is decreased in 
cells cultured on 804G-ECM. However, preliminary studies indicate that 804G-ECM does not 
induce overexpression of either c-FLIP or Bcl-2. Therefore, it remains to be assessed whether 
the long-term anti-apoptotic effect of ECM-induced ERK activation is related to altered gene 
expression or whether other mechanisms are involved.  
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Although the major findings and perspectives relative to Paper 1 and Paper 2 have 
been discussed in the previous sections, several points relative to this thesis work deserve 
additional discussion. First of all, why did we choose to use exclusively primary pancreatic beta 
cells? The difficulty of isolating the pancreatic beta cells, and therefore the difficulty to obtain 
enough material to perform biochemical experiments have led many groups to use transformed 
beta cell lines (that are often derived from insulinomas developed in transgenic mice expressing 
the SV40 T gene). Although some of these cell lines have been very useful for a large number 
of studies, and although they retain some major features of the normal beta cell, they are not 
always good substitutes for primary beta cells. This appears especially obvious in the context of 
studies assessing the role of ECM on beta cell survival and ECM-induced intracellular signaling, 
because the transformed cell lines are almost by definition anchorage-independent. In addition, 
each cell type expresses its own set of integrins leading it to interact with specific ECM proteins, 
and this is well recognized to be influenced by transformation. Furthermore, the signaling 
proteins activated by a given ECM and the hierarchy among these signaling pathways seem to 
differ between primary and transformed cells.  Indeed, when the effect of 804G-ECM on FAK 
and Akt phosphorylation was investigated in the cell line INS-1E derived from rat insulinoma, it 
was obvious that phosphorylation of these proteins in response to 804G-ECM was considerably 
different as compared to the primary beta cells. In addition, short-term exposure (1 h) of INS-1E 
cells to 804G-ECM did not affect DNA-binding activity of NF-κB. Therefore, we chose to perform 
all experiments with primary beta cells. Nevertheless, the exclusive use of primary cells has 
hampered us to go deeper into the activation of intra-cellular signaling pathways by 804G-ECM. 
For example, studies using pharmacological inhibitors need further confirmation by biochemical 
experiments (such as transfection of cells with dominant-negative and/or dominant-positive Akt 
mutants, for example). Such experiments remain very difficult to perform on primary beta cells.  
We observed that phosphorylation of the signaling proteins FAK, Akt and ERK induced 
by 804G-ECM is very weak as compared to that induced by growth factors, for example. It 
remains to be established whether an ECM that is “perfectly” adapted to the rat pancreatic beta 
cells (such as the one that naturally surrounds the islets in vivo, for example) would induce a 
greater increase in protein phosphorylation, or whether ECMs in general induce weak 
phosphorylation of these proteins as compared to growth factors in primary beta cells. In this 
context, it is interesting to note that others have reported that the ECM protein fibronectin 
induces a very weak phosphorylation of ERK in fibroblasts as compared to growth factors (170). 
This leads to the following question: is there truly a correlation between the intensity of 
activation of a given signaling pathway and its (positive) effect on the final biological outcome? 
In several different contexts, it has been proposed that a moderate and well-controlled activity of 
a given signaling pathway leads to a physiological effect, while constitutive or dysregulated 
activation of a signaling cascade can lead to deleterious effects that ultimately lead to serious 
illnesses such as cancer. If one views signaling cascades that coexist in the cell as an 
integrated network of pathways in a given place and at a given time-point in the cell, one might 
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speculate that a delicate balance exists between these pathways. Therefore, it appears that a 
moderate and controlled activation, in contrast to an exaggerated activation, of a given pathway 
or transcription factor will not disrupt the balance of signaling pathways in the cell. The intensity 
of a given stimulus in determining the biological outcomes of a given signaling pathway is 
therefore emerging as an important parameter to be taken in account. Much research is based 
on experiments performed using transient or stable overexpression of proteins. However, the 
physiological relevance of the observed effects induced by overexpression of proteins (in 
particular constitutive active mutants of kinases, for examples) is uncertain. Indeed, the 
observed effects induced by massive overexpression might be caused, at least in part, by non-
specific disruption of the balance coexisting between different signaling pathways.  
It is now quite clear that different signaling pathways do not exist independently of each 
other, but communicate, interact and cooperate in a synergistic way to promote cell survival. In 
addition to the nature and the intensity of a given stimuli, other important parameters that 
influence the endpoint of a given signaling pathway are emerging: the concept of space (the 
three-dimensional space inside the cell) and of time (duration and pulsatility of the signal). It has 
been proposed by Frisch and colleagues that the architectural state of the cytoskeleton can 
affect the interactions between signaling molecules in the three-dimensional space (56). For 
example, the endpoint of the ERK pathway has been shown to be affected by the state of the 
actin cytoskeleton. The state of the cytoskeleton is a parameter in addition to the regulation of 
gene expression that may explain the observed differences in the relative importance of the 
PI3K-Akt and ERK pathways in the protection of the beta cell against apoptosis in the short (4h) 
and long-term (48h) experiments (Paper 1). After 4h of culture, cells are only beginning to 
spread, while after 48h of culture they are completely spread, with a well-defined actin 
cytoskeleton on 804G-ECM. Therefore, it is tempting to speculate that the state of the 
cytoskeleton as well as the level of expression of 804G-ECM-induced proteins at a given time-
point are two factors that determine the importance of the PI3K-Akt and MAP kinase ERK 
pathways for pancreatic beta cell survival. The duration of a given signal now also appears to be 
crucial for the biological consequences of a given signaling pathway. This has been proposed 
for both the ERK pathway and the transcription factor NF-κB. Indeed, both ERK and NF-κB 
have been shown to be able to play contrasting roles (pro-apoptotic and anti-apoptotic roles, for 
example), and recent papers propose that it is the duration and/or the pulsatility of the stimuli 
inducing their activity that determine the ultimate fate of the cell.  
The findings reported in our second paper have led us to conclude that 804G-ECM-
induced NF-κB activity is beneficial for pancreatic beta cell function, at least in part because it is 
moderate and transient. Our results contrast with previous findings reporting that NF-κB plays 
deleterious roles in beta cells, leading to their dysfunction and death. In the context of diabetes, 
blocking NF-κB activity is considered by some researchers as a most promising therapeutic 
means to improve beta cell survival in order to prevent the onset of diabetes. However, these 
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studies have neglected the fact that the nature, intensity and/or duration of the inducing stimuli 
can affect the biological outcomes of NF-κB activity and have focused exclusively on NF-κB 
activity that is induced by long-term (at least 48h) treatment with high doses of cytokines. Our 
data showing that NF-κB might be essential for the pancreatic beta cell to function normally is 
supported by a recent study using transgenic mice expressing non-phosphorylatable 
IκBα (291). We therefore hope that these data showing a new facet of NF-κB function in the 
pancreatic beta cell will force some investigators to be cautious in initiating clinical studies 
aimed at blocking NF-κB activity in diabetic patients.   
A possible general role for ECM in the protection of islets against diverse insults 
leading to beta cell dysfunction and/or apoptosis and consequent loss of beta cell mass leading 
ultimately to a diabetic state in vivo remains to be unraveled. Studies using conditional knock-
out mice harboring beta cell-specific deletion of specific ECM proteins (such as laminin-5) 
and/or of specific integrins (such as β1 integrin) should provide clues for a possible general role 
of ECM in the prevention against diabetes. However, data from such transgenic models will 
need to be interpreted with caution given the possibility of compensation by parallel, possibly 
redundant, pathways.  
It has been reported that high glucose concentrations can modify expression of 
integrins, leading to altered cell-matrix interactions (292; 293). Furthermore, it has also been 
proposed that hyperglycemia can induce modifications (by nonenzymatic glycosylation) of ECM 
proteins that also results in modified cell-ECM interactions (294; 295). It is therefore tempting to 
hypothesize that altered cell-matrix interactions induced by hyperglycemia might lead to 
reduced protection of beta cells against pro-apoptotic stimuli. This could further accelerate the 
reduction of beta cell mass which is involved in the pathogenesis of diabetes. Therefore, it 
would be interesting to assess whether there is an alteration of the islet ECM and/or a 
modification of the beta cell integrin expression during the pathogenesis of diabetes. One 
animal model that could be used to verify this hypothesis is diabetes-prone mice fed with high-
fat diet. 
In conclusion, the findings of this thesis work demonstrate the importance of ECM for   
the pancreatic beta cell survival, as well as for the regulation of gene expression and the activity 
of kinases. ECM should therefore be viewed as a crucial part of the islet microenvironment that 
could provide protection of beta cells against apoptotic insults that are involved in the 
pathogenesis of diabetes.   
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